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CHAPTER I 
GENERAL INTRODUCTION 
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A)  LUNG TRANSPLANTATION 
Lung transplantation (LTx) is a life-saving surgical procedure in which diseased native lungs 
in patients suffering from end-stage pulmonary diseases are replaced by donor lungs. According 
to the ISHLT registry, the most common end-stage pulmonary diseases listed from 1995 up to 
2014 where lung transplantation was indicated, were: 1) chronic obstructive lung disease (32%), 
2) idiopathic pulmonary fibrosis (24%), 3) cystic fibrosis (16%), 4) alfa-1-antitrypsin 
deficiency (5%) and 5) idiopathic pulmonary arterial hypertension (3%). Since James Hardy 
performed the first lung transplant procedure in 1963 (1), the success of lung transplantation 
has grown enormously due to improved surgical techniques, perioperative management, 
immunosuppressive regimens, and strict long-term follow-up. Consequently, the overall 
survival for adult recipients is improving per era and the median survival of adults transplanted 
between 1990-2013 was 5.6 years (Figure I.1). 
 
Figure I.1 Kaplan-Meier survival per era. Figure adapted from ISHLT Adult Lung 
Transplantation Stat istics 2015. http://ishlt.org/registries/slides.asp?slides=heartLungRegistry  
Nowadays, more than 4000 procedures are performed annually worldwide (2). At the 
University Hospitals Leuven, the lung transplant program initiated in 1991, has grown up to a 
mean annual transplant rate of 61 procedures over the past 5 years (2011-2015) (Figure I.2).  
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The worldwide growth in LTx is mostly due to an increase in sequential single lung 
transplantation (SSLTx), where both diseased lungs are transplanted (=bilateral lung 
transplantation). The number of single lung transplant (SLTx) procedures, where only one lung 
is transplanted, is less frequently used due to an inferior survival of the recipient compared to 
SSLTx (3). 
Figure I.2 –The annual number of single lung, bilateral/double lung and total lung transplant 
procedures registered at the International Society of Heart and Lung Transplantation (ISHLT) 
are depicted on the left.  Lung t ransplant numbers from our University Hospitals Leuven are 
depicted on the right.  
The success of LTx is critically dependent on the number and quality of donor lungs. This is 
currently one of the main challenges to maintain and improve the outcome for recipients and 
patients on the waiting list. Currently, the overall number of available donor lungs is still 
inadequate (2). This limits the further expansion of lung transplant programs and leads to a 
persistent 15 % mortality for patients on the waiting list (2,4). In addition, inferior quality of 
the transplanted donor lung can lead to primary graft dysfunction (PGD), which is a form of 
acute lung injury appearing shortly after lung transplantation. PGD can be considered as an 
important parameter of overall donor lung quality as it determines early outcome after LTx, but 
also acute and chronic rejection and even long-term survival might be linked to PGD (5,6). 
  
5 
 
B)  DONOR ORGANS FOR LUNG TRANSPLANTATION 
Solid organ transplantation is only possible if a suitable organ is donated. The main source for 
organ donors in lung transplantation, are recently deceased patients, referred to as cadaveric 
organ donors.  Cadaveric organ donation is based on two types of donors: on the one hand, 
donors who die after brain death (DBD) and on the other hand donors who die after circulatory 
death (DCD). A person can become a cadaveric organ donor when he actively consented to be 
an organ donor (opting-in legislation), or when he did not register himself objecting to donate 
his organs (opting-out legislation). 
Brain death in DBD is still a clinical diagnosis, based on the cessation of clinical functions of 
the brain that will not resume. It is determined by the absence of capacity for consciousness, 
centrally mediated motor responses, brainstem reflexes, and capacity to breathe (7). Donor 
organs remain perfused as the heart of the DBD is still beating at the time of organ procurement. 
However, the process of brain death is associated with a systemic inflammation and leads to an 
autonomic dysregulation (storm + depletion) that also damages the donor lung by detrimental 
effects on the cardiovascular function. In practice, the majority of lung transplants still results 
from these DBDs. That is, only 2-32% of all lung transplants results from DCD organ donation 
(8,9). And although the first performed lung transplant was from a DCD donor, the use of DCD 
donors to enlarge the donor pool has only been reintroduced in the early 90’s (10,11).  
A DCD donor, is a donor with a critical medical condition where further treatment is considered 
futile and the decision is made to proceed with end-of-life care. Most often, these patients 
suffered devastating and irreversible brain injury, but do not meet the formal criteria of brain 
death. Withdrawal of care in these patients will lead to circulatory arrest and death, whereafter 
organs can be procured for donation. Therefore, with DCD, there is a certain delay between 
circulatory arrest (cessation of organ perfusion) and the start of organ cooling (cold ischemia). 
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This interval, called the asystolic warm-ischemic time (WIT), will rapidly lead to cellular 
damage and compromise organ function and quality.  
DCD donors were initially categorized (Table I.1) from I-IV according to the Maastricht 
classification (12). The Maastricht classification was later on modified and complemented with 
a fifth category in 2000 (13,14). Maastricht categories I and II (and V) are uncontrolled DCD 
donors (referring to the uncertainty of the exact moment of circulatory arrest), whereas class III 
and IV are controlled DCD donors (referring to the fact that the precise moment of circulatory 
arrest is documented). In the latter, treatment withdrawal in or near the operating room is 
followed by a stand-off period after cessation of circulation in the patient, followed by the 
declaration of death. After this controlled context of therapy withdrawal and circulatory arrest, 
the donor organs are retrieved. In contrast, uncontrolled DCD donors are found after circulatory 
arrest, and cardiopulmonary resuscitation is initiated in some of these patients until they are 
declared dead whereafter organ preservation measures can be started.  
Table I.1 –  Modified Maastricht Classification of donors who die after circulatory arrest (DCD)  
(13) 
 
Currently, the lung retrieval rate (% of donors eligible for lung donation) of a multi-organ donor 
remains as low as 20 to 30% (2,15). In combination with the growth in lung transplant programs, 
this had led to a critical shortage in usable donor lungs (Figure I.3). Over the past 5 years, the 
discrepancy between the amount of available donor lungs and the number of patients listed is 
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shrinking (but still existent), due to efforts made by the entire transplant community. 
Unfortunately, there remains a high mortality rate on the waiting list. Between 2005 and 2013, 
14.4% of patients listed for lung transplantation in the United States of America either died or 
were removed from the waiting list since they became too sick for a lung transplant procedure 
(4). In the same analysis, this percentage is as high as 22% for pediatric patients. Also within 
the Eurotransplant database, we report a persisting average mortality of 10% on the lung 
transplant waiting list between 2005 and 2015 (Eurotransplant database registry reports, Figure 
I.3). Therefore, the first major problem identified and addressed in this project will be: 
Problem 1: A shortage of suitable donor organs leads to a persistent 
mortality for patients on the waiting list and limits further increase in 
transplant activity. 
 
Figure I.3 –  Eurotransplant data depicting patients active on the waiting list, total number of 
patients transplanted, and waitlist mortality within the Eurotransplant database  (2).  
For all types of organ donors, strict criteria of a “standard-criteria donor” (SCD) have been 
defined historically, to be considered as an ideal lung donor candidate (Table I.2) (16,17). 
However, to increase the amount of transplantable donor organs, these criteria have been 
liberalized to “extended-criteria donors” (ECD). These are lung donors not matching the strict 
criteria of a SCD.  
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In our center, ECD lungs account for 63% of donor lungs. Percentages range from 30-60% 
(18,19) in other centers, yet an extended criteria donor (ECD) is defined differently in numerous 
reports (18). Although the use of ECD lungs does not impair long-term clinical outcome in our 
center, a negative impact on early outcome (prevalence of severe primary graft dysfunction, 
length of stay in intensive care unit (ICU), duration mechanical ventilation) has been reported 
(20). A recent analysis of the UNOS registry did show a reduced one-year survival in patients 
receiving ECD lungs, with the lowest survival in patients with a lung allocation score of 70 or 
greater (21). However, several centers are reporting similar long-term outcome with ECD 
compared to SCD. Therefore, we start to understand that not all ECD donors should be 
considered as “marginal” (20,22,23). High-risk donor organs can be considered for 
transplantation, but should be allocated wisely to the most suitable recipient.  
Table I.2 –  Ideal lung donor criteria , adapted from Sundaresan et al.  (17) 
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C)  PRIMARY GRAFT DYSFUNCTION 
Primary graft dysfunction (PGD) is a common complication immediately following 
transplantation of the lung graft, resulting in acute failure of its function. In the process of organ 
donation and lung transplantation, several harmful hits to the donor lung occur that may result 
in primary graft dysfunction (PGD). It already starts in the donor where prolonged mechanical 
ventilation, brain death or warm ischemia can trigger this injurious process. It continues during 
cold ischemic storage in preservation solution and peaks upon reperfusion inside the recipient’s 
chest with possible further injurious insults to the transplanted lungs in the peri-operative phase. 
Before the establishment of the clinical definition of PGD by the ISHLT PGD working group 
in 2005 (24), it was often referred to as ischemia-reperfusion injury (IRI), early graft 
dysfunction, primary graft failure or re-implantation edema.  
Clinical classification of primary graft dysfunction 
PGD occurs per definition within the first 72 hours after lung transplantation and is 
characterized by severe hypoxemia, apparent lung edema with diffuse alveolar damage and 
radiographic evidence of diffuse pulmonary infiltration without other identifiable cause 
(mechanical, immunologic or infectious causes that can mimic or confound the diagnosis of 
PGD). Since 2005, it is categorized by the ISHLT PGD working group as grade 0 to 3 based on 
oxygenation and chest X-ray (Table I.3) and is scored at several time points after reperfusion 
(T0, T12, T24, T48, T72) (25). Severe (grade 3) PGD occurs in 10-30 % of cases (26).  
Radiographic and histological findings are similar to acute respiratory distress syndrome 
(ARDS) (27,28). Initial epithelial denudation, in parallel with endothelial damage, leads to 
capillary leakage with interstitial edema that rapidly spreads to intra-alveolar edema which can 
be seen as diffuse parenchymal opacities on chest X-ray.  
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Table I.3 –  Gradation of PGD 
 
PGD gradation is based on PaO2 /FiO2 (PaO2:  partial oxygen pressure, FiO 2: fraction of inspired 
oxygen) and radiographic infiltrates that are consistent with pulmonary edema (right panel) (25) 
Outcome 
PGD results in impaired early outcome since it leads to prolonged length of mechanical 
ventilation, prolonged intensive care stay, prolonged hospital stay and even increased short-
term mortality (29–31). Severe (grade 3) PGD at 48 and 72 hours is linked with an increased 
90-day and 1-year mortality, with an absolute increase in mortality of 23% at 1 year (26).  
Interestingly, recent publications even show an impact on the later development of bronchiolitis 
obliterans syndrome (BOS), a phenotype of chronic allograft dysfunction (CLAD) (32,33), that 
limits long-term survival. PGD is associated with induced pro-inflammatory cytokines that can 
upregulate donor specific antigens to promote the development of donor allo-immunity (34). 
Increased levels of IL-6, IL-8 and TGF-β in bronchoalveolar lavage fluid (BAL) in patients 
with severe PGD (35–37) form an important mechanistic link between early post-transplant 
lung allograft injury and reported association with BOS. 
Pathophysiology 
The pathophysiology of primary graft dysfunction is the end-result of several injurious insults 
to the donor lung inside the donor, during preservation and upon reperfusion in the recipient.  
PGD results from a complex interplay between direct damage by ischemia and cold 
preservation, induction of cell death, production of reactive oxygen species (ROS) and the 
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activation of a damage-amplifying inflammatory cascade (38,39) (Figure I.4). All these changes 
result in a microvascular and epithelial dysfunction of the transplanted lung (40,41) with 
increased permeability of the alveolar membrane and development of lung edema. This is 
physiologically translated in an increased pulmonary vascular resistance (PVR), ventilation-
perfusion mismatch, decreased lung compliance (Compl), intrapulmonary shunting and 
impaired gas exchange (42). 
INFLAMMATION – The inflammatory cascade during IRI is organized in a biphasic response 
where resident macrophages are the motor of the pulmonary injury. In response to ischemia 
and/or hypoxia with subsequent upregulation of NADPH oxidase and ROS production, alveolar 
macrophages can produce a large amount of cytokines and procoagulant factors through NF-
KB signaling. NF-KB is the main transcription factor and an important regulator of 
inflammatory cytokines, chemokines, cell adhesion molecules and apoptosis signals involved 
in the process (42).  
Donor macrophages modulate the early phase of reperfusion injury and form the main initial 
source of TNF-α, IFN-γ, MCP-1 and IL-8 (43). This is followed by a delayed phase, with 
massive infiltration of recipient neutrophils upon reperfusion of the donor lung in the recipient’s 
chest. These are able to deliver elastases, proteases and toxic radicals which will further 
promote oxidative stress signaling and amplification of the pro-inflammatory cascade. Release 
of pro-inflammatory mediators and upregulation of adhesion molecules will attract more 
neutrophils and activate T-cells that will further nourish the pro-inflammatory environment of 
the lung (44–46). Significantly increased levels of pro- and anti-inflammatory cytokines such 
as TNF-α, IFN-γ, IL-8, IL-2, IL-6, IL-10, IL-12 and IL-18 are measured during both ischemia 
and reperfusion in the lung (bronchoalveolar lavage fluid (BAL), tissue) and serum of 
donor/recipient. The origin of these cytokines and chemokines are the inflammatory cells, but 
also structural cells (epithelial cells and endothelial cells) contribute to this damage-amplifying 
12 
 
pro-inflammatory cascade. IL-8 levels in BAL even correlate with graft function after lung 
transplantation and are correlated with an increased risk of death from PGD (36). Macrophages 
also release procoagulant factors such as PAF. Platelet activation leads to formation of micro 
thrombi and activation of leukocytes to further enhance the inflammatory cascade in the late 
phase after reperfusion. Progressive microvascular obstruction is mediated by this release of 
procoagulant factors and the vasoactive effect of inflammatory mediators (47).  
ROS - During cold preservation, ischemia and/or hypoxia lead to depletion of ATP-stores and 
accumulation of ATP degradation products such as hypoxanthine and xanthine (41). The 
absence of flow and shear stress in the lung upregulates NADPH oxidase and xanthine oxidase 
which can produce massive amounts of superoxide anion, hydrogen peroxide and hydroxyl 
radicals (47). These upregulated enzymes can be found in high concentration on dysfunctional 
endothelial cells, but also on vascular smooth muscle cells, macrophages, neutrophils and 
platelets (48). ROS can cause direct damage to the pulmonary endothelium and epithelium by 
interacting with the phospholipids of the cell membrane. Oxidative stress stimulates the 
transcription of cell-surface adhesion molecules and release of cytokines that will attract and 
activate inflammatory cells after reperfusion (43).  
CELL DEATH – There are two forms of cell death: necrosis and apoptosis. Apoptosis is a 
relatively quiescent kind of cell death since it does not induce inflammation and cytokine 
release, as is seen in necrosis. Therefore, apoptosis is referred to as controlled cell death, while 
necrosis is an uncontrolled disintegration of the cell with release of its content (49).  
With prolonged periods of ischemia, the mode of cell death will be primarily necrosis. But for 
shorter periods of ischemia, the mode of cell death will be primarily apoptosis upon reperfusion 
of the graft. Therefore, apoptosis is thought to be the main mechanism of cell death observed 
during pulmonary IRI and increases rapidly after reperfusion with a peak that coincides with 
the highest caspase-8 levels two hours after reperfusion (42). Apoptosis is triggered by the 
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intrinsic pathway through stressors like oxidative stress that upregulate pro-apoptotic proteins 
such as BID and BAX. These proteins of the Bcl-2 family, lead to increased mitochondrial 
permeability in pulmonary epithelial cells with release of cytochrome c and apoptotic protease 
activating factor (APAF). Together with caspase-9, they form an apoptosome to activate 
effector caspase-3 and the subsequent caspase cascade towards cell apoptosis (50). The 
extrinsic pathway, triggered by activation of specific receptor-ligand signaling interactions 
through Fas/Fas ligand and TNF receptors, will give rise to a cascade of caspase activation such 
as caspase-8 (initiator caspase) and caspase-3, -6, -7 (executioner caspases), that ultimately 
results in DNA fragmentation and cell death (51).  
 
Figure I.4 –  Pathophysiology of PGD, dominated by donor macrophages in the early phase and 
recipient neutrophils in the delayed phase. A complex interplay of inflammation, apoptosis, 
reactive oxygen species ultimately results in diffuse alveolar damage wit h capillary leakage, 
interstitial and ultimately alveolar edema.  
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Risk factors 
There are several known risk factors for the development of PGD. The lung graft can 
accumulate numerous injuries at various stages during the lung transplant process: during the 
process of brain death (autonomic-humoral dysregulation) or circulatory death (warm 
ischemia), procurement and preservation of the donor organ (cold ischemia), reperfusion of the 
organ in the recipient’s chest and during the early postoperative stage after the transplant 
procedure. Donor smoking (especially > 20 pack years) is associated with the development of 
severe PGD, but is a controversial topic since the history of donor smoking is often inaccurate 
(5). Operative-related factors include single-lung transplant, prolonged cold ischemic time, 
intracellular type preservation solutions, high fractional inspired oxygen upon reperfusion, 
poly-transfusion and the use of cardiopulmonary bypass. Also recipient-related factors have 
been linked with an increased risk of developing PGD: overweight and obese body mass index, 
preoperative sarcoidosis, idiopathic pulmonary fibrosis, primary pulmonary arterial 
hypertension or increased pulmonary arterial pressures (26,52).  
Treatment 
Unfortunately, only supportive treatment is available once PGD has been established. This 
support includes lung-protective ventilation, restrictive fluid balance, inhaled nitric oxide (iNO) 
and extracorporeal membrane oxygenation (ECMO) as a final salvage strategy (5,53). Also 
preventive treatment options are not yet definitely proven to be clinically effective. Most 
clinical trials are based on small sample sizes and there are only a few randomized trials 
available. Surfactant instillation and iNO seemed promising, but there is a lack of efficiency for 
their use in clinical practice (54–56). Retransplantation can be considered in highly selective 
cases, however, predicted survival is poor and therefore retransplantation for severe PGD is not 
recommended (57). In case gas exchange is the main limiting factor, veno-venous ECMO can 
be safely chosen over veno-arterial ECMO. However, in case the symptoms progress towards 
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circulatory failure, veno-arterial ECMO should be considered (58,59). In conclusion, the second 
major problem identified and addressed in this thesis project will be: 
 
Problem 2: Currently, only supportive treatment options are available for 
PGD, which still occurs in up to 30% of patients after lung transplantation 
and limits both short- and long-term outcome. 
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D)  EX-VIVO LUNG PERFUSION 
Ex-vivo lung perfusion (EVLP) is a form of isolated lung perfusion in normothermic conditions. 
It can be achieved with a pump-driven perfusion machine that recirculates a preservation 
solution through the vasculature of the lung in addition to mechanical ventilation (Figure I.5). 
It is offered to assess the graft outside of the body, and to serve as an alternative to cold static 
lung preservation where lungs are stored on ice. Advancements in lung-preservation techniques 
in the pre-retrieval and post-retrieval periods aim at increasing the pool of available donors, and 
novel research and discoveries in this area steadily improve post-transplantation adverse events. 
Ex-vivo lung perfusion (EVLP) is such a novel technique for normothermic lung preservation 
to improve both number and quality of available donor lungs. 
History 
EVLP was introduced first by Jirsch in 1970 (60), who used perfused canine lobes in an ex-
vivo isolated perfusion model for evaluation of preservation strategies. Initial efforts failed 
however, due to the inability to maintain the integrity of the alveolar-capillary membrane, 
resulting in pulmonary edema. In 2001 Steen and colleagues succeeded in performing the first 
lung transplantation of uncontrolled DCD donor lungs that were evaluated ex-vivo prior to 
transplantation (61). EVLP was thus initially developed as a platform to carefully evaluate 
donor lungs to assess their transplantability based on physiological parameters. In 2008, the 
Toronto group pushed the limits with their technique of prolonged preservation (up to 12 hours) 
(62). This was a turning point because since then, lungs could be preserved safely for a 
prolonged period on EVLP. Lately, the interest in EVLP has further developed towards its usage 
as a platform for active reconditioning of donor lungs (63). Due to technical improvements and 
efforts of research groups around the world, EVLP could become a validated treatment platform 
for evaluation, preservation and even reconditioning of donor lungs (63). With EVLP, we aim 
at maintaining and even improving the quality of the donor organ. 
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Technique of ex-vivo lung perfusion 
During EVLP, lungs are mounted in an isolated system. Therefore, lungs have to be cannulated 
on ice in preparation for ex-vivo organ perfusion. A perfusion cannula is fixed in the pulmonary 
trunk. The left atrium can be cannulated with a funnel-shaped cannula or can be left open for 
drainage (64). Finally, an endotracheal tube is fixed in the trachea. All EVLP-circuits consist 
of a pump, gas exchanger with heater/cooler, a hard-shell reservoir and most often a leukocyte 
filter (Figure I.5). The system is primed with an extracellular dextran 40-based solution with 
optimal colloid pressure (with are without addition of albumin or red blood cells). The solution 
is further completed with additives (methylprednisolone, antibiotics, and heparin) and corrected 
for bicarbonate and glucose after biochemical analysis. The target flow during EVLP ranges 
from 40% to 100% of the estimated cardiac output depending on the protocol that is used. Lungs 
are ventilated with protective ventilator settings during EVLP, starting when a target outflow 
temperature is reached (32-34 °C). An overview of all settings in the 3 most used clinical 
protocols (Lund, Toronto, OCSTM) is provided in Table I.4 (adapted from Van Raemdonck et 
al. Transpl Int 2014). 
Table I.4 –  Different EVLP protocols  
OCS = Organ Care System (Transmedics, Andover, MA, USA );  CO = cardiac output; RBC’s = 
red blood cells; RR = respiratory rate; FiO 2 = fraction of inspired oxygen. Adapted from (65) 
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EVLP allows for careful physiological evaluation of the donor lung. During EVLP, we can 
measure oxygenation capacity (PaO2/FiO2) by sampling the perfusate at the outflow, evaluate 
lung compliance based on ventilatory parameters (Ppeak, Pplateau, compliance), and calculate 
pulmonary vascular resistance (PVR) (66) based on pulmonary artery pressure (PAP), left atrial 
pressure (LAP) and the flow (l/min). But also perfusate samples and bronchoalveolar lavage 
(BAL) fluid can be analyzed for evaluation of the metabolic status and inflammatory profile of 
the perfused lung graft (67,68). At 4 hours of EVLP, IL-8 is a good parameter to predict PGD3 
development for example (69). However, these analyses are not immediately available so we 
mainly rely on physiological parameters only.  
 
Figure I.5 –  A classic EVLP set-up (here depicted with an acellular perfused porcine lung) 
consists of an inflow cannula inserted on  the pulmonary artery, an outflow cannula (or open 
atrium), a reservoir that collects the perfusate draining out of the lung, a centrifugal (or 
pulsatile) pump, a heater -cooler system, gas exchanger, and a ventilator.   
Clinical experience and early outcome after EVLP lung transplantation 
Since the first clinical EVLP case was reported in 2001, many research groups have engaged 
themselves to use this new technology to increase the donor pool. Pre-clinical studies already 
showed that normothermic machine preservation could be superior to cold storage preservation 
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(70). And lately, early clinical experience showed comparable early outcome and incidence of 
primary graft dysfunction after EVLP (71,72), even when high-risk donors were used (73–75).  
Several groups reported their experience on transplanted lungs of initially rejected donor lungs 
after reconditioning ex-vivo (76–79). However, many of these lungs that are considered 
marginal or initially not transplantable are already transplanted as an extended-criteria donor 
without the use of EVLP in other centers (20,80). These centers also reported excellent 
outcome, which could indicate that EVLP is not always necessary to safely transplant marginal 
donor lungs (23).  
It is still not clear what the optimal time interval is to perform EVLP. This can range from a 
short assessment on EVLP, to a full replacement of the cold preservation time by normothermic 
preservation. Also, the potential combination with cold storage before and after EVLP is still 
not clarified. There might be an advantage of limiting the cold storage period to reduce IRI by 
a portable EVLP device. Early results after portable EVLP show excellent results (72). 
However, some groups showed better outcome when EVLP was applied after a longer initial 
cold storage period (81). This might allow safe transportation to an experienced EVLP center 
that could then evaluate and optimize the donor lung prior to a second cold preservation period 
during transport to the recipient center (82). From pre-clinical investigations, we know that cold 
storage after normothermic machine perfusion can safely be applied up to 10 hours (83) which 
further facilitates logistics for lung transplantation. Some groups even applied an initial cold 
preservation period prior to normothermic machine perfusion as an ischemic preconditioning 
strategy, and reported superior graft function (84,85). Vice versa, the portable lung perfusion 
device can also be used after a longer cold storage period when necessary (86). 
EVLP results in an increased use of offered donor lungs with comparable early outcome after 
lung transplantation. Moreover, not many groups reported the long-term effects of EVLP yet. 
Tikkanen and colleagues reported acceptable long-term survival, graft function and 
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improvement of quality of life after ex-vivo lung perfused lung transplantation that is 
comparable with the conventionally selected and cold-preserved lungs in a case series of 60 
EVLP cases (87). In their retrospective analysis, they even found that freedom from CLAD in 
DBD donors (and not DCD donors) was superior when EVLP was used prior to transplantation. 
Other investigators also observed this higher freedom from CLAD with EVLP (88). 
Reconditioning, a term for quality improvement 
Although EVLP was introduced as an evaluation tool to gain more information on questionable 
donor organs prior to transplantation, it has recently been put forward as an ideal treatment 
platform for active improvement of lung quality of initially rejected donor lungs. The term 
“reconditioning” of donor organs is introduced here, referring to any intervention that will 
restore the organ to become transplantable by improving its quality which was initially 
unsatisfactory. To improve the number of transplantable donor organs, we define 3 intervals for 
this potential quality improvement (or reconditioning): preconditioning, perconditioning and 
postconditioning (Figure I.6). 
First, “preconditioning” is defined as any intervention to optimize organ quality while the organ 
is still inside the donor (before onset of ischemia). This can be considered as classical donor 
management. 
Second, we consider “perconditioning” as any strategy applied during the ischemic interval. In 
practice, this means interventions during cold static preservation on ice.  
Finally, treatment interventions can also be applied after reinstallation of organ perfusion 
(“postconditioning”). This could be done in the recipient after transplantation. However, since 
the lung is normothermically perfused during EVLP, we also consider this technique as a 
platform for postconditioning without harming the recipient.  
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Figure I.6 –  Organ reconditioning (improving lung quality) can be done at three different stages: 
while the organs are still in the donor (preconditioning), during cold ischemic preservation 
(perconditioning) and while they are reperfused inside the recipient after transplantation (LTx) 
or on EVLP (postconditioning)  
Several clinical case reports of organ reconditioning have been reported. For example, 
neurogenic lung edema (89) or pulmonary congestion after contusion (90) can be salvaged by 
perfusing the graft with a high-oncotic perfusate. Fibrinolytics can be used to improve lung 
physiology and to reduce inflammation (91), and can result in resuscitation of lungs initially 
rejected due to large pulmonary emboli (92,93). Many anti-inflammatory therapies have been 
proposed and investigated in experimental settings: surfactant (94,95), ascorbic acid (96), 
adenosine receptor agonist (97,98), IL-10 vector (99), steroids (100). Also inhaled anti-
inflammatory agents have been investigated with promising results in pre-clinical models: 
hydrogen (101,102), beta2-agonist (103,104). Even microbial load could be reduced in an 
infected lung during EVLP (105,106). To solve the organ shortage issue for smaller recipients, 
EVLP could be used for graft downsizing while normothermically perfusing the lung (107). In 
this way, we could include marginal lungs and make them suitable for transplantation in smaller 
recipients. However, apart from isolated cases of active lung reconditioning, there are currently 
no validated treatment options we can use to recondition rejected donor lungs.  
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In summary, reconditioning is seen as an optimization of donor lung quality which can be 
achieved inside the donor (preconditioning), during cold preservation (perconditioning) or after 
reinstallation of perfusion on EVLP or inside the recipient (postconditioning). Experimental 
reconditioning strategies are needed for clinical translation and should be based on clear 
mechanistic hypotheses.  
Three reconditioning strategies will be investigated in this PhD project, which are selected 
based on their anti-inflammatory, pro-survival or immunoregulatory characteristics:  
1) glucocorticoids, 2) noble gases, and 3) mesenchymal cells.  
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E)  GLUCOCORTICOIDS 
Used clinically since the 1920s, corticosteroids interrupt multiple steps in immune activation. 
They are among the most potent anti-inflammatory and immunosuppressive agents due to their 
ability to inhibit antigen presentation, cytokine production, and proliferation of immune cells.  
There is a vast experience with corticosteroids in the field of transplantation, used as an 
immunosuppressive drug to prevent rejection and prolong graft survival (108). And also for the 
management of a brain-dead donor, steroids are often included as an organoprotective treatment 
strategy. Brain death induces a systemic inflammatory response with release of many pro-
inflammatory cytokines such as TNF-α, IL-1, IL-6 and IL-8 that can damage the donor organs. 
Therefore, blunting this inflammation with early glucocorticoid administration, could decrease 
cytokine production and may prevent alterations induced by pro-inflammatory mediators, 
stabilize cell membranes, reduce expression of cell surface adhesion molecules and avoid lipid 
peroxidation after the ischemic period (109). These actions will theoretically improve donor 
organ function. In the respiratory system, steroids can bind to the glucocorticosteroid receptors 
which are ubiquitously expressed in all cells throughout the airways. After translocation to the 
cell nucleus, they inhibit NFκ-B activation followed by blockage of the pro-inflammatory genes 
involved in IRI (21–23). It is therefore an ideal drug to improve donor lung quality by reducing 
IRI inherent to the transplant process.  
The CORTICOME study, investigating the effect of low-dose hydrocortisone administration in 
brain-dead donors, failed to increase organ recovery or early graft function however, early 
administration of low-dose hydrocortisone did result in hemodynamic stabilization of the donor 
(110). Therefore, routine steroid administration should be embedded in a multimodal approach 
of the hemodynamic unstable brain-dead donor.  Dhar et al showed that a lower-dose 
corticosteroid protocol had similar results as high-dose regimens, and donors had an improved 
glycemic control (111). The beneficial effect of corticosteroids on improved oxygenation, 
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increased organ recovery and organ function is based on observational studies only (112,113), 
and large randomized controlled trials are lacking. Current recommendations to use steroids for 
donor management of brain-dead donors, is therefore based on low-grade evidence (114,115).  
Besides their potential beneficial role in DBD donation, their role in DCD donation to protect 
against warm-ischemic injury has never been investigated since the dead-donor rule limits 
interventional studies in DCDs. Nevertheless, over 90% of centers using DCD organs report 
that steroids are applied prior to circulatory arrest (8). However, this practice is based on limited 
data from DCD observational studies only and pre-clinical research should be conducted to 
support this practice. 
 
We hypothesize that administration of steroids prior to the onset of warm-ischemic injury 
and during EVLP has a beneficial impact on pulmonary graft function. 
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F)  NOBLE GASES ARGON AND XENON 
Argon (Ar) and xenon (Xe), both noble gases, have gathered increased interest as an innovative 
reconditioning strategy. They have been shown to protect against ischemia-reperfusion injury 
and hypoxia in various organs including the brain (116–120), myocardium (121,122), vascular 
endothelium and kidneys (123,124). Despite being described as chemically inert, these noble 
gases have been repeatedly demonstrated to exhibit biological effects such as anesthesia (125) 
and inducing improved survival in hypoxic injury models (126). They have unique physico-
chemical properties that are summarized in Table I.5. They have the potential to interact with 
cell survival pathways and are therefore referred to as anti-apoptotic (127,128). Also, the 
gaseous nature of these components allows unique delivery through the airways in the alveolar 
spaces. This characteristic, together with its anti-apoptotic properties, makes them excellent 
candidates to be investigated in lung transplantation to tackle IRI and its clinical end-result, 
primary graft dysfunction. The main advantage in the search of a therapeutic intervention to 
attack pulmonary IRI, is that lungs can be approached at the epithelial side since the airways 
are continuously exposed to the environment. Therapeutics can therefore be delivered through 
distribution via bronchoscopy (instillation of therapeutics) or through ventilation (inhaled 
therapeutics). But also the conventional distribution via the vasculature of the lung can be 
chosen (saturation of perfusion solution). 
Table I.5 Physico-chemical properties of noble gases Ar and Xe  
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We know from electrophysiological studies that the neuroprotective effect of Xe arises from an 
inhibition of the N-methyl-D-aspartate receptor and activation of the TREK-1 channels (129). 
NMDA-receptor inhibition also results in its anesthetic effect (130), together with enhancing 
signal conduction of the GABA receptors (131,132). The organoprotective effects of Xe found 
in myocardial and renal ischemia models, are mediated by pro-survival signals that target 
MAPK and ERK-1/2 pathways (133,134), HIF-1α activation (135) and mitochondrial 
permeability (136). However, the mechanism of action for Ar is not yet unraveled (137). There 
is growing evidence that the ERK-1/2 signaling cascade is involved (138) but how the 
modulation of this signaling pathway might lead to organ protection, is not yet unraveled (139).  
 
Figure I.7 Summary of the  possible pro-survival working mechanisms of Ar and Xe to attenuate 
IRI. 
 
We hypothesized that modulation of survival pathways and ischemic injury by noble gases 
might improve pulmonary graft quality prior to lung transplantation. 
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G)  BONE-MARROW DERIVED MESENCHYMAL CELLS 
There is a growing interest in bone-marrow derived cell products as an innovative 
reconditioning strategy for acute organ injury for different reasons (140). First of all, they can 
differentiate into cells of different germ layers (141) and can produce trophic factors to 
stimulate resident progenitor cells for tissue repair and organ function recovery (142–144). 
Therefore, they are currently being investigated for improving neurological outcome after 
ischemic stroke (145) and improving cardiovascular function after acute myocardial infarction 
(146). Secondly, mesenchymal cell products have been shown to have immunoregulatory 
capabilities by mechanisms that have yet to be elucidated. They are known to modulate T-cell 
alloreactivity (147,148) and are therefore of interest in the treatment of immune and 
inflammatory disorders such as graft-versus-host disease (149,150), inflammatory bowel 
disease (151) and organ transplantation (152,153). Whether these immunoregulatory properties 
might also avoid chronic rejection in solid organ transplantation with low or no 
immunosuppression remains a topic of future studies (154,155).  No large well-designed trials 
are performed yet, and data of their immunoregulatory capabilities is mainly based on in vitro 
studies, therefore it is too early to know whether these therapeutic cell interventions can 
markedly improve outcome in well-selected patients (156). Results of the first Phase I and II 
trials do indicate that administration of mesenchymal cells is safe. However, efficacy is yet to 
be proven in Phase III trials (155).  
Also in the lung, mesenchymal cell products have been investigated in the setting of acute lung 
injury (157–159) and acute respiratory distress syndrome (160), which share common pathways 
with the pathophysiology of PGD. More specifically, pilot studies show that they can reduce 
IRI inherent to solid organ transplantation in the lung (161–163), but also in other organ systems 
(164,165). Here, their beneficial effects probably result from paracrine mechanisms and cell-
cell interaction rather than engraftment and repair of diseased tissue (166). An altered 
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inflammatory balance, with a decrease in pro-inflammatory and increase in anti-inflammatory 
cytokines, has been observed (161). In hypoxic conditions, such as ischemic injury models, 
secretion of growth factors such as VEGF and ANG-1 can stimulate angiogenesis and tissue 
repair (163,167).    
Mesenchymal stem cells and multipotent adult progenitor cells 
The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy defined human mesenchymal stem cells (MSC) using 3 minimal criteria. They must 
be adherent to plastic in standard culture conditions, must have a specific phenotypic profile 
based on positive (CD105, CD73, CD90) and negative (CD45, CD34, CD14 or CD11b, CD79α 
or CD19, HLA-DR) markers and must be able to differentiate in vitro into osteoblasts, 
adipocytes and chondroblasts (168). In 2002, a promising new mesenchymal cell type, the 
multipotent adult progenitor cell (MAPC) has been characterized. The MAPC has an important 
advantage over the MSC: they have a lower senescence than MSCs and can be replicated >70 
times, which allows banking of large amounts of cells and therefore a high potential for clinical 
applications. MAPC cells are now considered to be a distinct cell population (169) with a 
specific phenotypic profile (170). Both the MSC and the MAPC are bone-marrow derived cells 
with many similarities, but due to different culture conditions they adopt different phenotypes 
(169).  
The interest in MAPC cellular therapy in pathologies such as GVHD, chronic rejection in solid 
organ transplantation, inflammatory bowed disease, etc is based on the immunoregulatory 
effect of MAPC on the adaptive immunes system. That is, MAPC cells exert a strong 
immunosuppressive effect on T-cel proliferation, mediated by release of soluble factors such as 
IDO (147). However, the immunological mechanism of PGD mainly involves the innate 
immune system since the adaptive immune response is characterized by low kinetics and is only 
activated after a few days. Only limited in-vitro data of the effect of MAPC on the innate 
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immune system is available. MAPC cells are known to suppress the cytolytic activity of NK-
cells and induce shifting from M1 to M2 macrophage phenotypes by inhibiting release of pro-
inflammatory markers such as MMP-9 (171). An effect on neutrophils, the most important 
effector cell in the pathophysiology of PGD, has not been described so far. In our study, 
investigating new strategies to tackle PGD, we will focus on the impact of MAPC 
administration on the innate immune system which is largely unexplored so far. 
 
We hypothesized that the immunoregulatory properties of MAPC might form a mechanistic 
basis for improving pulmonary graft quality prior to lung transplantation. 
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The success of lung transplantation is critically dependent on the number and quality of donor 
organs. This is currently one of the main challenges to maintain and to improve the outcome 
for patients on the waiting list and recipients after transplantation. Therefore, the overall aim 
of this project is to provide insights in donor organ shortage and to develop strategies to increase 
the number and quality of available donor lungs to improve early outcome after lung 
transplantation.  
We identify two sequential time intervals prior to the lung transplant procedure that determine 
the number and quality of the pulmonary graft (Figure II.1). First, during the donor phase, a 
suitable donor has to be offered and selected for organ transplantation and donor organs have 
to be carefully evaluated in the donor chest or even be treated to improve their quality. Second, 
storage conditions during the preservation phase further define the quality of the lung graft. 
Organs can undergo an additional evaluation outside the donor’s chest during ex-vivo lung 
perfusion or can even be reconditioned prior to transplantation.  
 
Figure II.1 –  Two sequential time intervals where strategies can be implemented to increase both 
number and quality of available donor organs: the donor phase and preservation phase.  
Lung transplantation is a challenging process and its success is already partly determined in the 
donor phase. We will investigate how advancements during the donor phase can increase both 
number and quality of transplantable donor lungs (CHAPTER III). First of all, we will discuss 
a strategy of evaluating more organs (both in-vivo and ex-vivo) to increase the number of 
transplantable donor organs (CHAPTER III.A). Secondly, we aim to provide evidence to 
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support the practice of pre-arrest DCD donor treatment with steroids to improve the quality 
of the donor lung (CHAPTER III.B). 
In CHAPTER IV, we will investigate if EVLP is a useful strategy to increase the number of 
available donor organs during the preservation phase. In CHAPTER IV.A we aim to investigate 
the potential of EVLP to increase the number and quality of donor lungs by a retrospective 
analysis of our donor database data. By providing more information on donor lungs that are 
currently not used in our own transplant center, we will identify and calculate which donor 
organs can be salvaged by EVLP in the future. In CHAPTER IV.B the feasibility of EVLP 
implementation in clinical practice will be demonstrated by a case report of a pediatric 
combined liver-lung transplantation where the lungs were preserved on EVLP while the liver 
was implanted first.  
Reconditioning or actively improving lung graft quality, can be pursued by implementing 
strategies prior (preconditioning), during (perconditioning) or after (postconditioning) injury to 
the donor organ.  
In CHAPTER V, we will investigate reconditioning strategies with the noble gases argon (Ar) 
and xenon (Xe). To protect the alveolar-capillary wall integrity during lung preservation, a 
postconditioning effect (post-injury) of Ar and Xe on warm-ischemic injury will be investigated 
ex-vivo (CHAPTER V.A). In addition, also prolonged exposure to Ar to protect against 
ischemia-reperfusion injury will be investigated (CHAPTER V.B). In this chapter, the effect of 
exposure to Ar prior (preconditioning), during (perconditioning) and after (postconditioning) a 
cold-ischemic insult will be investigated.   
Finally, in CHAPTER VI, multipotent adult progenitor cells (MAPC, bone-marrow derived 
mesenchymal cells) will be investigated as an innovative reconditioning strategy to improve 
donor organ quality prior to lung transplantation by immunoregulatory mechanisms. In 
CHAPTER VI.A, the ideal route of administration (intravenous or intratracheal) will be 
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investigated in a porcine ex-vivo model of warm ischemia. The most potent administration route 
will be further investigated with a higher dose of MAPC to reveal a beneficial effect on the 
inflammatory profile of the donor lung (CHAPTER VI.B). 
 
 
In summary, we aim: 
 To investigate how advancements during the donor phase can increase the number and 
quality of transplantable donor lungs (CHAPTER III). 
 To investigate the potential and feasibility of EVLP as a platform to increase the number 
and quality of transplantable donor lungs during the preservation phase (CHAPTER IV). 
 To investigate the role of noble gases as a reconditioning strategy to improve donor quality 
by better preserving the alveolar-capillary wall integrity (CHAPTER V). 
 To investigate the role of multipotent adult progenitor cells as a reconditioning strategy 
to improve donor organ quality by an immunoregulatory effect (CHAPTER VI). 
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CHAPTER III 
DONOR ASSESSMENT AND TREATMENT 
 
 
 
III.A IN-SITU DONOR LUNG EVALUATION TO MAXIMIZE 
THE LUNG YIELD 
 
 
 
Adapted from: 
Martens A, Neyrinck A, Van Raemdonck D. Accepting donor lungs for transplant: let Lisa 
and Bob finish the job! Eur J Cardiothorac Surg. 2016 Nov;50(5):832-833  
(DOI: 10.1093/ejcts/ezw261) 
Permission to reprint via Copyright Clearance Center's RightsLink service (License Number: 3971301220354)  
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A)  PREFACE 
Until today, assessment of donor lung quality is still based on a limited amount of donor data 
in combination with in situ inspection of the lungs by the procurement team. Therefore, EVLP 
was introduced in 2001, as a method for additional evaluation of lung graft quality in a donor 
of unknown quality (1). Large randomized controlled clinical trials have demonstrated that 
normothermic EVLP for standard-criteria donor (SCD)  lungs is safe, and holds similar short-
term outcome for patients receiving a donor lung that was preserved on ice (2). More recently, 
clinical trials are looking into recruiting more extended-criteria donor (ECD) lungs with EVLP 
to enlarge the donor pool (3). ECD lungs are donor lungs not matching the strict criteria of the 
ideal lung donor. Many centers report similar long-term outcome for ECD lung transplantation 
compared to SCD transplantation. However, early outcome is negatively affected with 
increased duration of mechanical ventilation, prolonged ICU stay and higher incidence of 
primary graft dysfunction (PGD) (4). Careful evaluation of these ECD lungs is therefore 
pivotal. With this reason, retrieval teams are sent out more often to recruit these extended-
criteria donor lungs for EVLP. However, only a minority of extended-criteria donor lungs 
undergo an additional evaluation on EVLP in the end, and still, transplantation of ECD lungs 
seams safe and has similar long-term outcome compared to SCD lungs (5).  
In many transplant centers, donor organ yield has increased due to careful in-situ evaluation of 
the lungs in the donor chest. And thus, by merely evaluating lung quality in the donor chest 
more often, instead of relying on registered donor data only, we can recruit and transplant more 
donor organs.  
We have addressed this observation in an editorial comment on an original article of donor lung 
assessment with pulmonary venous blood gases in the donor chest (6).  
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B)  EDITORIAL COMMENT 
LISA and BOB are acronyms for look inside always and bottom of the basket. These terms are 
taught during training of new cashiers working in shopping centers to thoroughly check bags. 
“You don’t always have to spend thousands of dollars on security measures to prevent 
shoplifting. Taking just a few minutes a day to train your employees on simple tactics to thwart 
a theft will ultimately make your store much more profitable” (7). Similarly, our transplant 
fellows Lisa and Bob when going out on donor runs, should be taught to always look inside the 
chest cavity themselves and recruit the basal parts when assessing donor lungs. 
The selection of donor lungs for transplantation has always been a very subjective process (8). 
Beside interpretation of chest X-ray and bronchoscopic findings, oxygenation challenge with 
lungs ventilated on an inspired oxygen fraction (FiO2) of 1.0 and 5 cmH2O positive end-
expiratory pressure (PEEP) remains a key parameter to judge transplant suitability prior to 
organ recovery. In the early days of lung transplantation, a lower limit for the ratio of partial 
arterial oxygen pressure PaO2/FiO2 of 300 mmHg was arbitrarily chosen as the standard value 
for acceptance. This cut-off point, however, was not based on randomized trials and even not 
on comparative case series studying outcome between patient groups transplanted with donor 
lungs that fall above or below this value (9). PaO2 in the donor is often measured on a sample 
taken from a radial artery catheter. It is well known that this value may differ from samples 
taken more centrally and does not always reflect the true oxygenation capacity of the donor 
lungs. An arterial blood sample also reflects gas exchange in both lungs and does not provide 
any information on each individual lung. Previous studies have demonstrated that gas analysis 
on a sample taken from the pulmonary veins may better reflect the true oxygenation capacity 
of each lung separately (10,11). One study reported that differential pulmonary vein gases better 
predicted primary graft dysfunction after lung transplantation when compared to donor arterial 
blood gas measurements (12).   
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The article by Costa and co-workers from Columbia University Medical Center in New York, 
NY published in this issue of the European Journal of Cardiothoracic Surgery represents the 
largest reported single-center series so far on the use of selective pulmonary vein gas analysis 
in donor lung assessment (6). In a series of 259 brain-dead donors, the last PaO2 in the intensive 
care unit (ICU) poorly correlated with the intraoperative central PO2 taken in the aorta prior to 
cold flush. The investigators have found that intraoperative aortic PO2 had a high sensitivity 
(88%), but a low specificity (24%) with a high false positive rate of 76% when compared to the 
last gas sample taken in the ICU. The balanced accuracy of this test was only 56% indicating 
that many suitable lungs may not be offered with the donor still being in the ICU if low PaO2 
on its own is considered as an absolute contraindication for transplantation. In addition, blood 
samples were taken from left and right pulmonary veins and correlated with intra-operative 
central aortic PO2, bronchoscopic findings and visual assessment of lung collapse upon 
temporary disconnection from the ventilator during organ retrieval. Similar findings of high 
sensitivity, low specificity, high false positive rate, and limited accuracy for central aortic PO2 
were seen when this was correlated with right and left pulmonary vein PO2. PO2 in both right 
and left pulmonary vein was significantly associated (p<0.001) with findings at bronchoscopy, 
palpation, and visual assessment of lung collapse. The authors concluded that pulmonary vein 
gases will provide a more objective measure for the retrieving surgeon, allowing for more 
accurate assessment of individual lungs for transplant suitability. 
The level of arterial oxygen tension largely depends on the degree of shunt flow through 
atelectatic or consolidated lung areas. The central arterial PO2, therefore, reflects a value for 
both lungs together and may be falsely low or high depending on shunt flow in individual lungs 
or lobes. Appropriate ventilatory management of a brain-dead donor in the ICU with a small 
tidal volume (6-8 ml/kg predicted body weight), high PEEP (8 to 10 cmH2O), and continuous 
positive airway pressure during the apnea test and recruitment maneuvers is of paramount 
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importance to improve and maintain oxygenation capacity. In a study by Miñambres and 
colleagues, aggressive donor management resulted in an increase in lung yield with similar 
outcome (13). 
Sticking to ideal criteria will result in approximately 15-20% of donors having lungs suitable 
for transplant (8). Current evaluation of donor lung quality at the time of offer is often 
challenging and quite subjective as gas exchange, chest radiograph, and bronchoscopy may be 
assessed by personnel not familiar with lung transplantation practice and not being aware of 
results when using lung allografts from non-ideal, so called extended-criteria donors. Therefore, 
taking into account transportation costs for a retrieval team to arrive at the donor hospital, lungs 
should be inspected and evaluated inside the donor whenever possible prior to declining the 
offer. Gas exchange should be re-evaluated with the chest open and lungs fully ventilated after 
recruitment of atelectatic zones. It is interesting to see that with increasing practice of ex-vivo 
lung perfusion (EVLP), many more questionable donor lungs are now being accepted for 
immediate transplantation after arrival of the retrieval team in the donor hospital with no further 
need for assessment with EVLP when back in the recipient hospital. The lesson we should 
remember from this paper by the Columbia University transplant group is the following: “in 
order to maximize the yield of donor lungs for transplantation, a retrieval team should be sent 
to the donor hospital for in-situ evaluation whenever possible; let Lisa and Bob finish the job”. 
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CHAPTER III 
DONOR ASSESSMENT AND TREATMENT 
 
 
 
III.B PRE-ARREST DONOR TREATMENT WITH STEROIDS 
IMPROVES LUNG GRAFT FUNCTION 
 
 
 
Adapted from: 
Martens A, Boada M, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, et al. Steroids 
can reduce warm ischemic reperfusion injury in a porcine DCD model with EVLP evaluation. 
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A)  PREFACE 
In the previous chapter, we have shown that the number of transplantable donor lungs can be 
increased by careful in situ inspection of the lung graft. In this chapter, we will provide 
experimental data on a strategy to improve not only the number, but also the quality of the lung 
graft for transplantation. Donor management is an intensive task at the intensive care unit, 
aiming at stabilizing the brain-dead donor and attenuating the systemic inflammatory response 
that coincides with brain death. Forasmuch, current recommendations advice to implement 
corticosteroids in the management of brain-dead donors. For donors who die after circulatory 
arrest, such recommendations are non-existent since the dead-donor rule impedes any pre-
mortem intervention. Nevertheless, over 90% of centers using DCD organs report that steroids 
are applied prior to circulatory arrest in their center. However, this practice is based on limited 
data from DCD observational studies only. Therefore, we aimed at providing pre-clinical 
evidence to support this practice of pre-arrest DCD donor treatment with steroids to improve 
organ quality prior to transplantation.  
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B)  ABSTRACT 
Donation after circulatory death (DCD) is being used to increase the number of transplantable 
organs. The role and timing of steroids in DCD donation and ex-vivo lung perfusion (EVLP) 
has not been thoroughly investigated. In this study, we investigated the effect of steroids on 
warm-ischemic injury in a porcine model (n=6/group). Following cardiac arrest, grafts were 
left untouched in the donor (90 min warm ischemia). Graft function was assessed after 6 hours 
of EVLP. In MP-group, 500 mg methylprednisolone was given prior to cardiac arrest and during 
EVLP. In CONTR-group no steroids were added. Median lung compliance (13 ml/cmH20) was 
significantly better preserved in MP-group than in CONTR-group (30.5 ml/cmH20). Also, 
median wet-to-dry-weight (6.11 vs 6.94) and CT-density (182.5 vs 352.9 g/L) were 
significantly better in MP-group than in CONTR-group, respectively. There was no difference 
in oxygenation and pulmonary vascular resistance. Perfusate cytokine analysis showed a 
significant reduction in IL-1β, IL-8, IFN-α, IL-10, TNF-α and IFN-γ in MP-group. Cytokines 
in bronchoalveolar lavage were not decreased except for IFN-γ. We demonstrated that warm-
ischemic injury in DCD donation can be attenuated by steroids when given prior to warm 
ischemia and during EVLP. Ethical context of donor preconditioning should be discussed 
further.  
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C)  INTRODUCTION 
Lung transplantation remains the only life-saving treatment option for patients suffering from 
end-stage pulmonary disease. Due to its success, lung transplant programs worldwide are 
increasing with over 4000 lung transplant procedures performed annually (1). However, there 
is an on-going disparity between the number of patients on the waiting list and the number of 
good quality donor organs for transplantation. This leads to increased waiting times and a 
persistent mortality on the waiting list as high as 15% (2).  
Because of this organ shortage, other sources of organ recovery besides the classical brain-dead 
donor (DBD) are being addressed nowadays. Over the years, organ donation after circulatory 
death (DCD) has been re-introduced in transplant programs with a marked increase since 2001 
(3–5). On average only 7% of all lung grafts are derived from DCD donors according to the 
latest registry analysis; however in some programs this reaches up to 32% (3). Generally, DCD 
donation is classified into two main categories and further subdivided following the Maastricht 
classification (6). In uncontrolled DCD donation the patient is found with circulatory arrest, is 
dead upon arrival or dies after unsuccessful resuscitation. Controlled DCD donors represent 
patients who die after a switch-off of mechanical, ventilated or organ-perfusion supported 
therapies or when circulatory arrest occurs prematurely in a DBD donor. To optimize lung 
preservation and limit the impact of warm ischemic injury, several strategies have been 
explored. Topical cooling by insertion of chest tubes can be applied in the controlled setting, 
but is mostly used in uncontrolled DCD donation (7,8). In controlled donation the current 
clinical practice includes rapid flush perfusion (antegrade in the donor and retrograde at the 
back-table after organ recovery) (9). Pre-arrest interventions are mainly limited to 
heparinisation if legally authorized. This can theoretically be beneficial as confirmed by 
experimental data (10). However, clinical studies comparing strategies with and without 
heparin are lacking. In fact, several centers report good outcome without pre-arrest 
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heparinisation (11). These centers do use a retrograde flush in its heparin-free scenario which 
also seems protective (12).  
In all scenarios, DCD organs suffer from a variable period of warm ischemia which could lead 
to increased ischemia-reperfusion injury and a reduction in organ quality. The tolerable length 
of this warm-ischemic interval for lungs can be extended up to 60-90 minutes (13,14). To assess 
organ quality of lungs donated by a DCD donor prior to transplantation, ex-vivo lung perfusion 
(EVLP) has been developed (15). With this technique of machine perfusion, lungs are perfused 
by a pump and ventilated under normothermic conditions. During EVLP, lungs can be 
physiologically evaluated and nowadays new imaging techniques can even be applied to fully 
assess the organ of previously unknown quality (16). Since the introduction of EVLP in 2001 
by Steen et al (17) there is the actual potential to evaluate the donor organ prior to 
transplantation. This is especially recommended in uncontrolled DCD donation programs 
where outcomes are better when EVLP is applied (8). Currently, in only 12% of controlled 
DCD, EVLP is clinically applied (3). Some groups do report better outcome in controlled DCD 
donation (18) when lungs have been perfused and evaluated on EVLP. Therefore, it may be 
advisable to consider this technique as a platform to assess the risk for severe ischemia-
reperfusion injury (IRI) to decide on the optimal preservation strategy based on physiological 
evaluation. This opens up the ability to even recondition donor lungs of unknown or inferior 
quality prior to transplantation. Hereby, an increase in available donor organs with optimal 
quality is expected (19,20).  
Steroids are among the most potent anti-inflammatory and immunosuppressive agents. In the 
airways, they bind to the glucocorticosteroid receptors which are ubiquitously expressed in all 
cells throughout the airways. After translocation to the cell nucleus, they inhibit nuclear factor 
kappa B (NF-B) activation followed by blockage of pro-inflammatory genes (21–23). 
Therefore, steroids are of particular interest in ischemia-reperfusion injury remodeling. They 
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are already a component of the perfusate used in the majority of EVLP protocols (15). However, 
the exact role of steroids during EVLP has never been elucidated and comparative data of EVLP 
with- and without methylprednisolone is lacking. Besides ex-vivo administration of steroids, 
these immunomodulatory drugs can also be administered to the donor. Most brain-dead patients 
are now treated with steroids before procurement of the organs. The rationale to add steroids in 
the donor is to block the upregulation of several pro-inflammatory cytokines during the onset 
of brain death and improvement of hemodynamic instability following adrenal insufficiency  
(24). The evidence, however, is not robust based on a recent meta-analysis (25). In addition, 
besides these potential benefits in DBD donors, their role in warm-ischemic injury and DCD 
donation has never been investigated. Nevertheless, over 90% of centers using DCD organs 
report that steroids are applied prior to circulatory arrest (3). 
We aimed to investigate the role of steroids in DCD lung donation to protect against warm 
ischemia-reperfusion injury. Therefore, in this study, we hypothesized that administration of 
steroids prior to onset of warm ischemia and during EVLP has a beneficial impact on pulmonary 
graft function. 
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D)  METHODS 
This experimental study was performed in compliance with the Principles of Laboratory animal 
care published by the National Institute of Health Volume 25, No. 28 (revised 1996). Local 
ethics approval was obtained at the research institute (NTS P043/2014).  
Donor procedure 
Domestic pigs Topig 20 (mean 40.75 kg) were divided into 2 groups (n=6/group). Animals 
were anesthetized with an intramuscular injection of 5 mg/kg Zoletil 100® (Virbac, Carros, 
France) and 3 mg/kg Xyl-M® 2% (VMD, Arendonk, Belgium). Anaesthesia was maintained 
using 10 mg/kg/h propofol, 20 µg/kg/h fentanyl and intermittent boli of pancuronium 2 mg for 
muscle relaxation. Animals were intubated with a 7.0 mm endotracheal tube and ventilated 
(Aestiva 3000; GE Healthcare Europe GmbH, Little Chalfont, UK) with a tidal volume (TV) 
of 8 ml/kg, positive end-expiratory pressure (PEEP) of 5 cmH2O and FiO2 of 30%. Respiratory 
rate (RR) was adjusted to the end-tidal carbon dioxide (ETCO2) (45-55 mmHg). Blood pressure 
was monitored invasively in the right carotid artery. All animals died of cardiac arrest which 
was induced by direct electrical stimulation of the myocardium with an electrical pulse 
generator that led to ventricular fibrillation. Animals were disconnected from the ventilator 
when cardiac arrest was induced. Prior to cardiac arrest, all animals were heparinized with 300 
IU/kg. In group 1, 500 mg Solu-Medrol (Pfizer, Brussels, Belgium) was given prior to induction 
of ventricular fibrillation (MP-group). In group 2, no steroids were administered to the donor 
animal (CONTR-group). 
Following cardiac arrest in the donor, grafts were left untouched in the deceased donor for 90 
minutes after which they were flushed antegradely with 50 ml/kg cold thromethamol-buffered 
OCS Solution (Transmedics, Andover, USA). The heart-lung block was excised and a 
retrograde flush (1 L thromethamol-buffered OCS solution) was performed at the back table. 
Lungs were instrumented on ice for a short period of time (73.2  7.5 min) while the XVIVO 
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(Göteborg, Sweden) cannulas were secured in the pulmonary artery and atrial cuff. An 8.0 mm 
ET tube was secured in the trachea. The donor procedure was performed as previously 
described (26). 
Ex-vivo lung perfusion 
After a 1-hour rewarming period and slow increase of the flow to 40% of the estimated cardiac 
output (calculated as 100 ml/kg), lungs were further perfused and evaluated for 6 hours in total. 
Lungs are perfused with an acellular albumin containing dextran solution. The production of 
the perfusate and technique of EVLP are performed as described previously (26). In the 
CONTR-group, no steroids were added to the perfusate. In the MP-group, 500 mg Solu-
Medrol (Pfizer, Brussels, Belgium) was added to the perfusate to continue the steroid-
exposure to the preconditioned grafts in the MP-group in order to investigate the maximal effect 
of steroids to DCD-grafts. 
During 6 hours of EVLP we monitored dynamic airway compliance (Compl), oxygenation 
(PaO2/FiO2) and pulmonary vascular resistance (PVR) hourly. We analyzed end-experimental 
parameters only to dichotomize between acceptable and non-acceptable lungs. 
Tissue sampling 
At the end of the experiment, tissue samples were taken for histological evaluation and wet-to-
dry-weight (W/D) ratio calculation (after 48 hrs in the oven at 80°C). Pathology samples are 
scored by a blinded pathologist for neutrophilia, congestion and presence of eosinophils. 
Bronchoalveolar lavage with 2 times 30 cc saline 0.9% was performed in the right middle lobe. 
Pooled fractions were returned and the supernatant was analyzed with a porcine multiplex 
ELISA kit for IL-1β, IL-4, IL-8, IL-10, IFN-γ, IFN-α and TNF-α according to the 
manufacturer’s protocol (Thermo Fisher Scientific Inc, Massachusetts, USA). Also perfusate 
samples from the end of the experiment were analyzed with the same ELISA analysis. The left 
lung was inflated at 25 cmH2O, frozen solid in the fumes of liquid nitrogen and scanned with 
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Siemens Somaton CT scanner (Siemens Healthcare, Erlangen, Germany). Lung mass, volume, 
and density were measured on the basis of the CT-scan, using imaging software (HorosTM) in 
which the lung is manually delineated and the number of voxels and mean density of the voxels 
within the volume is determined (27). 
Statistical analysis 
All data are expressed as median with IQ range when depicting physiological variables in time 
or as a scatter plot with median and IQ range when comparing variables at the end of the 
experiment (GraphPad Prism 4, GraphPad Software Inc, La Jolla, USA). Permutation tests were 
conducted in R (R Foundation, Vienna, Austria) using the “coin” package to compare data at 
the end of EVLP. Baseline parameters of the donor animals are described as median (25% QI 
– 75% QI) and are analyzed with the same permutation test.  
In cases where lungs could not sustain the full 6 h of EVLP, data points recorded in the next 
hours after the premature end of EVLP were considered the same as the last data point available 
to allow comparison at all evaluation points. Therefore, at the end of EVLP the last available 
data point is included for the statistical analysis. Graft survival on EVLP is analyzed with a log 
rank test in GraphPad Prism 4 (GraphPad Software Inc, La Jolla, USA). 
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E)  RESULTS 
Groups 
Baseline parameters are illustrated in Table III.1. 
Table III.1 –  Baseline parameters of the donor animals.  
 
 
Data are presented as median (25% - 75% IQR); p-value permutation test.  
TV = tidal volume; HR = heart rate; MAP = mean arterial pressure; Compl = Dynamic airway 
compliance; PaO2/FiO2 = partial oxygen pressure over fractional inspired oxygen 
concentration; Hct = hematocrit; WBC = white blood cell count; CIT = cold-ischemic time 
Functional assessment of pulmonary grafts during EVLP 
Figure III.1A depicts the change of dynamic airway compliance over time (median ± IQR). It 
is similar at the onset of evaluation (starting after 1 hour of EVLP). After the first recruitment 
maneuver at 1.5 hrs perfusion, compliance increased in both groups followed by a gradual 
decrease. When comparing the dynamic airway compliance at the end of EVLP (Figure III.1B), 
we noted that it was significantly better preserved in the MP-group (median Compl 13.0 
ml/cmH20 in CONTR vs 30.5 ml/cmH20 in MP-group; p=0.03). 
Figure III.1C depicts the change in oxygenation (evaluated by PaO2/FiO2) over time (median ± 
IQR).  PaO2/FiO2 decreased in both groups and was also not significantly different when 
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comparing it at the end of the experiment (median PaO2/FiO2 487 in CONTR vs 430 in MP-
group; p=0.59) (Figure III.1D).  
Figure III.1E depicts the change in pulmonary vascular resistance (PVR) over time (median ± 
IQR). PVR is low in both groups at the first evaluation moment (1 hr perfusion). During the 
experiment, PVR slowly increases in both groups. When comparing PVR at the end of EVLP 
(Figure III.1F), we observed a similar PVR in both groups (median PVR 474 dynes*s*cm-5 in 
CONTR vs 430 dynes*s*cm-5 in MP group; p=0.82). 
 
Figure III.1 –  Dynamic airway compliance, oxygenation (PaO2/FiO2) and pulmonary vascular 
resistance are depicted during the 6 hours of ex -vivo lung perfusion in figure 1A, C, E 
respectively (median ± IQR) for both groups. Compliance, oxygenation and PVR are depicted at 
the end of EVLP (scatter plot median ± IQR) in figure 1 B, D, F respectively. A permutation test 
shows significantly better airway compliance at the end of EVLP in the MP -group (p=0.0304). 
All other parameters are not significantly different.  
For all experiments in the MP-group, grafts could be perfused for 6 hours. In the CONTR-group 
however, there was a drop-out of 3 experiments where perfusion was ended on 3.75, 4.0 and 
4.5 hrs respectively due to excessive edema formation (Figure III.2). The superior survival of 
the grafts in the MP-group nearly reaches significance (p=0.06). 
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Figure III.2 –  Survival of the lung graft on EVLP, perfusion was ended when 1000  ml of perfusate 
was transformed in lung edema and ventilation was impossible. There was a trend in better graft 
survival in the MP-group that only just failed to reach sig nificance (log rank test p=0.06).  
Assessment of pulmonary edema 
A high W/D (median 6.9) is observed in the CONTR-group, and a low W/D (median 6.1) in 
the MP-group. W/D weight ratio is significantly lower (p=0.02) in the group that received 
methylprednisolone (Figure III.3A). Density measurements on CT-scan confirmed this excess 
of extravascular lung water accumulation and showed a significantly higher (p=0.002) density 
in the CONTR-group (median 353 g/L) compared to the MP-group (median 183 g/L) (Figure 
III.3B). Septal thickening and severe lung edema can clearly be visualized in the CONTR-group 
(Figure III.3C) in comparison to the MP-group (Figure III.3D). 
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Figure III.3 –  A) W/D is depicted as a scatter plot (median ± IQR). A permutation test of the 
W/D shows significantly less lung edema  in the MP-group (p=0.02). B) CT-scan density is 
depicted as a scatter plot (median ± IQR). A permutation test shows a significantly higher CT-
density in the CONTR-group compared to the MP-group (p=0.002). C) CT-scan of left lower lobe 
in CONTR-group. D) CT-scan of left lower lobe in MP-group.  
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Histology 
Histological analysis of lungs in the MP-group did not reveal any significant differences in 
congestion (p=0.58), neutrophil invasion (p=0.13) and membrane disruption (p=0.21) 
compared to the CONTR-group (Figure III.4). 
 
Figure III .4 –  Similar histologica l findings in CONTR-group (left) as in MP-group (right)  
Immunological evaluation 
Porcine multiplex analysis of the perfusate sample (Figure III.5) at the end of EVLP showed a 
median IL-1β level of 124.6 pg/ml in the CONTR-group vs 39.8 pg/ml in the MP-group 
(p=0.002); a median IFN-α level of 94.6 pg/ml in the CONTR-group vs 0.7 pg/ml in the MP-
group (p=0.004); a median TNF-α level of 3181 pg/ml in the CONTR-group vs 226 pg/ml in 
the MP-group (p=0.008); a median IL-10 level of 94.6 pg/ml in the CONTR-group vs 0.7 pg/ml 
in the MP-group (0.004) and a median IFN-γ level of 2.8 pg/ml in the CONTR-group vs 0.08 
pg/ml in the MP-group (p=0.005). IL-8 was above detection limit in the CONTR-group (highest 
standard depicted), but low in the MP-group (median 45.3 pg/ml). IL-4 was below the detection 
limit. 
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Figure III.5 –  Porcine multiplex analysis of the perfusate samples at the end of EVLP. IL-1β,  
IFN-α , TNF-α , IL-10 and IFN-γ  are all significantly lower in the MP-group. IL-8 was above 
detection limit in the CONTR-group, but low in the MP-group. IL-4 was below detection limit 
and is not depicted. Data points are depicted  in a scatter plot with median ± IQR and the 
resulting p-value of the permutation test.   
Multiplex analysis of the BAL fluid at the end of EVLP showed a median IL-1β level of 36.5 
pg/ml in the CONTR-group vs 34.2 pg/ml in the MP-group (p=0.29); a median IFN-α level of 
0.36 pg/ml in the CONTR-group vs 0.38 pg/ml in the MP-group (p=0.56); a median TNF-α 
level of 234 pg/ml in the CONTR-group vs 105 pg/ml in the MP-group (p=0.17) and a median 
IL-8 level of 174.2 pg/ml in the CONTR-group vs 61.8 pg/ml in the MP-group (p=0.06). IFN-
γ was significantly lower (p=0.02) in the MP-group (median 0.05 pg/ml) compared to the 
CONTR-group (median 0.1 pg/ml). IL-10 and IL-4 were both below the detection limit. 
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F)  DISCUSSION 
We report our experimental findings on the role of steroids in a DCD model of organ donation. 
To our knowledge, this is the first experimental report on the use of steroids in a DCD donor. 
We demonstrated that administration of steroids prior to warm ischemia and during EVLP 
evaluation significantly improved lung function, lung edema and reduced a subset of 
inflammatory markers. 
By giving steroids to the donor prior to the onset of warm ischemia and further exposure to 
steroids during EVLP, we observed improved lung compliance at the end of EVLP. Pulmonary 
vascular resistance and oxygenation did not differ between both groups. However, it has 
previously been advocated that compliance is the best parameter to predict donor lung quality 
(28,29) since this parameter directly reflects the impact of fluid extravasation in the lung. Also, 
physiological acceptance criteria for transplantation after EVLP are not yet been agreed upon, 
and other groups do advocate the use of oxygenation and pulmonary vascular resistance as the 
best evaluation parameters with excellent results after transplantation (30). W/D is still the 
golden standard for estimation of lung edema, and in our experimental study it was significantly 
lower in the MP-group. This could be further validated by a lower density measurement in the 
methylprednisolone group on CT-scan. The latter provides assessment of the whole lung 
surface, while a biopsy provides information only on a small portion of the tissue. 
Implementation of CT-scanning might be considered as a valuable non-invasive tool to measure 
pulmonary edema. 
The cytokine expression profile of lungs in both groups was represented by evaluating 
cytokines in both the circulating perfusate and BAL (at the end of EVLP). Administration of 
steroids to the donor in addition with exposure to steroids during EVLP resulted in a decreased 
level of cytokine production and release, especially in the perfusate. Also, this reflects a reduced 
organ inflammation, but the role of cytokine expression on EVLP is still largely unknown (31). 
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It might be that a different pattern of cytokines is expressed during ex vivo organ perfusion that 
does not completely reflect the in vivo reperfusion situation. We used an acellular perfusate and 
the reperfusion injury observed during our set-up is mainly driven by resident leukocytes in the 
pulmonary graft. This expressed cytokine panel also suggest an important role for macrophage 
secretion. The observation that the anti-inflammatory cytokine IL-10 was also significantly 
reduced indicates that we should better look at the balance between pro- and anti-inflammatory 
mediators, rather than the absolute concentration. 
Early outcome after lung transplantation is mainly impaired by the occurrence of severe primary 
graft dysfunction (PGD) driven by ischemia-reperfusion injury and occurs in up to 30% of lung 
transplant recipients (32,33). Despite better supportive treatment options such as extra-
corporeal membrane oxygenation (34) to limit early mortality from severe PGD, this syndrome 
has a significant impact on long-term outcome with an increased 90-day and 1-year mortality 
after severe PGD at 72 hrs after lung transplantation (33). Also, there is an increased risk to 
develop bronchiolitis obliterans syndrome (BOS) (32,35–37) following high-grade primary 
graft dysfunction. 
In addition, the use of DCD organs itself seems to be an increased risk factor for PGD. Although 
similar short- and long-term outcomes between DBD and DCD donors have been reported (38–
40). Therefore, it is of great interest to limit primary graft dysfunction after lung transplantation 
with a specific strategy such as steroid administration. The possible benefit of steroid 
administration is already been highlighted in brain-dead organ donation (25,41). That is, 
steroids can suppress the cytokine release during the catecholamine storm and improve 
hemodynamic stability in adrenal insufficient patients (25,42). Controlled DCD donors suffer 
an agonal phase that is unpredictable, prior to circulatory arrest. This agonal phase can add a 
large variability to the injury and is difficult to standardize. In a previous study (43) we have 
investigated the impact of different modes of death in DCD donation. We could identify that 
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hypoxic arrest was more detrimental to the graft quality (44). In our current study, we have 
chosen to work with a standardized warm-ischemic porcine DCD model, with immediate onset 
of the warm-ischemic interval by induction of ventricular fibrillation and disconnection of the 
ventilator (in a paralyzed animal). In this way, we could better standardize the warm-ischemic 
injury (still the most important component of IRI in DCD donation). The effect of steroids in a 
controlled DCD model induced by hypoxic arrest with variable periods of warm ischemia is 
also an interesting study to conduct in the future. 
The major limitation of this study is the absence of a control group where steroids are used only 
in the donor animal. However, steroids are included in all EVLP protocols without convincing 
evidence for a beneficial effect on PGD. Based on previous preliminary data in our laboratory 
we are confident that steroid administration post-injury during EVLP only, cannot reverse 
warm-ischemic injury. This is also shown from other research experiments where steroids are 
applied in the perfusate in both control and treatment groups (45–47). Therefore, we believe 
that it is the administration of steroids to the DCD donor prior to circulatory arrest that is 
important for optimal organ preservation to alleviate warm-ischemic damage. The 
administration window of preconditioning and preservation strategies is still largely unknown. 
In order to avoid missing any positive effect by focusing on a narrow window, we chose to 
expose the grafts to steroids throughout the whole experiment. Of course, further experiments 
should now be designed to elucidate the role of the pre-arrest donor treatment or treatment of 
the graft during EVLP only. Also, our findings need to be validated in a transplant model. 
In case of donation after brain death (DBD), the advantage of using steroids has been 
investigated previously (25). However, the role of steroids in DCD donation has never been 
investigated. The reason is two-fold: firstly, DCD donation has only recently become of higher 
interest and research in donor management of the DCD donor is limited and difficult to design. 
Secondly, the dead donor rule impedes on any intervention in the patient awaiting therapy 
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withdrawal (controlled DCD donor) (48). However, harmless therapies such as the use of 
heparin have been widely adopted in various European countries to be used in DCD protocols 
(3,10). A relation between the administration of heparin and the acceleration of the dying 
process has not been demonstrated so far. We do not know if there is a relation between the 
dying process or length of the agonal phase and the administration of high dose glucocorticoids. 
This opens up the discussion about expanding donor management to DCD, as it is more and 
more applied in DBD programs.  Since steroids are not harmful to patients, we believe that 
steroid administration to DCD donors should be considered. Despite this ethical issue, the latest 
report of the DCD-registry within the International Society of Heart and Lung Transplantation 
noted that already over 90% of the participating centers give steroids to the DCD donor prior 
to declaration of dead (3). Unfortunately, there is no data available on the doses, frequency and 
timing of steroid administration in the DCD donation process. We therefore do not know 
whether steroids were administered during the ICU admission as a treatment to reduce cerebral 
edema, or whether it was administered to optimize donor organ quality. If these steroids would 
have been administered intentionally to optimize donor quality, this course of action coincides 
with the dead-donor rule since therapy is given to a patient who is not declared dead yet. Some 
believe that this policy could bring harm to transplant programs. However, others believe that 
once the decision for switch-off and organ donation has been made, one can go forward with 
donor management and optimization protocols which should be performed by an independent 
team to avoid any conflict of interest or harm to the donor. We believe that our findings should 
further be embedded in an ethical discussion to decide if pre-treatment in a DCD donor is 
ethically and legally acceptable. Donor management of a DCD donor would however be most 
feasible with interventions that are beneficial when applied only just prior to circulatory arrest 
(as shown in these experiments). This avoids implementation of complex and time-consuming 
management protocols prior to the controlled DCD procedure.  
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We conclude that administration of steroids to a DCD donor and during ex-vivo lung perfusion 
attenuates warm ischemia-reperfusion injury. The role of steroids during ex-vivo lung perfusion 
only should be the subject of future research. In addition, a study on the effect of steroids 
administered only to the donor, in a controlled DCD model with hypoxic arrest will also add 
knowledge in the future. We advocate the use of steroids in clinical DCD programs worldwide, 
with caution to further introduce preconditioning strategies prior to declaration of death in organ 
donation programs. 
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A)  PREFACE 
In the previous chapter (chapter III), we showed that advancements during the donor phase can 
increase both number and quality of transplantable donor lungs. In this chapter, we will focus 
on optimization of the preservation phase by investigating the actual potential and clinical 
implementation of ex-vivo lung perfusion (EVLP). EVLP is a normothermic preservation 
strategy, used as an alternative to cold static preservation. It allows for additional evaluation, 
optimal preservation and even improvement of lung quality prior to transplantation. Therefore, 
it is introduced as the ideal method to increase both number and quality of donor lungs. 
However, the true impact of EVLP is still largely unknown. In this chapter, we report on our 
analysis of registered donor data of donors whose lungs were not transplanted, to provide 
insights in which lungs can potentially be recovered by EVLP to increase number and quality 
of transplantable donor lungs.  
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B)  ABSTRACT 
Background - Ex-vivo lung perfusion (EVLP) is already being used for both standard and 
extended-criteria donor (ECD) lungs. For further expansion of the transplant activity, we might 
have to extend the threshold for ECD donation. The purpose of this study was to estimate how 
many of those ECD lungs could be recruited by EVLP. 
Methods - We reviewed all multi-organ donors (MODs) from our collaborative donor hospitals 
(January 2010 - June 2015). All unused lung donors, were categorized using registered donor 
data and evaluated by two independent investigators to identify which lungs could be 
transplanted after EVLP. 
Results - 584 MODs were registered at our transplant center within our collaborative donor 
hospitals network. 268 (45.9%) were declined as lung donor at the moment of registration 
(“declined as lung donor”) and 316 (54.1%) were considered as a donor for lung transplantation 
("considered as lung donor"). In the latter, lungs from 220 (37.7%) donors were transplanted 
and 96 donors (16.4%) were not. Donors whose lungs were not transplanted (declined and 
considered) were categorized as: no consent; donor-related factors; death-related organ injury; 
logistical reason; unknown. Across the different groups, we identified 78 out of 364 declined 
donors (21.4%) whose lungs could benefit from EVLP; and potentially become suitable for 
lung transplantation.  
Conclusions – With this retrospective database analysis of unused lung donors, we identified 
a large potential for EVLP to further increase the donor pool in transplant centers where the 
majority of donor lungs are already extended. 
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C)  INTRODUCTION 
Lung transplantation has become a successful treatment strategy for an increasing amount of 
well-selected patients with end-stage pulmonary diseases, due to surgical improvements and 
the development and optimization of immunosuppressive therapy. Unfortunately, only a small 
proportion of multi-organ donors (MODs) are currently suitable to donate lungs for 
transplantation. Reported acceptance rates vary from 15 to 35% between centers (1,2). 
Consequently, the patients on the waiting list outnumber the amount of transplantable organs, 
resulting in a persistent waitlist mortality (3).  
Therefore, many strategies have been explored to increase the availability of transplantable 
donor lungs to improve outcome for patients in need of a pulmonary allograft (4,5).  
First, we are increasingly transplanting donor organs that do not fulfill the strict criteria of lung 
transplantation, the so-called extended-criteria donors (ECD) to enlarge the existing pool of 
standard-criteria donors (SCD) (6). Secondly, ex-vivo lung perfusion (EVLP) was introduced 
in the lung transplant field by Stig Steen in 2001, as a tool to expand the current donor pool by 
re-evaluating donor lungs prior to transplantation (7). EVLP is a normothermic perfusion 
technique that can be achieved by a pump-driven perfusion machine which circulates a 
preservation solution through the vasculature of the lung. Lungs are also ventilated ex-vivo and 
can be continuously monitored and evaluated. Therefore, it has been proposed as the ideal 
method to recruit more donor organs as we can evaluate questionable donor organs and 
potentially even increase their quality. Recently we became interested in not only re-assessing 
the donor organ on EVLP, but also preserving it in superior circumstances compared to static 
cold preservation. 
Several research groups have already published their initial experience with perfusing high-risk 
or extended-criteria donor lungs with EVLP prior to transplantation to expand the donor pool 
(8,9). However, although some groups classify these ECD donor lungs as “initially rejected 
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donor lungs” (10,11), we believe that EVLP is not always mandatory to safely transplant ECD 
lungs. Both short-term and long-term outcome after ECD lung transplantation without EVLP 
has been reported to be comparable with SCD donor lung transplantation provided that they are 
allocated to a suitable patient with an acceptable survival probability (12,13). Also in our center, 
ECD lung transplantation results in comparable long-term outcome compared to SCD lung 
transplantation (6,14). 
If we want to further implement EVLP in clinical practice, it is crucial to estimate the potential 
of EVLP to increase transplant activity and donor organ quality. Therefore, the aim of this study 
was to retrospectively review our database of multi-organ donors and to analyze the reasons of 
donor lung decline and the conditions where lungs could be salvaged by EVLP technology. 
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D)  METHODS 
Data collection and categorization 
We retrospectively reviewed our database of all MODs offered to our center from January 2010 
until June 2015. Our transplant center is organized within a network of 33 collaborative donor 
hospitals and we report all offers within this network to Eurotransplant. 
First, we divided all MODs in two categories: “declined as lung donor” and “considered as 
lung donor”. The decision to consider a MOD as a potential lung donor, was driven by the 
expert opinion of our transplant physicians that is based on interpretation of both medical and 
technical information provided by the donor center. MODs considered to be good candidates to 
donate lungs for transplantation were allocated by Eurotransplant, based on international 
allocation rules (15). The actual number of donors whose lungs were finally accepted for 
transplantation were recorded, these lungs could be allocated by Eurotransplant first to other 
centers or were transplanted in our center based on our local allocation system. They were 
categorized as ECDs if one or more of the following criteria was met: age>55, PaO2/FiO2<300, 
abnormal chest x-ray, smoking history, presence of aspiration, presence of chest trauma or 
donation after circulatory death (DCD). All other lungs were considered SCDs. 
Secondly, we categorized all MODs whose lungs were not transplanted. This group included 
the lungs that were initially declined as lung donor (“declined as potential lung donor”), the 
grafts that were declined after receiving additional information from the donor center prior to 
leave for procurement (“declined without in situ evaluation”) and the grafts that were ultimately 
declined in situ after opening the chest with direct macroscopic assessment of the lungs 
(“declined after in situ evaluation”).  
Next, data of donors whose lungs were not transplanted were re-assessed individually by two 
independent investigators to identify the reason for decline. This assessment was done using 
the available donor data within the database and based on consensus between the investigators. 
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With this information, all non-transplanted donor lungs were assigned to subcategories listed 
in Table IV.1. If more than one reason was identified, the most important factor (as assessed by 
the investigators) was listed.  
Table IV.1 -  Subcategories of lung donors declined for transplantation  
 
EVLP candidate selection 
Finally, two investigators (A.M. & A.P.N) identified potential donor grafts among the non-
transplanted organs that could be salvaged by using EVLP technology. The manner of 
recovering these organs was based on reassessment (additional evaluation of the organ 
function), improved preservation (prolonged out-of-body time) and reconditioning (potential 
improvement of specific injuries during EVLP). The selection criteria for currently rejected 
donor lungs that potentially could be salvaged by EVLP were: neurogenic lung edema, 
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pulmonary emboli, PaO2/FiO2 below 300 without obvious explanation, minor pulmonary 
infections (consolidation on chest x-ray or purulent sputa with PaO2/FiO2 above 200), unknown 
warm-ischemic time and logistical reasons for donor lung decline (extended time for allocation 
or to schedule the transplant procedure) (Table IV.2). 
Table IV.2 –  Selection criteria for rejected donor lungs to be recovered by EVLP  
 
PaO2 / FiO2 = Partial oxygen pressure / fractional inspired oxygen concentration  
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E)  RESULTS 
Categorization of MOD offers 
584 MODs were recorded at our center between January 2010 and June 2015 (= “multi-organ 
donors”).  
Of those 584 MODs registered within our collaborative donor hospitals, 268 (45.9%) were 
declined as lung donor and lungs were not allocated (= “declined as potential lung donor”). 
316 (54.1%) MODs were considered as a lung donor (= “considered as potential lung donor”) 
and were reported to Eurotransplant for allocation. However, 53 (9%) were declined based on 
additional information or second evaluation of donor data by the transplant center to which 
lungs were allocated (= “declined without in situ evaluation”). Another 43 (7.4%) were 
declined upon procurement in the donor hospital (= “declined after in situ evaluation”).  
Lungs from 220 MODs were successfully transplanted (= “transplanted”). Of those, 72% could 
be categorized as ECDs based on previously published criteria (6), and only 28% were SCDs. 
Donor characteristics of the individual categories are listed in Table IV.3.  
Declined lung donors 
In the “declined as potential lung donor” group, 3 MODs were declined since there was no 
consent for organ donation. Donor-related factors (n=106) included: old age (n=58), a history 
of smoking or COPD (n=35), or a significant medical history (n=13) such as pulmonary 
hypertension, cardiovascular disease and malignancy. Death-related organ injury (n=150) 
included: abnormal chest X-ray/arterial blood gases/bronchoscopy results (n=71), pulmonary 
infection (n=32), aspiration (n=19), poly-trauma with lung contusion (n=14), DCD category II 
(n=7), a hemodynamic instable donor with unknown warm ischemic time (n=4), presence of 
pulmonary emboli (n=2), or neurogenic lung edema (n=1). In 9 cases, no obvious reason could 
be identified why lungs were not transplanted based on the registered donor data and medical 
investigations.   
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Table IV.3 –  Descriptive analysis of all MODs and their subgroups  
 
Lung donor score determined by Eurotransplant (ET) criteria (13) 
In the “declined without in situ evaluation” group (n=53), no suitable recipient could be found 
in time within the Eurotransplant database in 22 cases. The lung procurement team did not 
arrive on time in 4 cases where the abdominal procurement team already started to avoid long 
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warm ischemic times in a hemodynamically instable donor. Donor-related factors (n=13) 
included: a significant medical history that interfered with transplantability (n=10), a severe 
smoking history that was not previously reported (n=2), or high donor age (n=1). Death-related 
organ injuries (n=11) referred to an abnormal chest x-ray in 5 cases, to pulmonary infection in 
3 cases, or abnormal arterial blood gases in 3 cases. In another 3 cases, no obvious reason could 
be identified why lungs were not transplanted based on the registered donor data and medical 
investigations. 
In the “lungs declined after in situ evaluation” group (n=43), donor-related factors (n=16) 
leading to decline of the lung donor for transplantation included: intrinsic lung diseases such as 
emphysema (n=14), fibrosis (n=1) and pleural disease (n=1). Death-related organ injuries 
(n=21) that led to inability to transplant the donor lungs were identified as: a significant 
pulmonary infection (n=10), abnormal arterial blood gases (n=6), pulmonary emboli (n=2), 
parenchymal hematoma (n=2), or severe lung edema (n=1). In 6 cases, no obvious reason could 
be identified why lungs were not transplanted based on the registered donor data and medical 
investigations. 
All categories and subcategories, including the lung donors that were selected as candidates for 
EVLP-recovery are summarized in Figure IV.1. 
Candidates for ex-vivo lung perfusion 
In total, lungs of 78 lung donors were identified as potential candidates to be recovered by 
EVLP evaluation, preservation and reconditioning based on expert opinion. From the group 
“declined as potential lung donor”, these included: 8 MODs with minor pulmonary infection, 
7 DCD II donors, 7 MODs with low arterial blood gases without obvious reason, 5 with 
atelectasis, 4 hemodynamically unstable MODs with unknown warm ischemic time, 3 MODs 
with neurogenic lung edema, and 1 MOD with lung emboli.  
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In the “declined without in situ evaluation” group, cases in which a logistical reason led to 
refusal of the lung donor (n=26) and MODs with minor pulmonary infections (n=5) were 
considered as good candidates for EVLP evaluation-preservation-reconditioning. 
In the “declined after in situ evaluation” group, lungs of potential lung donors could potentially 
be recovered if they would have been carefully evaluated or actively reconditioned on EVLP in 
6 cases of minor infection, abnormal arterial blood gases (n=3), lung edema (n=1), or 
macroscopic appearance of lung emboli (n=2). 
 
Figure IV.1 - Overview of multi-organ donors (purple) that were further categorized as 
“declined as potential lung donor” (red) or as “considered as potential lung donor” (orange). 
Also in the latter, they could still be declined without in situ  evaluation (blue) or after in situ 
evaluation (yellow). Lungs of 220 out of 584 donors were actually transplanted. Lungs that were 
not transplanted, but could be candidates for ex -vivo lung perfusion evaluation, superior 
preservation or active rehabilitat ion are listed in the green boxes below.  
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F)  DISCUSSION 
In our study, we retrospectively analyzed donor data registered in our center to provide insights 
in MODs that are declined as lung donor in current clinical practice. We hypothesized that 
EVLP could increase the donor pool when lungs would be more carefully evaluated, preserved 
in superior conditions or even be actively reconditioned.  
In Belgium, deceased organ donation is based on presumed consent legislation (opting-out 
system) leading to a high rate of 29.1 deceased donations per million inhabitants (16). In this 
opting-out system every deceased individual is classified as a potential donor, in absence of an 
explicit opting-out for organ donation before death. In case family members object to organ 
donation of their relative, their wishes will be respected unless the patient is explicitly registered 
to be an organ donor (opting-in). In this database, organ donors that were not offered due to 
objection of the patient (opting-out) or family members were not registered because no consent 
was obtained (although legally this is not obligated because of the presumed consent 
legislation). In 2 cases, there was an unforeseen objection of the family during a second 
evaluation and the donor procedure was abandoned. In 1 particular case, the body was not 
released by the legal medical examiner after a suicide attempt, so we could not proceed to organ 
donation.  
The acceptance rate of MODs for lung transplantation in our study population was 37.7%. 584 
MODs were offered to our center by our own university hospital and a collaborative donor 
network of 33 local hospitals, over a period of 66 months (Jan 2010 – June 2015), which 
corresponds to an annual number of MODs of 88 (this does not include organs offered by ET 
out of our local donor network). On average in Belgium (2010-2015), 330 MODs are reported 
annually for transplantation to ET, of which 168 are considered as lung donor and 107 are 
actually used. This leads to an acceptance rate of 32.5% of all MODs for lung transplantation. 
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Overall in Eurotransplant, this percentage is even lower, between 2010-2015 the average 
acceptance rate of MODs for lung transplantation was 26.6% (3).   
We believe that improved donor management is an important cornerstone that might explain 
this high acceptance rate of our MODs. Efforts to improve management strategies have been 
incorporated in Intensive Care Unit practice. These include protective ventilation strategies 
(17), fluid restriction, steroid administration and early identification of potential donors (18,19). 
Our high acceptance rate supports that optimal management strategies with preset goals should 
never be completely abandoned in favor of machine perfusion.  
We defined a subset of criteria that could be used to select grafts that could be salvaged by 
EVLP. First, infection leads to a high number of rejected organs. Although it might not be 
feasible to completely resolve a pulmonary infection during only a limited perfusion time on 
EVLP, a reduction in the microbial load (20) and endotoxin levels has already been 
demonstrated and could increase the quality of the infected donor lung (20,21). Therefore, it 
seems feasible to transplant lungs that first seemed unfit because of pulmonary infections, since 
we can minimize the microbial load in those lungs with high dose antibiotic treatment. These 
lung grafts were also included as candidates for EVLP recovery. Secondly, EVLP could also 
provide a solution for many logistical issues since we can potentially prolong the preservation 
time of the donor organs before transplantation. This can be done by either placing the lungs 
on a portable EVLP device in the donor center (22), or alternatively, a stationary device after a 
longer cold ischemic time can be used (23). Which technique is superior is still a subject of 
debate. Thirdly, atelectasis could be reversed on ex-vivo lung perfusion by meticulous 
recruitment maneuvers without derecruitment by abdominal compression. Also, lungs with a 
low PaO2 without any obvious reason (such as infection) could be recruited and evaluated 
carefully. Fourth, lungs with neurogenic lung edema could be dried out by perfusing the lungs 
with a perfusate high on oncotic pressure or by activation of the alveolar fluid clearance during 
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normothermic metabolism. Lastly, lungs with pulmonary emboli could also be salvaged by 
perfusion alone where small emboli can be washed out, or by the addition of fibrinolytics 
(24,25). In many cases, lungs are re-evaluated ex-vivo to guarantee a qualitatively good donor 
lung for transplantation. Unfortunately, not all lungs can be recovered by EVLP. For example, 
lungs that are injured by direct trauma are difficult to preserve on EVLP due to air leak and 
leakage of perfusate in the alveoli. Therefore, structural damage was considered as not 
salvageable.  
Already in 2002, Ware et al estimated that 40% of lungs that were not suited for transplantation 
could be salvaged by more objective ex-vivo evaluation (26). Due to technical improvement 
and refinement of the technique, including the ability of longer perfusion time on EVLP, this 
percentage of organ recovery by EVLP could be higher as initially reported. The conversion 
rate of unused donor lungs to transplantable donor lungs with EVLP highly depends on the 
inclusion criteria for EVLP. Previous studies in experienced EVLP centers showed conversion 
rates of 55-95% with extended-criteria or high-risk donor lungs (8,9,20). Selection of EVLP 
candidates in this cohort among the rejected lungs remains a subjective process and goes beyond 
selecting extended-donor lungs such has been previously proposed. However, all donor data 
were independently evaluated by two EVLP experts who performed over 300 EVLP cases in 
clinical and pre-clinical setting.  
Early outcome after lung transplantation with EVLP seems promising; however, the long-term 
outcome is not well characterized yet. Tikkanen et al showed a similar 1-, 3-, and 5-year graft 
survival, chronic lung allograft dysfunction (CLAD)-free survival and quality of life in their 
cohort of 63 EVLP-grafts. Freedom from CLAD was even superior in brain-dead donors when 
EVLP was used. Up to now, data on outcome after EVLP is limited to ECD and SCD donor 
lungs that are often transplanted in other donor centers without perfusion on EVLP prior to 
transplantation. Therefore, further expansion of inclusion criteria for EVLP reconditioning 
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should be validated in pre-clinical safety models by a thorough evaluation of these rejected 
donor lungs on EVLP. We are convinced that our analysis contributes to a better insight in 
selection of EVLP candidates and to the development of strategies to successfully implement 
this technology in daily transplant activity. 
In this cohort, 72% of the used donors could be retrospectively categorized as ECD and were 
successfully transplanted. Our group has previously published similar long-term outcome for 
ECDs compared to SCDs in a cohort of 431 donors, from which 63% were ECDs (6).  
The limitation of this study is its retrospective nature using registry data. Also, the 
categorization was done using expert opinion since there is limited evidence reported to guide 
this analysis. However, this study did result in an improved donor database registration in our 
transplant center. Donor lungs that are not transplanted are now currently assigned to categories 
1-4 based on the medical history of the donor, acute donor or organ injury, logistical reasons, 
or technical investigations that led to organ decline. Also, the timing of refusal of the donor 
lungs will be registered for each declined lung donor. Figure IV.2 gives an overview of the set-
up of our current donor data registration system, which we recently implemented following the 
limitations we faced with the retrospective database analysis. These data can be used in the 
future for better prospective analysis of our registered donor data.  
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Figure IV.2 –  Donor lungs that are not transplanted will be assigned to category 1 to 4 based 
on the medical history of the donor, acute donor or organ injury, logistical reasons or technical 
investigations that led to organ decline. Also, the timing of refusal of the donor lungs will be 
registered for each declined donor lung.  
In addition, the ethical committee approved on our follow-up study (NH019 2015-10-S58330), 
where we procure lungs of DBD and DCD donors that are refused for lung transplantation, and 
transport these lungs to our laboratory for research purposes. Donor data will be registered as 
indicated above. In this follow-up study, we will evaluate the rejected human donor lungs 
during EVLP which will provide insights in the mechanisms why these lungs do not meet the 
acceptance criteria and which lungs could be salvaged by EVLP in a future clinical EVLP 
program for ECD lungs. Also, we will investigate the effect of EVLP on these rejected donor 
lungs by CT-scanning the lung grafts prior and after EVLP. Preliminary data (presented as an 
abstract at the ECTTA meeting in Barcelona, Oct 2016) are depicted in Figure IV.3. 
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Figure IV.3 –  RHL1 was declined due to increased pulmonary pressures and edematous lower 
lobes detected during in situ donor evaluation. During EVLP, we did not detect any sign of 
increased pulmonary pressures (Ppeak) or vascular res istance (PVR) and CT shows a reduction 
in edema after EVLP. RHL2 was declined for logistical reasons since there was no OR available 
at the time (otherwise qualitatively good donor lung). Lungs could potentially be preserved on 
EVLP until an OR became avai lable. RHL3 was declined due to bad arterial blood gases with 
consolidation and atelectasis in the left lower lobe. EVLP resulted in recruitment of the lungs 
and a decrease in infiltrates on CT scan. RHL4 was rejected based on bad arterial blood gases 
with parenchymal infiltrates shown on CT scan. EVLP showed a stable physiological evaluation 
and CT post EVLP showed a reduction in parenchymal infiltration.  
Although inclusion of EVLP in several clinical program has led to an increase in the donor pool 
and transplant activity, the use of these donor lungs without EVLP has also been implemented 
with good short-term outcome compared to SCD lung transplantation. Therefore, the question 
remains what the real impact of EVLP could be, if lung donors declined by experienced ECD 
lung transplant centers are selected for EVLP recovery. With this first retrospective data 
analysis of unused lung donors, we identified that there is a large potential for EVLP to increase 
the donor pool. Preclinical studies will have to validate this hypothesis and examine the safety 
of accepting these lungs for transplantation.  
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CHAPTER IV 
EVLP POTENTIAL AND FEASIBILITY 
 
 
 
IV.B CLINICAL IMPLEMENTATION OF EX-VIVO LUNG 
PERFUSION IN PEDIATRIC COMBINED LIVER-LUNG 
TRANSPLANTATION: A CASE REPORT 
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SE, Neyrinck AP. Sequence of combined liver-lung transplantation with normothermic lung 
preservation: how anesthesiologists should be involved, a case report 
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A)  PREFACE 
In this chapter, we show that EVLP not only holds great potential to increase the number and 
quality of transplantable donor lungs, but that it is also feasible for implementation in current 
clinical practice. Even in the most complex cases, such as a pediatric combined liver lung 
transplantation. In this case report, we preserved the lungs normothermically on a portable 
EVLP device, while the liver was transplanted first. Furthermore, we focus on the peri-operative 
period of this pediatric cystic fibrosis patient, to stimulate the community to involve 
anesthesiologists in the optimization of preservation strategies, since they are often confronted 
first with the impact of organ failure in the peri-operative period of solid organ transplantation.  
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B)  INTRODUCTION 
Combined liver-lung transplantation is considered a life-saving treatment option for well-
selected cystic fibrosis patients suffering from end-stage respiratory disease with liver failure. 
The major cause of morbidity and mortality in cystic fibrosis (CF) patients is respiratory 
disease, however, liver failure associated with CF is the fourth most prevalent cause of death 
among these patients (1). Experience with combined liver-lung transplantation is limited and to 
the best of the author’s knowledge, normothermic EVLP for a pediatric combined liver-lung 
transplantation has not been reported. Consequently, the authors show that normothermic EVLP 
is feasible for pediatric transplantation to limit prolonged cold ischemic time that is linked with 
primary graft dysfunction (PGD). However, also ischemia-reperfusion injury (IRI) of the liver 
can lead to PGD of the lung. IRI is inherent to the process of solid organ transplantation and 
has remote impact on all organ systems which may lead to serious consequences. The 
anesthesiologist is often confronted with the impact of IRI on the systemic physiology and is 
responsible of managing organ failure in the peri-operative phase. Therefore, the authors 
suggest to involve the anesthesiologists in the optimization of preservation strategies, including 
normothermic organ machine perfusion.   
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C)  CASE REPORT 
A 16-year old Caucasian female (ASA4, A Rh+, CMV-, 49.5 kg, 155 cm) was listed for a 
combined liver-lung transplant (written consent was obtained to publish the case report). She 
suffered from cystic fibrosis (genotype DF 508/Y1092X) complicated with liver cirrhosis and 
portal hypertension (MELD 14, CHILD PUGH B8). The portal hypertension resulted in severe 
hypersplenism, esophageal varices, thrombocytopenia, hypoalbuminemia and 
hyperammonemia for which a transjugular intrahepatic portosystemic shunt (TIPS) was applied 
at the age of 8 years old. Her pre-transplant forced expiratory volume in 1 second (FEV1) and 
forced vital capacity (FVC) were 0.89 L (35% predicted value) and 1.98 L (67% predicted 
value), respectively. Prior to surgery, she had normal serum electrolytes and kidney function 
but suffered from an increased bleeding tendency (INR 1.7 and thrombocytopenia 45.000). The 
patient was hospitalized 23 days prior to the liver-lung transplant procedure for intravenous 
antibiotic treatment, because of persistent fever with known colonization of P. aeruginosa and 
A. Xylosoxidans.  
After 110 days on the waiting list, a 47-year old Caucasian female brain-dead donor 
(hemorrhagic stroke, A Rh+, CMV-, 55kg, 165cm) was matched for liver and lung donation. 
The double-lung block was procured with a cold antegrade flush (4L of Organ Care System 
(OCS) solution plus 50mg nitroglycerin) and normothermically preserved on the OCS LungTM 
device (Transmedics, Andover, MA, USA). The liver was flushed with cold IGL-1 Solution 
(5L) and stored on ice for 438 minutes. The rationale to transplant the liver first derives from 
the theoretical advantage of limiting the cold ischemic time of the liver to prevent biliary 
strictures, restore coagulation disorders prior to the lung transplant procedure to prevent 
massive transfusion, and to let the native lungs capture the liver IRI instead of the newly 
transplanted lungs (2). 
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Normothermic lung preservation 
After in situ cold flush, lungs were slowly rewarmed on the Organ Care System (OCS) device 
in the donor hospital and kept in preservation mode for 667 minutes according to the OCS 
protocol. Pulmonary vascular resistance and peak airway pressure were stable throughout the 
entire ex vivo perfusion time with acceptable PaO2/FiO2 ratios (partial oxygen pressure over 
fractional inspired oxygen concentration, normal value >300) at the initial and final evaluation 
(FIGURE IV.4A). After OCS preservation, the lungs were again antegradely cold-flushed with 
2 L of buffered OCS solution and split into a left and right graft for immediate implantation. 
The posterior side of the left lung appeared somewhat edematous (FIGURE IV.4B).  
 
FIGURE IV.4 –  A) Stable pulmonary vascular resistance (PVR) and peak airway pressure 
(Ppeak) during the 667 minutes of normothermic machine preservation. Initial PaO2/FiO2 and 
final PaO2/FiO2 ratio are shown at respectively 69 and 632 minutes. B) Dorsal aspect of the 
lungs after 667 minutes of normothermic machine perfusion. The left inferi or lobe looks more 
edematous than the right lung.  
Peri-operative care 
Anesthesia was induced with 10µg of sufentanil and 100mg of propofol via a peripheral 18 Ga 
intravenous access (IV). A single lumen tube (7.0) was placed after neuromuscular blockade 
with rocuronium 50mg. Anesthesia was maintained with sevoflurane (2.5% inspiratory 
fraction) and intermittent boli of sufentanil (1µg/kg/h). Neuromuscular blockade was 
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maintained with rocuronium (0.5-1mg/kg). Ventilatory settings (Tidal Volume, Respiratory 
Rate, Positive End-Expiratory Pressure, maximum Peak Pressure, Fraction of inspired Oxygen) 
were adjusted according to arterial blood gases and surgical needs (single-lung ventilation). A 
20Ga arterial catheter was placed in both left and right arterial catheter. And a triple lumen 
central venous catheter and pulmonary artery catheter (CCOmbo 744HF75, Edwards Life 
Sciences®) were placed in the right internal jugular vein. Finally, a gastric tube, bladder 
catheter, temperature probe and transesophageal ultrasound probe were inserted. Hypothermia 
was prevented using a Hotline (Smiths Medical), Ranger (3M) and Bair Hugger (3M) for patient 
warming.  The patient was already under quadruple intravenous antibiotic therapy 
(minocycline, co-trimoxazole, tazobactam, tobramycin). The peroperative hemodynamic 
parameters (blood pressure, heart rate, pulmonary artery pressure, cardiac output) together with 
vasopressive/inotropic drugs and administered fluids are depicted in FIGURE IV.5.  
First, orthotopic liver transplantation was performed via a bisubcostal incision under portocaval 
bypass for hemodynamic stabilization. Therefore, an extracorporeal heparin coated centrifugal 
pump system diverts blood from the femoral vein (20Fr) and portal vein (28Fr) to the axillary 
vein (15Fr). After 101’ minutes the patient was successfully weaned of portocaval bypass. 
Hemodynamic support with noradrenaline was increased up to 0.2 µg/kg/min during the 
anhepatic phase with increasing lactate values (max. 4.2mg/dl). During the reperfusion phase 
of the graft, lactate levels returned to their preoperative values. 
After hemostasis, the incision was closed before a bilateral thoracotomy in the fifth intercostal 
space was performed to proceed with the sequential single lung transplant procedure. The single 
lumen endotracheal tube was replaced by a left-sided double lumen endotracheal tube 35 Fr. 
The right lung was implanted first based on the perfusion scan (42% of perfusion to right lung).  
After reperfusion of the first lung, pulmonary artery pressures (PAP) steadily increased (PAPmax 
66 mmHg) and 20 ppm inhaled nitric oxide was started. During implantation of the second graft 
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on the left side, IRI of the first lung led to high ventilation pressures and increasing demands of 
hemodynamic support. There was no extra-corporeal membrane oxygenation (ECMO) applied 
since CO was maintained and gas exchange was acceptable, although with high doses of 
noradrenaline and adrenaline. This resulted in a rise in lactate levels towards the end of the 
procedure to a maximum of 6.2mg/dl. 
 
 
Figure IV.5 –  Perioperative parameters. A) Stable arterial blood pressure (ABP) and heart rate 
(HR) B) pulmonary artery pressure (PAP) with preserved cardiac output (CO) under only a 
minimal support of noradrenaline  during liver transplantation. C) Higher need for noradrenaline 
(NOR) and adrenaline (ADR) during the lung transplant phase with rising lactate and PAP. D) 
Total volume of infused fluids during the procedure  
Postoperative stay Intensive Care Unit 
Her postoperative stay in the intensive care unit (ICU) was 36 days during which the patient 
was mechanically ventilated for 8 days. Cardiovascular function was stable with minimal 
vasoactive and inotropic support (FIGURE IV.6A).  
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LIVER - The liver function disorders rapidly declined after the liver transplant with 
normalization of the liver function tests (FIGURE IV.6B). Duplex of the transplanted liver 
initially showed higher hepatic artery resistive indices due to fluid overload and IRI, which 
decreased upon normalisation of the fluid status. Systolic acceleration times were normal at all 
times.  
LUNG - Reperfusion edema in the early postoperative hours after ICU admission was treated 
successfully with high PEEP, protective ventilation and inhaled NO. At day 5, a first 
spontaneous breathing trial led to extubation but because of vastly increasing work of breathing 
and increasing oxygen needs the patient was re-intubated after 3 hours. A second attempt on 
day 8 was successful. Postoperative oxygenation capacity and ventilatory support are depicted 
in FIGURE IV.6C. On day 24 a new air leak on the chest drain was observed and bronchoscopy 
confirmed limited dehiscence of the right main bronchial suture line (MDS-classification 
M2bD0bS1f (3)). Treatment was conservative and 6 days later, bronchoscopy could not detect 
a bronchopleural fistula anymore and the air leak was no longer present. 
KIDNEY - Acute kidney failure stage 3 (Kidney Disease Improving Global Outcomes 
(KDIGO)) developed and continuous veno-venous hemofiltration (CVVH) was initiated at 
postoperative day 2 (FIGURE IV.6D). After 23 days, CVVH was switched to intermittent 
hemodialysis (IHD). After 1 month stay at the ICU, her diuresis was slightly improving to 
200ml/day with increasing creatinuria as a sign of her kidney recovery and she eventually 
became dialysis independent, with normalization of the estimated glomerular filtration rate. 
Immunosuppression was started with tracrolimus (Prograft® 2x2mg), mycophenolate mofetil 
(CellCept® 1.5g 2x/d) and steroids (Solumedrol® 20mg/d). However, because of an epileptic 
insult due to posterior reversible encephalopathy syndrome, tacrolimus was switched to 
cyclosporine (Neoral® 125mg 2x/d) and low-dose valproate (Depakine®) was added with full 
neurological recovery. 
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The patient is now alive and has resumed school, with normal hepatic (total bilirubin 0.74 
mg/dl), pulmonary (FEV1 77%) and renal function (creatinine 0.75 mg/dl), 14 months after 
transplantation. 
 
Figure IV.6 –  Day 0 is the arrival at ICU. A) Hemodynamic support with  adrenaline (ADR) and 
noradrenaline (NOR). B) Liver function resembled by Prothrombin Time (PT) gradually 
normalized in the postoperative period . C) Lung function is depicted as oxygenation (PaO 2 /FiO2  
ratio).  The patient was weaned from intermittent positi ve pressure ventilation (IPPV) to b iphasic 
positive airway pressure  (BIPAP) and continuous positive airway pressure ventilation  (CPAP). 
At day 8 she was extubated and supplemental O2 was administered with a nasal cannula until 
day 20. D) Acute kidney failure (peak creatinine levels) required CVVH (started at day 2),  which 
was switched to IHD at day 22.  
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D)  DISCUSSION 
We report the first pediatric combined liver-lung transplantation with normothermic 
preservation of the lungs, performed in our center. Combined liver-lung transplantation is a 
complex procedure and is applied only in well-selected patients. We have recently reported our 
overall single-center experience of combined liver-lung transplantation (2). Historically, the 
sequence is most frequently performed as lung first, followed by liver transplantation. The main 
reason is the ischemic tolerable cold ischemic interval, which is believed to be shorter for lungs 
than livers. Occasionally, the liver has been implanted first in case of severe liver failure, 
applying the principle of “sickest organ first”. In addition, there is also a theoretical 
immunological advantage to transplant the liver first (2).  
The potential limitations due to the ischemic tolerance of pulmonary grafts is currently 
challenged, since we have better strategies to optimize cold ischemic tolerance (4) and 
normothermic preservation with ex-vivo lung perfusion (EVLP) has emerged as a promising 
technique to prolong preservation time (5). This technology is also being investigated to 
preserve liver grafts in normothermic conditions. 
Historically, the focus and interest of anesthesia practice and research in organ preservation is 
limited. However, the anesthesiologist is often confronted with the impact of organ failure 
resulting from ischemia-reperfusion injury. This injury has a serious impact on the specific 
organ system and may lead to multiple systemic consequences.  
In case of liver transplantation, metabolic acidosis, hyperkalemia, hypoglycemia and 
coagulopathy might be life-threatening complications (6). A specific issue in case of 
transplanting lungs after liver, is the added risk to develop additional lung injury (7). This might 
be related to transfusion, severe systemic inflammation, hemodynamic instability and IRI of 
the liver with its remote effect on the freshly transplanted lungs. A lung protective ventilation 
strategy is therefore crucial (8). Portopulmonary hypertension and hepatopulmonary syndrome 
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(9) should also be considered as underlying respiratory disorders complicating the anesthetic 
management.  
The reperfusion injury following lung transplantation is referred to as primary graft dysfunction 
(PGD). PGD compromises the systemic oxygen delivery and forms a serious threat itself for 
other organ systems. It occurs within 72 hours after implantation and is characterized by severe 
high permeability pulmonary edema. Therapy for established PGD remains generally 
supportive and includes protective ventilation strategies, extracorporeal membrane oxygenation 
and selective pulmonary vasodilators such as inhaled nitric oxide (10). Despite acceptable 
management, we would consider earlier use of ECMO during this procedure in order to stabilize 
systemic oxygen delivery and hemodynamics. Peri-operative risk factors for PGD include high 
pulmonary artery pressures, the use of cardiopulmonary bypass, blood transfusion and 
increased intraoperative fluid administration (11,12).  
Kidney dysfunction might compromise the outcome following both lung or liver transplantation 
(13,14). In case of combined organ transplantation, prolonged hemodynamic instability and 
secretion of toxic mediators might severely increase the risk to develop acute kidney failure. 
Besides the severe challenges to manage these patients peri-operatively, we should increase our 
awareness and interest in these new normothermic preservation strategies. The principle for 
EVLP is based on an in-depth physiological evaluation outside the body, prior to implantation. 
Quality of the graft is assessed using perfusion parameters, ventilation parameters and 
oxygenation capacity (15). However, there is currently limited data available how to use the ex 
vivo data as a predictor for in vivo performance of the graft (16).  
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E)  CONCLUSION 
Combined liver-lung transplantation is considered a life-saving treatment option for cystic 
fibrosis patients suffering from end-stage respiratory disease with liver failure. However, 
experience with pediatric combined liver-lung transplantation is limited.  Ischemia-reperfusion 
injury (IRI) is inherent to the process of solid organ transplantation and this injury has serious 
impact on all organ systems and may lead to serious consequences. The anesthesiologist is often 
confronted with the impact of IRI on the systemic physiology. Besides the severe challenges to 
manage these patients peri-operatively, we should also increase our awareness and interest in 
the optimization of preservation strategies, including normothermic ex-vivo lung perfusion.  
We report our experience and anesthetic consequences on a case of combined liver-lung 
transplant with prolonged normothermic preservation of lungs on a portable ex vivo device 
prior to transplantation.  
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CHAPTER V 
EX-VIVO RECONDITIONING WITH 
NOBLE GASES 
 
 
 
V.A EX-VIVO POSTCONDITIONING WITH NOBLE GASES 
TO ATTENUATE PULMONARY ISCHEMIA-REPERFUSION 
INJURY 
 
 
 
Adapted from: 
Martens A, Montoli M, Faggi G, Katz I, Pype J, Vanaudenaerde BM, et al. Argon and xenon 
ventilation during prolonged ex vivo lung perfusion. J Surg Res. 2016 Mar;201(1):44–52 
(DOI: 10.1016/j.jss.2015.10.007) 
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A)  PREFACE 
Ex-vivo lung perfusion (EVLP) has been put forward as the ideal platform for active 
improvement (reconditioning) of donor lung quality. Reconditioning could be pursued by 
inhalational therapy, which is an ideal route of drug delivery since the lungs are approached at 
the epithelial side of the alveolar membrane to tackle IRI. Noble gases have previously been 
shown to be organoprotective due to their anti-apoptotic and anti-inflammatory properties in 
other organ systems, but not in the lung. Therefore, they are of particular interest to modulate 
ischemia-reperfusion injury in lung transplantation. Ventilation with noble gases during EVLP 
allows for an optimal delivery route and immediate assessment of the impact of the 
reconditioning strategy prior to transplantation.  
In this chapter, we investigated if noble gases (argon and xenon) could improve warm-ischemic 
injured donor lungs when administered by ventilation during EVLP.  
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B)  ABSTRACT 
Introduction - Evidence supports the use of ex-vivo lung perfusion (EVLP) as a platform for 
active reconditioning prior to lung transplantation to increase the potential donor pool and to 
reduce the incidence of primary graft dysfunction (PGD). A promising reconditioning strategy 
is the administration of inhaled noble gases based on their organoprotective effects. Our aim 
was to validate a porcine warm ischemic lung injury model and to investigate postconditioning 
with argon (Ar) or xenon (Xe) during prolonged EVLP. 
Methods - Domestic pigs were divided in 4 groups (n=5/group). In the negative control (NC) 
group lungs were flushed immediately. In the positive control (PC) and treatment (Ar, Xe) 
groups, lungs were flushed after a warm ischemic interval of 2 h in situ. All grafts were 
evaluated and treated during normothermic EVLP for 6 h. In the control groups, lungs were 
ventilated with 70% N2/30% O2 and in the treatment groups with 70% Ar/30% O2 or 70% 
Xe/30% O2, respectively. Outcome parameters were physiological variables (PVR, Ppeak, 
PaO2/FiO2), histology, wet-to-dry weight ratio (W/D), bronchoalveolar lavage (BAL) and CT-
scan.  
Results - A significant difference between NC and PC for PVR, Ppeak, PaO2/FiO2, W/D, 
histology and CT-imaging was observed. No significant differences between the injury group 
(PC) and the treatment groups (Ar, Xe) were found.  
Conclusion - We validated a reproducible prolonged 6 h EVLP model with 2 h of warm 
ischemia and described the physiological changes over time. In this model, ventilation during 
EVLP with Ar or Xe administered post-injury, did not improve graft function. 
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C)  INTRODUCTION 
Lung transplant programs are being hampered by organ shortage due to a low recovery rate of 
donor lungs from multi-organ donors (1). Successful efforts have been made to increase the 
donor pool including the use of donors after circulatory death (DCD) and extended-criteria 
donors (ECD) (2,3). However, further expansion with acceptable grafts is still requisite. In 
addition, the problem of primary graft dysfunction (PGD), resulting from ischemia-reperfusion 
injury (IRI), decreases early post-transplant outcome (4,5). To enlarge the donor pool and to 
improve outcome, active resuscitation of donor organs prior to transplantation is a promising 
strategy. 
Normothermic ex-vivo lung perfusion (EVLP) is entering the clinical reality as a tool for graft 
evaluation and preservation (6). This technique was developed to evaluate DCD donor lungs 
prior to transplantation (7). EVLP was further successfully applied to assess and recruit 
previously rejected organs (8). Currently, research is investigating the potential to actively 
recondition lung grafts with EVLP (9), serving as a platform to stimulate repair mechanisms 
while organs are metabolically active. Prolonged and stable perfusion times are essential 
conditions for EVLP rehabilitation, which can be extended up to 12 hours (10).  
Inhalational therapy for lung rehabilitation is an excellent administration route, and research on 
inhalational therapy like carbon monoxide (11) and hydrogen therapy (12) have already been 
investigated. However, the effects of noble gases on IRI have not been investigated so far. 
Noble gases, including argon (Ar) and xenon (Xe), are chemically inert, but exhibit biological 
effects (13,14). Various in vitro and in vivo injury models in the brain (15,16), myocardium 
(17) and kidneys (18,19) have shown a protective effect of argon and xenon attributed to anti-
apoptotic and anti-inflammatory properties (20–25). The problem with Xe is its scarcity (0.9 
ppm), while in contrast Ar is the third most abundant gas in the earth’s atmosphere (9300 ppm). 
Therefore, the use of Ar treatment could be of higher economic benefit.  
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Potential organ-protective effects on pulmonary grafts have not been explored and IRI might 
be a perfect target for noble gas treatment.  A major advantage is the possible administration of 
these gases through ventilation. In addition, higher concentrations in the gas phase can be 
administered during EVLP without additional risk for the recipient.  
This study aims to investigate the potential of pulmonary allograft reconditioning using ex-vivo 
noble gas treatment during 6 hours of normothermic EVLP in a 2-hour warm ischemic injury 
model.  
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D)  METHODS 
Animals 
Domestic male pigs (Topigs 20, 36-42 kg) were used. Local ethical approval was obtained at 
the research institute (NTS P043/2014). All animals received humane care in compliance with 
the 'Principles of Laboratory Animal Care' formulated by the National Society for Medical 
Research and the 'Guide for the Care and Use of Laboratory Animals' prepared by the Institute 
of Laboratory Animal Resources and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1996). 
Animal anesthesia and baseline 
Anesthesia was induced by an intramuscular injection with 5 mg/kg Zoletil 100® (Virbac, 
Carros, France) and 3 mg/kg Xyl-M 2%® (V.M.D., Arendonk, Belgium). Muscle relaxation 
and analgesia were maintained with 2 mg pancuronium and 20 µg/kg/h of fentanyl. Continuous 
intravenous infusion of 10 mg/kg/h propofol was used for anesthesia maintenance. Animals 
were intubated with a 7.0 mm endotracheal tube and ventilated (Aestiva 3000, GE Healthcare 
Europe GmbH, Little Chalfont, United Kingdom) with a tidal volume (TV) of 8 ml/kg, PEEP 
of 5 cmH2O and FiO2 of 30%. Respiratory rate was adjusted to ETCO2 (45-55 mmHg). Invasive 
blood pressure was monitored. Animals received 1 g cefazolin, 500 mg solumedrol and 300 
IU/kg of heparin.  
Study groups 
Animals were divided in 4 groups (n=5/group): negative control (NC); positive control (PC); 
argon group (Ar) and xenon group (Xe).  
In the PC and treatment groups, circulatory and respiratory arrest was induced by myocardial 
fibrillation with an electrical pulse generator and ventilator disconnection. Animals were left 
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untouched at room temperature (warm ischemic interval of 120 min in situ). In the NC group, 
no warm ischemia was induced and lungs were procured immediately. 
Procurement of donor lungs 
A median sternotomy was performed following baseline assessment in NC, and 15 min prior to 
completion of warm ischemia in PC, Ar, and Xe. The pulmonary artery and caval veins were 
encircled and a purse-string was sutured on the right ventricular outflow tract to secure the 20 
Fr flush cannula in the pulmonary trunk. Following inflow occlusion, lungs were cold flushed 
(4 °C) in an antegrade way with 50 mL/kg THAM-buffered Perfadex® (XVIVO Perfusion AB, 
Goteborg, Sweden). To optimize flush conditions, lungs were protectively ventilated 
(inspiratory pressure of 15 cmH2O and PEEP of 5 cmH2O). After explantation, an additional 
retrograde flush (1 L) was performed and the lungs were cannulated with the XVIVO Lung 
Cannula SetTM with closed atrium. An endotracheal tube of 8.0 mm was secured in the trachea.  
Perfusate 
The perfusate (1.5 L) was composed of THAM-buffered Perfadex® with 70 g/l of human 
albumin (C.A.F.-D.C.F., Neder-Over-Heembeek, Belgium). Also, 2.5 g glucose, 1 g cefazolin, 
500 mg solumedrol, 50 mEq sodium bicarbonate, 0.18 g calcium and 30 IU of insulin were 
added. Baseline samples of the priming solution were analyzed.  
Ex-vivo lung perfusion 
Our EVLP circuit consisted of a centrifugal pump, a gas exchanger, a reservoir and a leukocyte 
filter as previously described (26). Oxygenated normothermic flow to both lungs (37°C) was 
gradually increased over one hour to a target of 40% of the estimated cardiac output (0.1 mL/kg 
of the body weight). Left atrial pressure was kept between 3 and 5 mmHg (27). Once the effluent 
reached 34°C, volume-controlled ventilation was started with a TV of 7 mL/kg, 7 breaths/min 
and PEEP 5 cmH2O. Grafts were ventilated with 30% oxygen in each group and recruited 
hourly. According to the study group, 70% nitrogen (N2, PC), Ar or Xe were added (Air Liquide 
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Santé France, Gentilly, France). The gas exchanger in the circuit was switched to a mixture of 
oxygen, CO2 and nitrogen to compose a mixed venous gas concentration at the inflow. 
Recording of pulmonary vascular resistance (PVR[dynes/sec/cm-5]=((PAP[mmHg]-
LAP[mmHg])*80)/Flow[L/min], Peak airway pressures (Ppeak) and blood gases for 
oxygenation were performed hourly. Total EVLP time was 6 hours; however, experiments were 
prematurely ended when the reservoir was empty due to lung edema formation. EVLP was 
aborted when the reservoir went empty instead of refilling it with solution to avoid dilution of 
toxins and inflammatory mediators which could alter the outcome. 
Tissue sampling 
At end of EVLP, following biopsies were taken: right upper lobe (RUL); lower part of the right 
lower lobe (RLL/L); middle part of the right lower lobe (RLL/M). Biopsies were fixed in 6% 
formaldehyde, embedded in paraffin and stained with hematoxylin-eosin. The presence of 
alveolar necrosis, alveolar macrophages, alveolar neutrophils and bronchial inflammation was 
scored by a blinded reviewer (28). The mean severity score of the 3 samples per lung was 
analyzed. Wet-to-dry weight ratio (W/D) of a second RLL sample was determined to quantify 
lung edema (29).  
A 30 cc saline bronchoalveolar lavage (BAL) was performed in duplicate in the right middle 
lobe as previously described (28). Returned fractions were pooled and a cytospin was stained 
with Diff-Quick (Dade Behring, Newark, NJ) to perform differential cell counts.  
Finally, the left lung was inflated at 25 cmH2O with an FiO2 of 30% and frozen in liquid nitrogen 
vapor to allow computed tomography (CT)-scanning and radiographic analysis as described 
previously(30,31). This imaging analysis yielded measures of ground glass opacity as a general 
marker of acute alveolar injury and septal thickening and consolidation as markers of lung 
edema. These variables were scored by a blinded reviewer.  
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Statistical Analysis 
Data analysis was performed with the statistical software package Graphpad Prism 4 (GraphPad 
Software Inc., CA, USA). All data are expressed as median ± interquartile range (IQR). In the 
cases where lungs could not sustain the full 6 hours of EVLP, data points recorded in the next 
hours after the premature end of EVLP were considered the same as the last data point available 
to allow comparison at all evaluation points. Data were compared with a non-parametric 1-way 
ANOVA (Kruskal-Wallis) for one time-point and a repeated measures 2-way ANOVA for 
evaluation of the variables in time. When the overall p-value was significant, a Dunn’s multiple 
comparison test (1-way ANOVA) or Bonferroni post-hoc test (2-way ANOVA) was performed, 
comparing all groups to the PC group. The level of significance was set at p < 0.05. 
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E)  RESULTS 
Study Groups 
Baseline parameters of donor animals and composition of the priming solution were comparable 
between all groups (Table V.1).  
Table V.1 –  Comparable baseline parameters and perfusate composition.  
 
Data are expressed as median (IQR); 1 -way ANOVA for group comparison (Kruskal -Wallis) 
TV = tidal volume; HR = heart rate; MAP = Mean Arterial Pressure; Ppeak = Peak Airway 
Pressure; WBC = total white blood cell count; Hct = haematocrit; Alb = albumine; Osm = 
osmolality; Na = sodium; K = potassium; Cl = chloride; Bic =  bicarbonate; Ca = calcium; 
Gluc = glucose 
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Graft Survival 
For all experiments in the NC group, EVLP could be performed for 6 hours. However, in the 
other groups, there was a drop-out (4 drop-outs in PC and Ar; 2 drop-outs in Xe) due to 
extensive lung edema (Figure V.1).  
 
Figure V.1 –  Proportional survival of lungs on EVLP. No drop out in the NC group, 2 early drop 
outs in Xe Group, 4 early drop outs in PC and Ar Group.  
Functional assessment of pulmonary grafts during EVLP 
Ppeak gradually declined in the NC group (Figure V.2). In PC and treatment groups, Ppeak 
initially declined but deteriorated after 3 hours. At 5 and 6 hours, Ppeak was significantly 
different between NC and PC. No differences in Ppeak were found between the treatment 
groups and PC.  
PaO2/FiO2 ratio was stable in the NC group and clearly declined in the PC and treatment groups, 
however, did not reach the level of significance (Figure V.2). At the end of EVLP, oxygenation 
was significantly different between the NC and PC group (p<0.05). No effect was observed in 
the treatment groups.  
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Figure V.2 –  Assessment of functional parameters during EVLP. All data are depicted as median 
± IQR. A, C analyzed with repeated measures 2 -way ANOVA. B, D analyzed with non-parametric 
1-way ANOVA. Time 0 represents start of perfusion on EVLP; time 1 is the first evaluation 
moment.  
Stable Ppeak in NC, increased Ppeak in PC (p<0.05 hrs 5, 6), Ar (NS), Xe (NS)  
Ppeak at the end of EVLP significantly differs between NC and PC (p<0.05), no difference 
between PC and Ar, Xe (NS)  
Stable PaO2/FiO2 in NC, decreased P/F in PC (NS), Ar (Ns), Xe (NS)  
PaO2/FiO2 at the end of EVLP significantly differs between NC and PC (p<0.05), no difference 
between PC and Ar, Xe (NS)  
At first evaluation (1h of EVLP), PVR was similar in all groups (Figure V.3). In NC, PVR was 
stable throughout the whole experiment. However, in PC, Ar and Xe, PVR gradually increased, 
although not statistically significant. Comparing PVR at the end of EVLP, a significant 
difference between NC and PC (p<0.05) was present. No significant differences were found 
between the treatment groups and the PC group. Both pump flow (l/min) and measured 
pulmonary artery pressure (mmHg) are depicted for all groups (Figure V.3). 
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Figure V.3 –  Assessment of pulmonary vascular resistance (PVR). All data are  depicted as 
median ± IQR. A was analyzed with repeated measures 2 -way ANOVA. B was analyzed with non-
parametric 1-way ANOVA. Time 0 represents start of perfusion on EVLP; time 1 is the first 
evaluation moment.  
Stable PVR in NC, increased PVR in PC (NS), A r (NS), Xe (NS) 
PVR at the end of EVLP significantly differs between NC and PC (p<0.05), no difference between 
PC and Ar, Xe (NS) 
Evaluation of pump flow (40% of the estimated cardiac output) and the measured pulmonary 
artery pressure (PAP) 
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Assessment of pulmonary edema and BAL-analysis 
A significant difference in W/D between NC and PC was observed, validating our injury model 
(p<0.05). However, no treatment effect of Ar or Xe was observed (Figure V.4A). No differences 
in BAL analysis of macrophages, neutrophils or lymphocytes were found (Figure V.4B). 
 
Figure V.4 –  Assessment of lung edema and BAL fluid analysis. All data are depicted as median 
± IQR 
Non-parametric 1-way ANOVA of W/D shows significant difference between NC an PC (p<0.05) 
but no difference between PC and Ar, Xe (NS)  
2-way ANOVA of BAL fluid shows no significant difference (NS)  
Histology and Imaging 
Histology (Figure V.5A) indicated the absence of alveolar necrosis in the NC group in contrast 
to all other groups (p<0.05). Histological sections of all groups are shown in Figure V.6. Other 
parameters such as the presence of alveolar macrophages, neutrophils and bronchial 
inflammation were not significantly different between groups. CT-imaging analysis (Figure 
V.5B) showed that NC and PC groups significantly differed in the presence of ground glass 
opacities (p<0.01) and septal thickening (p<0.05), but not in the amount of consolidation. No 
differences in these CT-parameters were measured between the PC and treatment groups. 
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Figure V.5 –  Analysis of histology-scoring and CT-imaging. All data are depicted as median ± 
IQR, both graphs were analyzed with a 2 -way ANOVA 
The mean of the histology scoring in the 3 biopsies (score range 0 -3) shows significant difference 
between NC and PC, Ar, Xe regarding presence of alveolar necrosis (p<0.05). No differences 
were found in the other variables.  
Scoring analysis of CT-imaging shows significant difference between NC and PC regarding 
ground glass opacities (p<0.01) and septal thickening (p<0.05), not f or consolidation (NS). No 
significant differences were shown between PC and treatment groups (NS).  
 
Figure V.6 –  Histological sections of lung tissue in NC, PC, Ar and Xe group.   
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F)  DISCUSSION 
In this study we have demonstrated that xenon and argon ventilation at reperfusion could not 
significantly reduce the development of IRI during EVLP in a pig model with 2 hours of warm 
ischemia.  
To our knowledge, we are the first to investigate the potential effect of noble gases on 
pulmonary IRI. More than 15 years have passed since the first beneficial effect of noble gas 
therapy has been reported (6). Since then, several organoprotective effects have been described. 
Most evidence is derived from cerebral or myocardial ischemic injury studies, both in vitro (32–
35)  and in vivo (36–39). On the one hand, the heterogeneity in these data makes it difficult to 
extrapolate them to other organ systems. On the other hand, clear evidence is provided by these 
models to reduce infarct size and improve neurological performance by exposure to noble gases. 
Also in the field of transplantation, a rat model has shown improved functional and 
morphological outcome in kidney transplantation after perfusion with noble gas saturated fluid 
(18,19).  These protective effects, however, could not be demonstrated in our model. 
A first reason to explain our findings is the choice of a postconditioning setting during EVLP 
alone. This ex-vivo postconditioning strategy has many advantages since we can apply and 
monitor the treatment outside the donor (following procurement) and prior to implantation in 
the recipient. We believe this procedure would be the most feasible for a future translation to 
clinical practice. 
Normothermic conditions allow for different repair mechanisms to be activated. Experimental 
EVLP treatments include adenoviral vectors to transfer IL-10 (40) and the addition of steroids 
(41), adenosine-agonists (42), high doses of antibiotics (43) or surfactant (44). Clinically, the 
administration of fibrinolytics (45,46) has been performed, but it has limited indications. In our 
study, the lack of response might be due to the introduction of the noble gas only after the IRI 
insult to the lung. That is: after the warm ischemic interval and even after reperfusion was 
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started. Indeed, ventilation was only started once the outflow temperature reached 34°C and 
thus, reperfusion injury was already initiated. Other injury models studying organoprotective 
effects of noble gases have included pre-injury exposure (13,21,35,47). The rationale for 
postconditioning is our extensive experience with DCD lung transplantation (26,48,49) and the 
potential of therapies in the ex-vivo setting.  
Secondly, the 2-hour warm ischemic interval is longer than restricted intervals of 60 min by 
other groups (50–52). We have previously demonstrated that warm ischemia is tolerable for up 
to 90 minutes (49) and a 2-hour interval was chosen for substantial injury based on previous 
validation of this model (53). The use of this extended warm ischemic interval of 120 minutes 
in our study design is further supported by other investigators (54,55). However, our current 
data indicate excessive structural damage with findings of alveolar necrosis which is potentially 
unsuitable as a substrate for noble gas rehabilitation. This was further supported by the 
observation that in some experiments excessive edema limited perfusion time. Continuous 
infusion of fresh perfusate to prevent the reservoir of running out of perfusion solution would 
be an excellent way of preventing drop-out and allow recalculation of diluted metabolites in 
future experiments. Based on these results, we discourage the use of a 2-hour warm ischemic 
interval in the use of prolonged ex-vivo lung perfusion for graft reconditioning in a future 
experimental study design. However, extensive reperfusion injury can also occur in clinical 
practice and the absence of an improvement in graft function or decrease in lung edema 
formation merely shows that this extensive injury cannot be reversed by noble gas ventilation.  
Thirdly, the nature of reperfusion injury using acellular perfusate (Steen® solution) in 
comparison to blood (in vivo IRI) should be considered to explain some findings. Due to the 
absence of leukocytes, the inflammatory injury might be damped as seen on BAL analysis. The 
flow of oxygenated perfusate in the lung vasculature does mimic IRI and also induces 
mechanical shear stress and ROS that play a central role in the development of PGD (4,56–59). 
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However, the nature of the ROS introduced might be slightly different since Steen solution has 
some antioxidant activity (60). Furthermore, differences in viscosity and density, as well as the 
continuous flow with the centrifugal pump, will result in a different shear stress compared to 
in-vivo IRI. 
Finally, the concentration of noble gas was limited to 70%. In this study, an FiO2 of 30% was 
chosen which is within the wide range of 12 to 50% advocated in other EVLP protocols (6). 
Future studies might modify the FiO2 and noble gas concentration to investigate dose-response 
effects. Data on biological dose-responses are also limited in other organs (25).  
Interpretation of the ventilator parameters is complex using gas mixtures with different physico-
chemical properties. Ppeak is a common variable used to evaluate lung quality during EVLP; 
however, it is problematic to use when ventilation is performed using different gas mixtures 
because all else being equal, the gas mixture with higher density and viscosity will result in a 
greater Ppeak (61). Furthermore, common ventilators are not calibrated for noble gas mixtures. 
We measured the ventilator variables at the proximal end of the endotracheal tube using the 
IntelliVue 60 spirometry module (Philips Healthcare, DA Best, The Netherlands). Since this 
module is calibrated for 100% oxygen, volumes had to be corrected for the density of each 
specific gas with the following formula: TVmeasured=TVactual*√(ρtest gas/ρ100%O2). The density for 
100%O2, 70%N2/30%O2, 70%Ar/30%O2 and 70%Xe/30%O2 are 1.257, 1.148, 1.477 and 3.991 
kg/m³, respectively (62,63). By correcting the tidal volumes, the actual tidal volume delivered 
in the lung during EVLP was equal in all experiments: 7ml/kg. The pressure drop across the 
endotracheal tube is also function of the gas and thus should be omitted from the peak pressure 
measurement if we want to know the actual peak airway pressures. The inspiratory flow of 
5.9±0.4 l/min (mean ± SD), which can be calculated based on TV, RR and I:E ratio, results in 
a pressure drop across the endotracheal tube of 0.41±0.03, 0.53±0.04 and 0.63±0.05 cmH2O for 
70%N2/30%O2, 70%Ar/30%O2 and 70%Xe/30%O2, respectively. Since these pressure drops 
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are not significantly different for the used gas mixtures, we chose not to correct our measured 
ventilator pressures and displayed the measured values only. In future research different 
methods to assess aerodynamics should be used instead of Ppeak. 
The strength of our study design is the inclusion of positive and negative control groups to 
enable rigid validation of the injury model, and prolonging EVLP up to 6 hours. These 
conditions have not been studied experimentally in combination with different injury models. 
Despite increasing experience with EVLP (64,65), consensus about the value of the 
physiological parameters is still required to predict post-transplant performance (6). We 
observed that the first parameter to decline was Ppeak (in contrast to PVR and P/F) after a 
minimum reperfusion time of 4 hours, despite extensive injury.  
In conclusion, in this study we have validated a reproducible prolonged EVLP model with a 2-
hour warm ischemic interval and demonstrated that Ppeak, PVR and P/F could discriminate 
between non-injured and injured lungs. This was validated with W/D, histology and CT-
imaging. In addition, we are the first to report on noble gas therapy in lung transplantation. 
Treatment with Ar or Xe post-injury did not improve graft function in our model of prolonged 
EVLP. However, a positive effect might be missed due to the severity of the warm ischemic 
injury inducing extensive and probably irreversible damage. 
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A)  PREFACE 
In the previous chapter, we have investigated if postconditioning with noble gases during 
EVLP, could reduce ischemia-reperfusion injury (IRI). However, no beneficial effect was seen 
on the lung physiology of warm-ischemic injured lungs when exposed to argon or xenon after 
the ischemic insult on EVLP (postconditioning effect). To investigate a potential interventional 
effect of noble gases in lung transplantation, we therefore prolonged the exposure time to the 
noble gas to preconditioning (prior to the ischemic injury), perconditioning (during the ischemic 
injury) and postconditioning (after the ischemic injury) instead of postconditioning alone. In 
addition, in this study we investigated the treatment effect on cold-ischemic injury rather than 
warm ischemia, since our previous ischemic injury model with 2 hours of warm ischemia 
seemed too severe to study IRI modulation. Finally, in this model we studied the effect of Ar 
alone given its wider application potential due to a reduced production cost compared to Xe. 
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B)  ABSTRACT 
Background - Argon (Ar) is a noble gas with known organoprotective effects in rodents and, 
in in vitro models. In a previous study we could not detect a postconditioning effect of Ar during 
ex-vivo lung perfusion (EVLP) on induced warm-ischemic injury in a porcine model. In this 
study, we further investigated a prolonged exposure to Ar to decrease cold ischemia-reperfusion 
injury after lung transplantation with EVLP assessment (porcine model). 
Methods - Domestic pigs (n=6/group) were pre-conditioned for 6 hours with 21% O2 and 79% 
N2 (CONTR) or 79% Ar (ARG). Subsequently, lungs were cold flushed and stored inflated on 
ice for 18 hours with the same gas mixtures. Next, lungs were perfused on ex-vivo lung 
perfusion (EVLP) (acellular) for 4 hours while ventilated with 12% O2 and 88% N2 (CONTR 
group) or 88% Ar (ARG group). The perfusate was saturated with the same gas mixture but 
with the addition of CO2 to an end-tidal CO2 of 35-45 mmHg. The saturated perfusate was 
drained and lungs were perfused with whole blood for an additional 2 hours on EVLP.  
Results - Evaluation at the end of EVLP did not reveal a significant effect on the physiologic 
parameters by a prolonged exposure to Ar. Also wet-to-dry weight ratio did not improve in the 
ARG group.  
Conclusion - Although in other organ systems a protective effect of Ar has been shown, we did 
not detect a beneficial effect of a high concentration of Ar on cold pulmonary ischemia-
reperfusion injury after prolonged exposure to the noble gas. 
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C)  INTRODUCTION 
Lung transplantation is still hampered by a shortage of transplantable donor grafts, and those 
grafts that are available are often of limited quality (1). More and more, extended-criteria donor 
lungs are being used for organ transplantation. And although there is a similar 1-year survival 
(2), there is a higher incidence of severe primary graft dysfunction (PGD) among recipients of 
an extended-criteria donor lung (3). PGD is the end-result of ischemia-reperfusion injury (IRI) 
attacking the integrity of the alveolar membrane leading to pulmonary edema and impaired 
oxygenation (4,5). Severe PGD is associated with an impaired short-term and long-term 
outcome (6). Therefore, we have to tackle the development PGD by improving donor lung 
quality, which is referred to as “reconditioning”. Organ reconditioning can be achieved at three 
different stages: prior to organ injury (preconditioning), during organ injury (perconditioning) 
or after organ injury (postconditioning). Preconditioning is known as classical donor 
management, perconditioning involves optimization of the “out of body” time (preservation) 
and postconditioning is seen as strategies after reinstallation of perfusion. 
Our previous study which investigated a postconditioning effect of argon (Ar) (and xenon (Xe)) 
on pulmonary ischemia-reperfusion injury did not reveal a reconditioning effect (7); although 
beneficial postconditioning effects of Ar have been shown in other injury models such as 
cardiac arrest (8,9), brain injury (10), and neonatal asphyxia (11). Noble gases Ar and Xe have 
also previously been investigated as a reconditioning strategy in IRI kidney transplant models 
with  beneficial effects on graft function after exposure to these noble gases (12,13). But since 
the protective effect of Ar seems to be dose-dependent (14), a higher and longer exposure to Ar 
to protect against pulmonary ischemia reperfusion injury seemed justified.  A prolonged 
exposure to Ar can be achieved by introducing the gas earlier in the process of organ donation 
(15). During prolonged ventilation of the donor, Ar might protect and precondition the 
pulmonary graft prior to the ischemic insult (“preconditioning”). In addition, the lung can be 
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inflated with the potentially protective gas mixture during cold storage (“perconditioning”). 
Ventilating the donor lung prior to transplantation, in normothermic conditions with 
inhalational therapy is feasible due to the technique of ex-vivo lung perfusion (EVLP) (16,17). 
Also, the perfusion solution on EVLP could be saturated with Ar, such has been used with 
success in experimental perfusion of kidneys preceding transplantation (12,13). Replacing N2 
with Ar in the gas mixture for the ventilator and for the gas exchanger in the EVLP system, 
results in a dual exposure of the pulmonary graft to Ar, at both the endothelial and epithelial 
side (“postconditioning”). 
This study aimed to investigate the effect of Ar on pulmonary ischemia-reperfusion injury when 
administered prior (preconditioning), during (perconditioning) and after (postconditioning) the 
ischemic insult to donor lungs. Normothermic EVLP was used to evaluate the treatment effect 
on graft function.  
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D)  METHODS 
Animals 
Domestic pigs (35.81.6 kg) were used. Local ethical approval was obtained at the research 
institute (P043/2014). All animals received humane care in compliance with the “Principles of 
Laboratory Animal Care” formulated by the National Society for Medical Research and the 
“Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory 
Animal Resources and published by the National Institutes of Health (NIH Publication No. 86-
23, revised 1996). 
Animal anesthesia and study groups 
Anesthesia was induced with an intramuscular injection of 5 mg/kg Zoletil 100 (Virbac, Carros, 
France) and 3 mg/kg Xyl-M 2% (VMD, Arendonk, Belgium). After placement of an 18GA 
peripheral line (v. auricularis) muscle relaxation and analgesia were maintained with 2 mg 
pancuronium boli and 20 µg/kg/h fentanyl. Anesthesia was maintained with continuous 
infusion of 7-10 mg/kg/h propofol. Animals were intubated with a 7.0 mm endotracheal tube 
and ventilated with a tidal volume (TV) of 8 ml/kg and 5 cmH2O positive end expiratory 
pressure (PEEP). Respiratory rate was adjusted to obtain an end-tidal carbon dioxide (ETCO2) 
of 35-45 mmHg. Invasive arterial blood pressure (ABP) was measured in the right carotid artery 
and a 7.5 Fr Swan Ganz catheter (Edwards Lifesciences, CA, USA) was introduced through the 
right internal jugular vein to measure pulmonary pressures. Vigilance monitor (Edwards 
Lifesciences, CA, USA) was connected to monitor mixed venous saturation (SvO2) and 
continuous cardiac output (CCO).  
Animals (n=6/group) were divided into two groups: CONTR group and ARG group (Table 
V.2). After baseline instrumentation, animals were preventilated (preconditioned) for 6 hours 
with either 21% O2 / 79% N2 (CONTR group) or 21% O2 / 79% Ar (ARG group). The tidal 
volume of 8 ml/kg was corrected for density differences in the ARG group with the following 
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formula: TVmeasured = TVactual x √(ρtest gas/ρ100%O2). The density of the test gas (21% O2 / 79% 
Ar) is 1.505 kg/m3. Respiratory rate was adjusted to maintain an ETCO2 of 35-45 mmHg. Every 
hour, lungs were recruited by increasing the PEEP temporarily from 5 cmH2O to 20 cmH2O. 
After 6 hours of preconditioning, animals were heparinized (300 IU/kg) and 1 L blood was 
drained to be stored with CPDA on room temperature until the next day. Lungs were cold 
flushed antegrade (50 ml/kg) with OCS Solution (Transmedics, Andover, USA) while 
ventilated with 7 ml/kg TV and 8 cmH2O PEEP. Lungs were then inflated with the same gas 
mixture used during the preconditioning phase, and clamped for preservation at 25 cmH2O. A 
retrograde flush was performed on the back table before storing the lungs on ice for a prolonged 
period of cold ischemia of 18 hours. The following day, lungs were cannulated for EVLP with 
the XVIVO Lung Cannula Set (XVIVO Perfusion, Göteborg, Sweden) and an 8.0 mm 
endotracheal tube. A postconditioning (after the ischemic insult) exposure to Ar was introduced 
for 4 hours during acellular (OCS solution + albumin) EVLP in a dual way (via ventilator and 
gas exchanger penetrating both epithelial and endothelial sides). In the ARG group, N2 was 
replaced by Ar in the gas mixture of the ventilator and the gas mixture of the gas exchanger. 
The gas mixture settings of the gas exchanger for Ar or N2 (3 L/min) plus CO2 and O2 were 
chosen to establish equilibrium in the oxygen content at the inflow and outflow with an ETCO2 
of 25-35 mmHg. Lungs were ventilated with either 12% O2 / 88% N2 (CONTR) or 12% O2 / 
88% Ar (ARG). In the ARG group, density corrections for the tidal volume with the test gas 
(12% O2 / 88% Ar) were calculated with the same formula (test gas density 1.533 kg/m
3). Lungs 
were ventilated with a TV of 7 ml/kg, 7 breaths per minute respiratory rate and 5 cmH2O PEEP. 
After 4 hours of postconditioning, an additional 2 hours of EVLP was performed to assess the 
lungs. Therefore, the acellular perfusate in the reservoir was drained and the system was primed 
with 1 liter of whole blood (stored on CPDA at room temperature). During this 2-hour 
evaluation period, lungs were ventilated with air in both groups with 8 ml/kg TV, 12 times per 
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minute. The perfusate was deoxygenated in the gas mixture using 10 L/min N2 plus CO2 and 
O2 to obtain a mixed venous partial oxygen pressure with ETCO2 values between 25 and 35 
cmH2O. A summary of the study protocol is visualized in Table V.2.  
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Sampling and statistics 
During the preconditioning phase in-vivo, arterial blood samples were taken hourly. Also, the 
following hemodynamic parameters were monitored continuously and recorded hourly: arterial 
blood pressure (ABP), heart rate (HR), pulmonary artery pressure (PAP), mixed venous 
saturation (SvO2), continuous cardiac output measurement (CCO) and central venous pressure 
(CVP). After 6 hours of preconditioning, blood samples and tissue samples of liver and kidney 
(both fixed in formaldehyde 6%, embedded in paraffin and stained with hematoxylin-eosin) 
were taken to screen for potential injury due to toxicity of prolonged Ar exposure.  
During postconditioning and evaluation on EVLP, physiological parameters (LAP, PAP, PVR, 
Ppeak) were monitored and perfusate samples were taken hourly. A 2-way ANOVA was used 
to compare physiological parameters and gas concentration in the perfusate during EVLP 
postconditioning. All data was analyzed with Graphpad 4 (GraphPad Software Inc. La Jolla 
CA, USA) and the level of statistical significance was set at p<0.05).  
Lung grafts were only evaluated at the end of the evaluation period and values were compared 
with a Mann Whitney test. Tissue samples for histology were fixed in formaldehyde 6%, 
embedded in paraffin, stained with hematoxylin-eosin and scored based on injury severity by 
an experienced pathologist (18). Tissue samples for wet-to-dry weight ratio (W/D) calculation 
were taken at the end of the protocol. A bronchoalveolar lavage 30 ml saline was performed in 
duplicate in the right middle lobe for cytokine analysis (Cytokine Swine Magnetic 7-plex Panel 
for Luminex, Thermo Fisher Scientific Inc, Massachusetts, USA). Finally, the left lung was 
inflated at 25 cmH2O, frozen solid in the fumes of liquid nitrogen and scanned with Siemens 
Somaton CT scanner (Siemens Healthcare, Erlangen, Germany). Lung mass, volume, and 
density were measured on the basis of the CT-scan, using imaging software (HorosTM) as 
previously described, in which the lung is manually delineated and the number of voxels and 
mean density of the voxels within the volume is determined (19).  
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E)  RESULTS 
In vivo assessment  
During the 6 hours of preconditioning in-vivo, animals showed a stable and comparable 
continuous cardiac output measurement (CCO), mixed venous saturation (SvO2), mean 
pulmonary artery pressure (mPAP) and peak ventilator pressures (Ppeak) in both the CONTR 
and the ARG group (Figure V.7).  
 
Figure V.7 –  Continuous cardiac output (CCO), mixed venous saturation (SvO2), mean 
pulmonary artery pressures (mPAP) and peak ventilatory pressures (Ppeak) we re monitored 
during the preventilation period. Results are depicted as median   IQR.  
After 6 hours of preconditioning, where animals in the ARG group were exposed for 6 hours to 
Ar through ventilation, serum analysis for kidney and liver function did not show an elevation 
in liver and kidney tests compared to control animals (Table V.3).  
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Table V.3 –  Liver and kidney serum analysis.  
 
Normal parameters are shown for both groups. Results are depicted as median (IQR). Alk fosf = 
alkaline phosphatase; AST = aspartate transaminase; ALT = alanine aminotransferase; Gamma 
GT = gamma glutamyl transpeptidase; LDH = lactate dehydrogenase; Bili = total bilirubine; 
CRP = C-reactive protein  
Histology sections of the liver showed normal structure of liver lobules with no infiltration of 
inflammatory cells (Figure V.8). Histology sections of the kidney showed intact glomeruli and 
normal proximal and distal tubuli. There was no infiltration of inflammatory cells or deposition 
of necrotic epithelial cells.  
 
Figure V.8 –  Normal histology of liver and kidney after 6 hours ventilation with Ar (ARG) or air 
(CONTR).  
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Preservation on ex-vivo lung perfusion 
During the 4 hours of postconditioning on EVLP, PO2 was stable and similar at the inflow and 
outflow indicating stable gas concentrations of the perfusate (Figure V.9). 
 
Figure V.9 –  Stable PO2  shown in out- and inflow. Results are depicted as median   IQR and 
analyzed with a 2-way ANOVA (no difference between both groups).  
During the postconditioning on EVLP, Ppeak and PVR remained stable in both groups and 
were not significantly different (Figure V.10) 
 
Figure V.10 –  Stable airway peak pressures (Ppeak, left graph) and pulmonary vascular 
resistance (PVR, right graph) during postconditioning on EVLP. Data are depicted as me dian ± 
IQR and analyzed with a 2-way ANOVA (no differences between both groups).  
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Evaluation of graft quality 
After 2 hours of perfusion with whole blood, final evaluation of physiologic parameters on 
EVLP did not show a significant difference in PaO2/FiO2, Ppeak or PVR. Also, estimation of 
lung edema (W/D and CT-density) did not show a significant difference between the two groups 
(Table V.4). 
Total cell count in BAL and differential cell count (% of macrophages, neutrophils, 
lymphocytes) in BAL did not show a difference between both groups at the end of the 
evaluation on EVLP (Table V.4). 
Histological sections of lung tissue showed a similar severity score (0-3) for congestion, 
necrosis, neutrophil influx and influx of mononuclear cells in the bronchovascular, pleuroseptal 
and alveolar compartment (Table V.4).  
Measured cytokine levels of porcine INF-α, IFN-γ, TNF-α, IL-8, IL-1β, IL-10 and IL-4 in BAL 
and perfusate are shown in Table V.4. There were no significant differences between the 
CONTR and ARG group.  
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Table V.4 –  Evaluation at the end of EVLP.  
 
No differences were found between both groups (Mann -Whitney testing) at the end of EVLP at 
the final evaluation of graft quality in physiological parameters, lung edema estimation, BAL 
cell count, Injury severity scores (ISS) on histology, or cytokine levels in perfusate or BAL.  
PaO2/FiO2 = partial oxygen pressure/fractional inspired oxygen concentration; TCC = total cell 
count; ISS = injury severity score; BAL = bronchoalveolar lavage  
152 
 
F)  DISCUSSION 
In this paper, we report the results of a porcine study investigating the effect of prolonged 
exposure to Ar on cold-ischemic lung injury with ex-vivo assessment. 
Following a previous porcine pulmonary ischemia-reperfusion injury study where no effect was 
found by postconditioning with Ar, we designed an experimental protocol to allow a maximal 
exposure to Ar. The pulmonary graft was therefore exposed to Ar prior to the ischemic interval 
(preconditioning), during the cold ischemic injury (perconditioning) and after the ischemic 
interval during reperfusion on EVLP (postconditioning). The concentration of oxygen in the 
gas mixture for lung ventilation (FiO2, fractional inspired oxygen concentration) was chosen, 
to obtain the highest concentration of Ar possible (or N2) without inducing hypoxia to the lung 
tissue. During the preconditioning phase, while the animal was still alive, the FiO2 of air was 
chosen (21%) and in the ARG group the N2 in air was replaced by 79% of Ar. To allow for 
perconditioning, the lungs were exposed to Ar during cold preservation by inflation with the 
same gas mixture used as during the preconditioning phase (FiO2 21% with 79% N2 or Ar). The 
postconditioning phase during EVLP was optimized compared to the previous postconditioning 
protocol (7). That is: the oxygen concentration in the gas mixture of the ventilator was lowered 
to 12% instead of 21% to allow for a higher Ar concentration of 88% (or 88% N2 in the CONTR 
group). And in addition, the perfusate was saturated with Ar via the gas exchanger to expose 
both the epithelial and the endothelial side of the alveolar membrane during EVLP. This 
saturation of the perfusion solution with Ar has also been tested in experimental kidney 
perfusion with improved graft function after kidney transplantation (12,13).  
During 6 hours of preconditioning with Ar in-vivo, stable hemodynamic parameters were 
observed. Animals had normal pulmonary and systemic blood pressures, normal heart rates and 
normal peak ventilation pressures during the total perfusion time of 6 hours. After 6 hours of 
preconditioning, tissue samples from kidney and liver were taken and the pathology report did 
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not reveal any sign of injury to kidney or liver due to toxicity. Serum samples tested for liver 
and kidney function were similar between both groups. These early findings suggest that 
prolonged ventilation with Ar in-vivo is safe.  
Maintaining a steady state of oxygen delivery and gas exchange during preservation on EVLP 
is a technique that has been introduced by Transmedics in the OCSTM Lung protocol (20). In 
this set-up, partial oxygen concentration is kept stable at in- and outflow meaning no gas 
exchange takes place. This allows for lower gas consumption since N2 or Ar are not 
continuously washed out in the gas exchanger. This technique is chosen instead of the complete 
wash-out of oxygen with high flow rates of N2 or Ar, because of the scarcity and higher cost 
price of noble gases (21,22). During EVLP, we can monitor physiologic parameters over time 
while lungs are exposes to Ar and compare them with the physiologic parameters of the control 
group.  
To fully study the effect of Ar on IRI, neutrophils will have to be present in the perfusion 
solution since they are the key players in the pathophysiology of ischemia-reperfusion injury 
(4). Therefore, after 4 hours of ex-vivo postconditioning with Ar, lungs were perfused for an 
additional 2 hours with whole blood containing neutrophils. With this approach, transplantation 
was mimicked by adding an additional two hours of perfusion with all essential blood 
components present. However, it can never replace the in-vivo environment and remains a 
surrogate for transplantation. In particular, the perfusion settings with a centrifugal pump result 
in a different shear stress environment and flow conditions when compared to the in-vivo 
pulsatile cardiac reperfusion of the lung. 
At the end of this 2-hour additional whole-blood perfusion period, the pulmonary graft was 
evaluated by comparing physiological data, tissue samples and BAL. A median W/D of 7.4 was 
observed in the CONTR-group and no irreversible necrosis was seen on lung histology. In 
combination with an increased PVR and increased Ppeak, we can conclude that sufficient injury 
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was inflicted to the lung graft by our injury model to study IRI. Surprisingly, no beneficial 
effect was detected in physiologic parameters (Ppeak, PVR, PaO2/FiO2), histology, BAL cell 
count and cytokine measurements or lung edema (W/D and CT density) after prolonged 
exposure to argon in the ARG-group. We therefore concluded that attenuation of cold ischemic 
injury by Ar reconditioning is not beneficial in this setting. However, in other organ systems, 
both pre- and postconditioning by Ar have been described and the mechanisms of these effects 
should be further unraveled.  
Evidence of an organoprotective effect in solid organ transplantation has mainly been 
demonstrated in kidney transplantation. Both Faure et al and Irani et al showed that saturation 
of the cold preservation medium with argon, resulted in a better preserved renal architecture 
with improved early functional recovery, graft quality and survival after kidney transplantation 
in their rat and pig models (12,13). Niemann et al (23) showed that hypothermia alone, in brain-
dead donors also results in a reduced rate of delayed graft function among kidney transplant 
recipients. The effect of hypothermia or noble gases alone, has not been thoroughly investigated 
in solid organ transplantation so far. It might be, that an organoprotective effect of noble gases 
in solid organ transplantation is based on an interaction with the hypothermic protective effect. 
Mechanisms of a combinational therapy of hypothermia and noble gases, in combination with 
the interval of exposure (pre-, per-, postconditioning) should therefore be investigated further 
to demonstrate a protective effect in lung transplantation. 
Enhancement of the neuroprotective effect of cooling by combining it with Ar exposure, has 
also been shown by Broad et al who demonstrated improved brain energy metabolism, faster 
EEG recovery and reduced cell death on TUNEL staining in a new-born piglet encephalopathy 
model (24). Notably, the reported functional and histopathological neuroprotective effect in 
other traumatic, hypoxic and ischemic brain injury models has also been demonstrated in 
normothermic conditions (11,25–28). A neuroprotective effect of noble gases can therefore not 
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be explained by an augmented protective effect of hypothermia alone. It might therefore still 
be possible that Ar could attenuate pulmonary injury other than (cold-) ischemic injury. For 
example, brain-dead donors suffer from a systemic inflammation and activation of apoptosis 
which could trigger the onset of severe IRI (29,30). Considering the mechanisms of brain-dead 
induced pulmonary damage and the potential of noble gases to promote ERK1/2 signaling 
through activation of MAPK in both normothermic and hypothermic conditions (31,32), further 
animal research, preferably using a brain-dead injury model combined with protective 
hypothermia and transplantation, seems appropriate. 
We conclude that, although beneficial effects on ischemic injury in various other organ systems 
have been reported, we did not detect an improvement in pulmonary graft function after 
prolonged exposure to Ar in our cold-ischemic injury model with EVLP assessment. Further 
animal research, preferably using a brain-dead injury model, including an in-depth mechanistic 
investigation of the lung-protective effect of Ar, should be conducted.   
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A)  PREFACE 
In the previous chapter, we have investigated the reconditioning potential of noble gases to 
improve lung quality prior to transplantation. In this chapter, we will focus on mesenchymal 
cell treatment to regulate the inflammatory process of ischemia-reperfusion injury (IRI) that 
can lead to severe primary graft dysfunction. In vitro and small rodent studies have shown that 
cellular therapy can have a beneficial immunoregulatory effect via various pathways. However, 
there is no data available in pre-clinical models on timing, dosing or route of administration of 
these cells. Therefore, we will focus on the ideal route of cellular therapy administration in the 
first part. We will investigate if cells should be administered in the airways or via the blood 
stream to tackle IRI and protect the alveolar capillary membrane.  
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B)  ABSTRACT 
Introduction - Primary graft dysfunction (PGD) compromises early outcome after lung 
transplantation. Others previously showed that administration of multipotent adult progenitor 
cells (MAPC) can be beneficial in modulating acute lung injury. Ex-vivo lung perfusion could 
serve as the ideal platform for cell administration and treatment evaluation. We report our first 
experience in administrating MAPC during EVLP in a large animal model (porcine), comparing 
intravascular (IV) and intratracheal (IT) administration to modulate PGD following warm 
ischemia-reperfusion injury. 
Methods - Porcine lungs were evaluated during 6 h of EVLP after a warm ischemic interval of 
90 minutes. Animals (n=6/group) were divided into 4 groups. In MAPC-IV 10*106 MAPC cells 
were administered intravascular at the onset of EVLP, in CONTR-IV no cells were added to 
the perfusate. In MAPC-IT and CONTR-IT, 40 ml of PBS was instilled in the airways at onset 
of EVLP. In MAPC-IT only, 10*106 MAPC were mixed with the PBS. At the end of EVLP, 
compliance, pulmonary vascular resistance, PaO2/FiO2, wet-to-dry weight ratio (W/D) and CT-
density were evaluated. Early depletion of the perfusate due to excessive edema formation was 
documented. Cytokine analysis was performed on perfusate and bronchoalveolar lavage fluid.  
Results – In both the IV and IT comparison, no differences were detected in physiological 
parameters, metabolism, graft survival or cytokine analysis. No differences were detected in 
W/D when MAPC cells were administered IV. However, there was less edema formation in the 
MAPC-IT groups compared to the CONTR-IT group (median W/D 6.6 vs 7.1). 
Conclusion – We conclude that EVLP is a useful tool for administration and evaluation of 
cellular therapy. Only IT administration of MAPC resulted in less edema formation, however 
no significant differences were detected in lung physiology or the inflammatory profile of the 
donor lung. Future experiments should focus on timing and dosing of MAPC in the airways to 
detect a beneficial effect on the pathophysiology of PGD.    
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C)  INTRODUCTION 
In lung transplantation, severe primary graft dysfunction (PGD) still occurs in up to 30% of all 
transplanted patients with immediate impact on both short-term and long-term outcomes (1). 
PGD occurs within 72 hours after lung transplantation and presents itself with impaired 
oxygenation, lung edema and diffuse chest infiltrates (2). It is the end-result of a severe 
inflammatory reaction with early activation of donor macrophages, release of reactive oxygen 
species (ROS) and infiltration of recipient neutrophils which ultimately leads to diffuse alveolar 
damage (3). Clinically, only supportive treatment such as positive pressure ventilation, fluid 
restriction and extra-corporeal membrane oxygenation are available. To improve early outcome 
after lung transplantation, it is therefore crucial to modulate this inflammatory environment of 
donor lungs that occurs with ischemic injury during the process of organ donation, to reduce 
the incidence of PGD (4).  
Bone marrow-derived mesenchymal cells such as the mesenchymal stem cell (MSC) and 
multipotent adult progenitor cell (MAPC), are increasingly being investigated in a wide 
spectrum of inflammatory and auto-immune disorders because of their immunoregulatory 
properties (5,6). Since they have limited immunogenicity, they are found to be safe and 
potentially efficacious (7) even in lung diseases such as acute respiratory distress syndrome that 
shares similar pathophysiology with PGD (8,9). These cells could therefore have the potential 
to modulate the rapidly evolving inflammatory cascade during reperfusion of the donor lung, 
based on their immunoregulatory properties. A reconditioning effect could be based on homing 
and differentiation of these mesenchymal cells into new structural cells. However, in the acute 
phase early after reperfusion, it is most likely the release of paracrine soluble factors and cell-
cell interactions between these cells and structural and inflammatory cells of the lung grafts that 
are responsible for modulation of ischemia-reperfusion injury (IRI). For example, Mordant et 
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al have shown that infusion of human MSCs was associated with increased levels of human 
VEGF, which resulted in a decrease of porcine IL-8 expression, a marker of PGD (4).  
To our knowledge, comparative data on the ideal route of administration of MAPC to the lung 
has not been published before. Both intratracheal (IT) and intravenous (IV) administration have 
been tested in separate investigations with similar outcome  (4,10). In the lung, cellular 
treatment can thus be administered via the vasculature of the lung, or via the airways through 
bronchoscopy during ventilation.  
As an alternative for cold static storage that leads to hypoxic lung injury, ex-vivo lung perfusion 
was introduced in 2001 by Stig Steen as a normothermic machine-perfusion technique with 
simultaneous ventilation of the donor lung in an ex-vivo setting. EVLP allows for more careful 
evaluation of the donor lung, but more importantly, could serve as the ideal treatment platform 
to improve organ quality prior to transplantation. That is, we do not compromise the donor nor 
the recipient in this way, and we can immediately evaluate the physiological effect of our 
treatment prior to transplantation. EVLP allows for administration of cells in the circulating 
perfusate to reach the alveolar-capillary membrane at the endothelial side, or can be used to 
administer cells in the airways while ventilated to reach the epithelial side.  
We hypothesized that administration of MAPC at the start of EVLP would decrease IRI that 
leads to primary graft dysfunction. We compared the impact of MAPC administration in the 
airways (IT) and through perfusion (IV) vs their controls in a porcine model of reperfusion 
injury following warm ischemia. EVLP will be used as a platform for cellular therapy and for 
evaluation of the donor lung quality in an ex-vivo setting (11,12).  
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D)  METHODS 
Animals 
Male domestic pigs (Topigs 20, 36-42 kg) were used and received proper care in compliance 
with the European Directive 2010/63/EU on the protection of animals used for scientific 
purposes. The Ethical Committee of the KU Leuven approved our experimental protocol (NTS 
P043/2014).  
Animal anesthesia and baseline 
Anesthesia was induced by an intramuscular injection with 5 mg/kg Zoletil 100 (Virbac s.a., 
Carros, France) and 3 mg/kg Xyl-M 2% (V.M.D. s.a, Arendonk, Belgium). A 20 GA peripheral 
intravenous catheter (Becton Dickinson Inc, Utah, USA) was inserted in the ear vein. 
Pancuronium bromide 2mg (Inresa Pharma, Bartenheim, Germany) and 20 µg/kg/h of fentanyl 
(Janssen-Cilag n.v., Beerse, Belgium) were administered for muscular relaxation and analgesia. 
General anesthesia was maintained with continuous intravenous infusion of 10 mg/kg/h 
Propofol-Lipuro 2% (B. Braun Medical n.v., Diegem, Belgium). All animals were intubated 
with a cuffed endotracheal tube of 7.0 mm internal diameter (MallinckrodtTM Covidien Inc, 
Dublin, Ireland) and ventilated in a volume-controlled mode (Aestiva 3000, GE Healthcare 
Europe GmbH, Little Chalfont, United Kingdom) using a tidal volume of 8 ml/kg, PEEP of 5 
cmH2O and FiO2 of 30%. Respiratory rate was set between 20-25 breaths/min to maintain an 
end-tidal carbon dioxide (ETCO2) that was stable between 45 and 55 mmHg. Invasive blood 
pressure was monitored through a 14 GA cannula inserted in the right carotid artery (Secalon-
TTM, Becton Dickinson Inc, New Jersey, United States).  
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Study groups 
Animals were divided into 4 groups (n=6/group) (Figure VI.1):  
 MAPC-IV group (10*106 MAPC cells were diluted in priming solution and 
administered IV at onset of ventilation during EVLP) 
 CONTR-IV group (no cells were added) 
 MAPC-IT group (10*106 MAPC cells in 40 mL Phosphate Buffered Saline (PBS) were 
instilled in the airways at onset of ventilation during EVLP)  
 CONTR-IT group (40 mL without cells was instilled in the airways at onset of 
ventilation during EVLP) 
In all groups, circulatory and respiratory arrest was induced by myocardial fibrillation through 
percutaneous puncture of the myocardium with an electrical pulse generator (current max 300 
mAmp, frequency 50 Hz) and disconnection from the ventilator. Animals were then left 
untouched at room temperature (warm ischemic interval (WIT) of 90 min in situ).  
 
Figure VI.1 - Study groups 
WIT = warm-ischemic time; CIT = cold-ischemic time 
Procurement of donor lungs 
A median sternotomy was performed 15 min prior to completion of the warm ischemic interval. 
The pericardium was opened and the pulmonary artery, superior and inferior caval veins were 
encircled. A purse-string was made on the right ventricular outflow tract to secure the 20 Fr 
CONTR-IV
BASELINE 90' WIT 75' CIT 6hrs EVLP
MAPC-IV
BASELINE 90' WIT 75' CIT    ↘34°C: add 10*106 MAPC IV
6 hrs EVLP
CONTR-IT
BASELINE 90' WIT 75' CIT 6hrs EVLP
MAPC-IT
BASELINE 90' WIT 75' CIT    ↘34°C: add 10*10
6
 MAPC IT
6 hrs EVLP
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flush cannula in the pulmonary trunk (DLP Inc., Grand Rapids, Michigan USA). Following 
inflow occlusion through the caval veins, lungs were cold flushed (4 °C) in an antegrade way 
with 50 ml/kg THAM-buffered OCSTM Solution (TransMedics Inc. 
Andover, USA) according to the manufacturer’s instructions. To optimize the flush conditions, 
lungs were protectively ventilated with a pressure-controlled ventilation mode using an 
inspiratory pressure of 15 cmH2O and a PEEP of 8 cmH2O. 
Following the antegrade flush, the heart-lung block was excised, the heart was removed and the 
organs were additionally flushed in a retrograde way with a total volume of 1000 ml of OCSTM 
Solution. Subsequently, lungs were cannulated with the XVIVO cannulation set with closed 
atrium (XVIVO Perfusion AB, Göteborg, Sweden). An endotracheal tube of 8.0 mm internal 
diameter (Mallinckrodt Medical, Athlone, Ireland) was secured in the trachea.  
Perfusate 
1.5 liters of a laboratory prepared acellular solution was used. The perfusate was composed of 
THAM-buffered Perfadex (XVIVO Perfusion AB, Göteborg, Sweden) with 70 g/l of human 
albumin. Also, 15.000 IU heparin, 3.0 g glucose, 60 meq sodiumbicarbonate, 0.18 g calcium 
and 20 IU of insulin were added. Baseline samples of the priming solution were analyzed.  
Ex-vivo lung perfusion 
First, the PA cannula was de-aired and connected. Once there was flow, we also connected the 
outflow cannula with a vacuum effect on the reservoir (XCoatingTM, Terumo NV, Leuven, 
Belgium) to avoid high outflow pressures due to an air lock at the onset of EVLP. Oxygenated 
normothermic flow (temperature of perfusate set at 37°C) was gradually increased over a time 
period of one hour to a target of 40% of the estimated cardiac output, calculated as 0.1 ml/kg 
of the measured body weight. Left atrial pressure was kept between 3 and 5 mmHg at all times 
(13,14). Once the effluent reached a temperature of 34°C, volume-controlled ventilation was 
started with the following settings: TV of 7 ml/kg, 7 breaths/min, PEEP 5 cmH2O and FiO2 
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30%. The gas exchanger in the circuit was then provided with a mixture of oxygen, CO2 and 
nitrogen to compose a mixed venous gas concentration through the inflow. Recording of blood 
gas results for oxygenation ((Partial oxygen pressure (PaO2 [mmHg]) / Fractional Inspired 
Oxygen (FiO2 [%])), dynamic lung compliance (Compl [ml/cmH2O), and pulmonary vascular 
resistance (PVR[dynes/sec/cm-5] = ((PAP[mmHg]-LAP[mmHg])*80) / Flow[L/min], were 
started after 1 hour of onset of EVLP until 6 hours of reperfusion. Hourly recruitment 
maneuvers were performed. Experiments were prematurely ended when the perfusate reservoir 
lost 1000ml of perfusate due to lung edema formation (defined as graft survival).  
10x106 MAPC (provided by the Stem Cell Institute Leuven, Leuven, Belgium) were 
administered in the MAPC-IT and MAPC-IV group at the onset of ventilation. For IT 
instillation, the cells were diluted in 40 ml of pH-neutral PBS and distributed throughout the 
whole lung by bronchoscopy. In the MAPC-IV group cells were diluted in 20 ml of priming 
solution and slowly injected at the inflow over a period of 5 minutes. At 3 hours of EVLP 1 g 
of glucose and 15 meq bicarbonate were added in all experiments. 
The laboratory set-up using a warm-ischemic injury model and EVLP with acellular perfusate 
has been previously used and is validated in our laboratory (15,16). 
Tissue sampling 
Lung edema of the RLL/L sample was measured using the gold standard for lung edema 
estimation: wet-to-dry weight ratio (W/D) (17). 
At the end of the protocol tissue samples were taken and a 30 cc bronchoalveolar lavage (BAL) 
was performed in duplicate in the right middle lobe as previously described (18). Returned 
fractions were pooled and an undiluted 100 µl cytospin was stained with Diff-Quick (Dade 
Behring, Newark, NJ) to obtain differential cell counts. IL-1β, IL-4, IL-8, IL-10, IFN-γ, IFN-α 
and TNF-α were quantified in BAL supernatant with a porcine magnetic 7-plex panel 
(LSC001M, Thermofisher Scientific, Waltham, MA, USA). 
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Statistical Analysis 
Each intervention group was compared with its own control (two by two comparison). MAPC-
IT was compared with CONTR-IT, and MAPC-IV was compared with CONTR-IT. 
Data analysis was performed with the statistical software package Graphpad Prism 4 (GraphPad 
Software Inc., CA, USA). All data were expressed as median ± interquartile range (IQR). In 
the cases where lungs could not sustain the full 6 hours of EVLP, data points recorded in the 
next hours after the premature end of EVLP were considered the same as the last data point 
available to allow comparison at all evaluation points. Statistical analysis was performed on the 
data at the end of EVLP (or last recorded data-point in case of early drop-out) with a Mann-
Whitney test. Graft survival on EVLP was analysed with a log rank test. The level of 
significance was set at p < 0.05.  
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E)  RESULTS 
Donor Animals 
Donor animals were comparable in weight between the CONTR-IT and the MAPC-IT group 
(p=0.39), Table VI.1, and between CONTR-IV and MAPC-IV (p=0.39), Table VI.2. 
Physiological parameters during EVLP 
 
 
Figure VI.2 –  Physiological parameters of  CONTR-IT vs MAPC-IT groups in the upper panel; 
and of CONTR-IV vs MAPC-IV in the lower panel . Data are expressed as Median ± IQR 
(n=6/group).  
Physiological parameters of IT-groups are depicted during the 6-hour observation on ex-vivo 
lung perfusion (upper panel Figure VI.2). Data registration started after a slow incremental 
increase in flow and temperature during the first hour. Oxygenation decreased over time in both 
groups and was not significantly improved in the MAPC-IT group vs CONTR-IT group, at the 
final evaluation moment after 6 hrs of EVLP (p=0.82). Compl initially increased due to hourly 
recruitment maneuvers starting at 1.5 hrs after onset of EVLP. Afterwards, Compl decreased in 
both IT-groups with no significant difference at the end of EVLP (p=0.39). PVR started low 
but slowly increased in both IT-groups over time. There was no significant improvement in 
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PVR in the MAPC-IT group at the end of EVLP (p=0.94) compared to CONTR-IT. 
Physiological parameters at the end of EVLP for the IT-groups are shown in Table VI.1.  
Physiological parameters of IV-groups are depicted during the 6-hour observation on ex-vivo 
lung perfusion (lower panel Figure VI.2). Oxygenation also decreased over time in both IV-
groups and was not significantly improved in the MAPC-IV group when looking at the final 
evaluation moment after 6 hrs of EVLP (p=1.0). Compl initially increased due to hourly 
recruitment maneuvers starting at 1.5 hrs of EVLP, similar as in IT-groups. Afterwards, Compl 
decreased in both IV-groups, with no significant difference at the end of EVLP (p=0.70). PVR 
started low, but also slowly increased over time in both IV-groups. There was no significant 
improvement in PVR in the MAPC-IV group at the end of EVLP (p=0.48) compared to its 
CONTR. Physiological parameters at the end of EVLP for the IV-groups are depicted in Table 
VI.2. 
Graft Survival 
  
Figure VI.3 –  Log-rank analysis showed a trend towards better g raft survival in MAPC-IT vs 
CONTR-IT (left panel).  There was no difference in graft survival on EVLP between the CONTR -
IV and MAPC-IV groups (right panel).  
Lung perfusion was stopped when more than 1000 ml of perfusate was lost due to excessive 
lung edema formation since the perfusate level in the reservoir became critically low. Total 
perfusion time was documented and depicted in Figure VI.3 to analyze graft survival on EVLP, 
defined by this perfusate decrease. 
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In the CONTR-IT group only 2 grafts were perfused for the full 6 hrs (median perfusion time 
5.4 hrs), in the MAPC-IT groups only 2 grafts dropped out early at 5.5 hrs (median perfusion 
time 6.0 hrs). However, there was no significant difference between the 2 groups in graft 
survival (p=0.19).  
In the CONTR-IV group, there were 3 drop-outs (median perfusion time 5.3 hrs) whereas in 
the MAPC-IV group there were 4 drop-outs (median perfusion time 4.8 hrs). There was no 
significant difference in perfusion time between both groups (p=0.75) (Figure VI.6). The 
development of lung edema matched with the decline in physiological parameters in all 
experiments. 
Metabolism 
Glucose consumption and lactate production are depicted in Figure VI.4 for IT-groups (upper 
panel) and IV-groups (lower panel). After 3 hrs of perfusion, glucose levels increased due to 
the addition of 1 g glucose in all experiments. At the end of EVLP, there was no significant 
difference between CONTR-IT vs MAPC-IT in glucose consumption (p=0.18) or lactate 
production (p=0.39) (Table VI.1). Also in the CONTR-IV vs MAPC-IV groups, there was no 
difference between both groups in glucose consumption (p=0.48) or lactate production (p=0.94) 
at the end of EVLP (Table VI.2). 
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Figure VI.4 –  Glucose consumption and lactate production are depicted over time  for CONTR-
IT vs MAPC-IT groups in the upper panel,  and for CONTR -IV vs MAPC-IV groups in the lower 
panel. Data are expressed as Median ± IQR (n=6/group).  
Estimation of Lung Edema 
Lung edema estimation at the end of EVLP showed a significantly lower W/D ratio in the 
MAPC-IT group compared to the CONTR-IT group (p=0.03) (Figure VI.5 left panel). 
However, W/D ratio did not differ between the CONTR-IV and MAPC-IV group (p=0.70) 
(Figure VI.5 right panel).  
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Figure VI.5 W/D ratio was significantly reduced in the MAPC -IT vs CONTR-IT group, however 
was not reduced in the MAPC-IV vs CONTR-IV group. Data are depicted as boxplot and 
compared with a Mann-Whitney test.  
Cytokine Analysis 
Results of the Multiplex ELISA analysis of the BAL fluid of the CONTR-IT vs MAPC-IT is 
shown in Table VI.1. IL-8 and IL-1β were above and below detection limit, respectively. There 
were no significant differences between the IT-groups in IL-10 (p=0.31), IFN-α (p=0.82), IFN-
γ (p=0.48), TNF-α (p=0.39) or IL-4 (p=0.48). 
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Table VI.1 –  Donor animal characteristics, EVLP parameters at the end of EVLP, ELISA-analysis 
of BAL fluid and metabolic  parameters at the end of EVLP compared between CONTR-IT and 
MAPC-IT group.  
 
Data are compared with a Mann-Whitney test and are depicted as median (25% QI - 75% QI).   
Results of the Multiplex ELISA analysis of the BAL fluid compared between CONTR-IV vs 
MAPC-IV, are shown in Table VI.2. IL-1β was below the detection limit. There were no 
significant differences between the IV-groups in IL-10 (p=0.94), IFN-α (p=0.39), IFN-γ 
(p=0.48), TNF-α (p=0.59), IL-4 (p=0.94) or IL-8 (p=1.00). 
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Table VI.2 -  Donor animal characteristics, EVLP parameters at the end of EVLP, ELISA -analysis 
of BAL fluid and metabolic parameters at the end of EVLP, compared between the CONTR -IV 
and MAPC-IV group. 
 
Data are compared using a Mann-Whitney test and are depicted as median (25% QI -75% QI).  
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F)  DISCUSSION 
In this study, we have demonstrated that administration of cellular therapy during EVLP in the 
airways (IT) (not when administered via the vasculature (IV)) can reduce lung edema formation 
in a porcine model with warm-ischemic lung injury. Graft function after administrating 10*106 
MAPC in the airways (IT) or in the vasculature (IV) of the lung, during ex- vivo lung perfusion, 
was compared with physiological and immunological assessment with EVLP. 
With these experiments, where we administered cellular therapy in both airways and in the 
pulmonary artery, we confirm that EVLP is an excellent platform for ex-vivo organ treatment 
prior to transplantation (12). However, up to now, there is no consensus on how to deliver 
cellular therapy to the lungs, either via the airways or via the blood stream. If stem cells are 
injected intravenously, they are initially trapped inside the lungs due to their large cell size (15-
19 micrometre) (19). This phenomenon is often referred to as the pulmonary first-pass effect 
(20). Although this effect might impede a potential therapeutic effect in other organ systems 
after intravenous administration, this effect is beneficial for the lungs since most are trapped in 
the lung in the acute setting. Nonetheless, there is an increased risk of pulmonary hypertension 
due to micro-thrombi formation which can lead to increased PVR and hydrostatic pulmonary 
oedema. Beneficial effects of stem cell administration to reduce pulmonary injury has been 
described with both delivery in the airways or in the vasculature of the lungs (4,11,21). 
However, since primary graft dysfunction starts with diffuse alveolar damage and epithelial 
denudation that results in capillary leakage, we hypothesized that instillation of stem cells at 
the epithelial site could be most beneficial (22). Also, we are the first to investigate the effect 
of MAPC in a controlled animal study of pulmonary IRI.  
Less edema formation was detected in the MAPC-IT group based on a lower W/D at the end of 
EVLP. This effect was not seen when stem cells were administered IV. Therefore, we conclude 
that a beneficial effect of cellular treatment has the greatest potential when cells are 
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administered in the airways. Unfortunately, this reduction in lung edema in the MAPC-IT group 
was not translated into improved physiological parameters compared to its CONTR-IT group. 
However, until today there is no consensus on which parameters are most reliable for the 
evaluation of pulmonary graft function ex-vivo. More and more, lung compliance is chosen 
over pulmonary vascular resistance and oxygenation capacity since it is the first parameter that 
changes with the development of lung edema (23).  Also in our experiments we see that 
oxygenation remains stable longer in comparison with lung compliance (and pulmonary 
vascular resistance). Prediction of graft quality after lung transplantation based on physiological 
parameters remains therefore difficult. So although no differences were found in physiologic 
parameters in our experiments, there was less edema formation in the MAPC-IT group. 
Therefore, MAPC cells delivered in the airways did effect the end-result of ischemia-
reperfusion injury: accumulation of alveolar edema. A transplant model with evaluation of the 
graft quality after whole-blood perfusion in the recipient could therefore shed more light on the 
true effect of mesenchymal cell administration.  
In addition to a lower W/D ratio, grafts that received multipotent adult progenitor cells in the 
airways tend to drop-out later on EVLP (median perfusion time 6.0 hours (5.5 – 6.0 IQR)) than 
pulmonary grafts in all other groups (median perfusion time 5.25 hours (4.0 – 6.0 IQR)). 
Although this effect was statistically not significant (p=0.19), we did feel that this was an 
important tendency for future experiments.  
In solid organ transplantation, cellular ex-vivo treatment focuses on mesenchymal cells. Both 
the mesenchymal stem cell (MSC) and the multipotent adult progenitor cell (MAPC) are bone-
marrow derived mesenchymal cells with similar immunoregulatory properties (24,25). The 
MSC has already been investigated in ischemia-reperfusion injury models of kidney and liver. 
In both these models, there was a better preserved histological architecture, and enhanced graft 
function after transplantation when stem cells were administered to the graft (26,27). Also in 
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lung transplantation, pre-clinical data on graft enhancement has been published now (4). 
Preliminary data with similar results in pulmonary grafts have been published for the MAPC 
(10), however comparative pre-clinical data is lacking. Therefore, we believe that more research 
needs to be conducted before this therapy can be safely introduced in current clinical solid organ 
transplant programs. 
Although an effect was detected by other research groups, we did not detect an alteration in 
graft function based on physiologic parameters and cytokine expression profiles after 
administration of 10 million cells in lungs that were injured by warm ischemia. However, some 
limitations in this study might have led to false-negative results. First, timing and dosing of 
cellular treatment has not been widely investigated. In mice studies, 0.5 to 2 million cells are 
usually administered however, these doses correspond to 100 to 200 million cells/kg which is 
widely irrelevant for clinical practice. In our study design, we administered a dose of 20 million 
cells / (kg lung weight). We based the dosing on the lung weight rather than on body weight, 
since cells were administered to the lungs only in an ex-vivo setting. Other research groups in 
solid organ transplantation (liver, kidney) showed that an intermediate dose of 3.5 to 4.5 million 
cells / (kg total body weight) can reduce graft failure (26,27). This dose is based on total body 
weight, even though grafts are perfused ex vivo (4). If we were to calculate our administered 
dose on total body weight (mean 42.5kg), we can conclude that the used dose in this protocol 
(0.24 million/kg) might have been insufficient to induce a physiological improvement.  
Secondly, 90 minutes of warm ischemia after induction of ventricular fibrillation and ventilator 
switch-off was the chosen injury model in these experiments (16). Warm-ischemic injury 
models have been used by many research groups in the past, and also our research group has a 
lot of experience with this injury model (28). Different injury models to study ischemia-
reperfusion injury have been used in large animal models (29,30) and it is known that the mode 
of dying has a large impact on graft function (31). Therefore, also other types of injury models, 
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especially brain-dead, should be investigated to detect the impact of cellular therapy on the 
inflammatory cascade after ischemia-reperfusion injury (32). Thirdly, stem cells were 
administered after the injury was introduced (postconditioning). One could defend to introduce 
treatment earlier in order to prevent ischemia-reperfusion injury from happening 
(preconditioning). Wittwer et al showed that when MSCs were administered endobronchially 
prior to the preservation period (preconditioning the donor), dynamic lung compliance was 
better preserved compared to controls (21). We do have to keep in mind that this can be a 
logistical challenge in the timeframe of organ procurement and preservation, and that ex-vivo 
lung perfusion still gives us the ex-vivo advantage of not potentially harming the donor, nor the 
recipient.  
In conclusion, we can state that administration of 10 million MAPC intravenously, in a warm-
ischemic injured porcine lung, did not result in improvement of physiological parameters, lung 
edema formation, cytokine expression, or graft survival. Also after intratracheal administration 
of MAPC cells, no beneficial effect on lung physiology, metabolism or inflammation was 
detected. However, there was a tendency for longer graft survival on ex-vivo lung perfusion 
and there was a reduction in alveolar edema in the MAPC-IT group. Future experiments should 
explore the mechanisms of MAPC treatment, administered in the airways, that potentially lead 
to reduced IRI severity and incidence.    
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A)  PREFACE 
In the previous chapter, we investigated the ideal route of cell treatment (intratracheal or 
intravenous) in a pre-clinical porcine model. We concluded that administration of cells in the 
airways is most efficient based on less lung edema development. This matches with our 
hypothesis that the alveolar-capillary membrane is best reached from the epithelial side (the 
airways) since the injurious process of ischemia-reperfusion injury (IRI) starts with interstitial 
edema and denudation of the epithelial membrane. In the final chapter of my thesis, we will 
focus on the mechanisms of IRI reduction after multipotent adult progenitor cell (MAPC®) 
administration in the airways. We hypothesize that instillation of MAPC cells in the airways 
can have an immunoregulatory effect in the process leading to ischemia-reperfusion injury.  
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B)  ABSTRACT 
Introduction - Primary graft dysfunction (PGD) is considered to be the end result of an 
inflammatory response targeting the new lung allograft after transplant. Previous research has 
indicated that MAPC cell therapy might attenuate this injury by its paracrine effects on the pro-
/anti-inflammatory balance. This study aims to investigate the immunoregulatory capacities of 
MAPC cells in PGD when administered in the airways.  
Methods - Lungs of domestic pigs (n=6/group) were subjected to 90 min of warm ischemia. 
Lungs were cold flushed, cannulated on ice and placed on EVLP for 6 hours. At the start of 
EVLP, 40 ml of an albumin-plasmalyte mixture was instilled in the airways (CONTR-group). 
In the MAPC cell group, 150 million MAPC cells (ReGenesys/Athersys, Cleveland, USA) were 
added to this mixture. At the end of EVLP, a physiological evaluation (pulmonary vascular 
resistance, lung compliance, PaO2/FiO2), wet-to-dry weight ratio (W/D) sampling and a 
multiplex-analysis of bronchoalveolar lavage (BAL) (2x30 ml) was performed.  
Results - Pulmonary vascular resistance, lung compliance, PaO2/FiO2 and W/D were not 
statistically different at the end of EVLP between both groups. BAL neutrophilia was 
significantly reduced in the MAPC cell group. Moreover, there was a significant decrease in 
TNF-α, IL-1β and IFN-γ in the BAL, but not in IFN-α; whereas IL-4, IL-10 and IL-8 were 
below the detection limit. 
Conclusion - Although no physiologic effect of MAPC cell distribution in the airways was 
detected during EVLP, we observed a reduction in pro-inflammatory cytokines and neutrophils 
in BAL in the MAPC cell group. This effect on the innate immune system might play an 
important role in critically modifying the process of PGD after transplantation. Further 
experiments will have to elucidate the immunoregulatory effect of MAPC cell administration 
on graft function after transplantation.  
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C)  INTRODUCTION 
Anno 2016, lung transplantation has grown into a successful treatment option for patients with 
end-stage pulmonary disease. However, severe primary graft dysfunction (PGD) still occurs in 
up to 30% of transplanted patients. And although there is a low mortality of PGD due to 
successful supportive therapy nowadays, patients with severe PGD have poorer long-term 
outcome and a higher risk for developing chronic lung allograft dysfunction (CLAD). PGD is 
the end-result of ischemia-reperfusion injury (IRI) attacking the integrity of the capillary-
alveolar membrane leading to pulmonary edema and impaired oxygenation (1,2). It is based on 
an inflammatory cascade that is triggered by hypoxic stress and activation of donor 
macrophages which attracts many recipient neutrophils to the donor lung upon reperfusion in 
the recipient chest. Bone-marrow derived mesenchymal cells possess immunoregulatory 
capabilities and could therefore be of particular interest to attenuate PGD. They are already 
found to be a successful treatment option for patients suffering from acute-respiratory distress 
syndrome, which shares a similar inflammatory pathophysiology with PGD (3–5). More 
specifically, pilot studies show that they can reduce IRI inherent to solid organ transplantation 
in the lung (6–8), but also in other organ systems (9,10). Here, their beneficial effects result 
from paracrine mechanisms and cell-cell interaction rather than engraftment and repair of 
diseased tissue (11). An altered inflammatory balance, with a decrease in pro-inflammatory and 
increase in anti-inflammatory cytokines, is observed (6). In hypoxic conditions, such as 
ischemic injury models, secretion of growth factors such as VEGF and ANG-1 can stimulate 
angiogenesis and tissue repair (8,12). Mordant et al recently published their results on MSC 
administration to a porcine donor lung on EVLP which resulted in a reduction of IL-8, however, 
there was no effect on physiological parameters detected (13). The role in a reduction of 
inflammatory cytokines in an acellular ex-vivo perfusion set-up therefore still has to be 
unraveled.  
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There are two types of bone-marrow derived cells that are well characterized and could be good 
candidates for immunoregulation of the IRI pathophysiology: the mesenchymal stem cell 
(MSC) and MAPC cells (14). Both have similar immunoregulatory capabilities, but are 
characterized as individual cell types and adopt different phenotypes under certain culture 
conditions (15). One of the most advantageous characteristics of the MAPC cells is their large 
proliferation capacity and low senescence. Therefore, large batches of stem cells can be 
produced from one healthy donor (16,17). A clinical grade MAPC product (MultiStem®, 
Athersys, Cleveland, USA) has been developed for Phase I and II clinical testing. The 
MultiStem clinical grade product is based on MAPC cell isolation and expansion protocols 
under good manufacturing practice conditions (18,19). Our previous research indicates that 
intratracheal administration of cells holds the greatest potential to reduce IRI based on a 
reduction in lung edema formation. However, after administration of 10 million MAPC cells in 
the airways, a physiological improvement of lung function was not detected nor was there an 
alteration in the inflammatory environment of the lung tissue. Therefore, in this study we 
increased the dosing regimen to an intermediate dose of 3.75 million/kg in order to investigate 
a physiological improvement of lung function and to study this mechanism based on 
immunoregulation. Also for other solid organ transplant research, this intermediate dosing 
regimen of 3.5 - 4.5 million cells/kg has led to an improved graft function after transplantation 
(4,9,10).  
In order to administer these cells, ex-vivo lung perfusion (EVLP) has been put forward as a 
treatment platform of ex-vivo organ reconditioning. EVLP is a preservation technique of donor 
lungs in normothermic conditions, allowing for continuous evaluation of the donor lung by 
perfusing and ventilating the graft in an ex-vivo lung perfusion device. EVLP allows for 
assessment of higher risk donor lungs and might serve as the ideal platform for active treatment 
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since donor and recipient remain unharmed, and the treatment effect can be immediately 
evaluated by interpretation of the physiological parameters (20,21).  
The immunoregulatory properties of MAPC cells have not been widely studied in pre-clinical 
large animal models and most preliminary theories of working mechanisms are based on in-
vitro and rodent models. Therefore, in this large animal study, we aim to investigate if MAPC 
cell delivery in the airways during EVLP (i.e. postconditioning), can modulate the 
inflammatory process linked to IRI by immunoregulatory effects.   
 
  
190 
 
D)  METHODS 
This experimental study was performed in compliance with the European Directive 2010/63/EU 
on the protection of animals used for scientific purposes. The principles of laboratory animal 
care published by the National Institute of Health Volume 25, No. 28 (revised 1996) were 
followed. Local ethics approval was obtained at the research institute (NTS P043/2014).  
Donor procedure 
Domestic pigs Topig 20 (mean 40.8 kg) were divided into 2 groups (n=6/group). Animals were 
anesthetized with an intramuscular injection of 5 mg/kg Zoletil 100 (Virbac, Carros, France) 
and 3 mg/kg Xyl-M 2% (VMD, Arendonk, Belgium). Anaesthesia was maintained using 10 
mg/kg/h propofol, 20 µg/kg/h fentanyl and intermittent boli of pancuronium 2mg for muscle 
relaxation. Animals were intubated with a 7.0 mm endotracheal tube and ventilated (Aestiva 
3000; GE Healthcare Europe GmbH, Little Chalfont, UK) with a tidal volume (TV) of 8 ml/kg, 
positive end-expiratory pressure (PEEP) of 5 cmH2O and FiO2 of 30%. Respiratory rate (RR) 
was adjusted to the end-tidal carbon dioxide (ETCO2) (45-55 mmHg). Blood pressure was 
monitored invasively in the right carotid artery. All animals died of cardiac arrest which was 
induced by direct electrical stimulation of the myocardium with an electrical pulse generator 
that led to ventricular fibrillation. Animals were disconnected from the ventilator when cardiac 
arrest was induced. Prior to cardiac arrest, all animals were heparinized with 300 IU/kg. 
Following cardiac arrest in the donor, grafts were left untouched in the deceased donor for 90 
minutes after which they were flushed antegradely with 50 ml/kg cold thromethamol-buffered 
OCS Solution (Transmedics, Andover, USA). The heart-lung block was excised and a 
retrograde flush (1L thromethamol-buffered OCS solution) was performed at the back table. 
Lungs were instrumented on ice for a short period of time (mean 64.4 min) while the XVIVO 
(Göteborg, Sweden) cannulas were secured in the pulmonary artery and atrial cuff. An 8.0-mm 
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ET tube was secured in the trachea. The donor procedure was performed as previously 
described (22). 
Multipotent adult progenitor cell preparation 
Human MAPC cells were isolated by Athersys/Regenesys (Athersys, Cleveland, USA; 
Regenesys, Heverlee, Belgium) from bone marrow of healthy volunteers. Isolation and 
cultivation of the MAPC cells were based on previously published protocols (19,23). The 
Quantum Cell Expansion System (Terumo BCT, Lakewood, CO, USA) was used for ex-vivo 
expansion of large batches of MAPC. All cell batches were subjected to several quality control 
assays to test if all MAPC cell criteria were met. First of all, cell quality is assessed by 
measuring viability and plating efficiency. Secondly, cells are identified using qPCR and flow 
cytometry to test both negative and positive markers (24). A tube formation assay is done to 
define the proangiogenic activity (25), a CFSE assay (26) is performed for evaluating the 
immunoregulatory capacity.  
Ex-vivo lung perfusion 
Lungs are perfused ex-vivo with an acellular albumin containing dextran solution. The 
production of the perfusate and technique of EVLP are performed as described previously (27).  
After a 1-hour rewarming period and slow increase of the flow to 40% of the estimated cardiac 
output (calculated as 100 ml/kg) lungs were further perfused and evaluated for 6 hours in total. 
Once the outflow temperature reaches 34°C, ventilation was started with 7 ml/kg tidal volume 
for 7 breaths/min with 5 cmH2O PEEP. In the CONTR-group, 40 ml of acellular albumin (2.5%) 
– plasmalyte mixture was distributed with a bronchoscope throughout the lung when ventilation 
was started. In the MAPC cell group, 150 million MAPC cells were added to this mixture. The 
study protocol is outlined in Figure VI.8. Cells were thawed, PBS washed and diluted in 40 ml 
of the albumin - plasmalyte mixture after confirming that the donor lungs were free of adhesions 
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or infiltrates. During 6 hours of EVLP, dynamic lung compliance (Compl), oxygenation 
(PaO2/FiO2) and pulmonary vascular resistance (PVR) was recorded hourly.  
 
Figure VI.8 –  Study protocol with n=6/group.  
Tissue sampling 
At the end of the experiment, tissue samples were taken for histological evaluation and wet-to-
dry-weight (W/D) ratio calculation (after 48 hrs in the oven at 80°C). Pathology samples are 
scored by an experienced pathologist (EV) for congestion, neutrophil influx and necrosis. 
Bronchoalveolar lavage (BAL) with 2 times 30 cc saline 0.9% was performed in the right 
middle lobe. Pooled fractions were returned and a cytospin (100µl) was stained with Diff-Quick 
(Dade Behring, Newark, NJ) to perform total and differential cell counts. The BAL supernatant 
was analyzed with a porcine multiplex ELISA kit for IL-1β, IL-4, IL-8, IL-10, IFN-γ, IFN-α 
and TNF-α according to the manufacturer’s protocol (Thermo Fisher Scientific Inc, 
Massachusetts, USA). The left lung was inflated at 25 cmH2O, frozen solid in the fumes of 
liquid nitrogen and scanned with Siemens Somaton CT scanner. Lung mass, volume, and 
density were measured on the basis of the CT-scan, using imaging software (Horos®) in which 
the lung is manually delineated and the number of voxels and mean density of the voxels within 
the volume is determined (28).  
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Statistical analysis 
All data are expressed as median with IQ range (IQR) when depicting physiological variables 
in time or as a scatter plot with median and IQR when comparing variables at the end of the 
experiment (GraphPad Prism 4, GraphPad Software Inc, La Jolla, USA).  
Mann-Whitney tests were conducted in GraphPad to compare data at the end of EVLP. We 
analyzed end-experimental parameters only to dichotomize between acceptable and non-
acceptable lungs. Baseline parameters of the donor animals are described as median (25% QI – 
75% QI) and are analyzed with the same statistical test. The level of statistical significance was 
set at p<0.05. 
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E)  RESULTS 
Baseline 
Baseline animal parameters and the perfusate are similar between both groups (Table VI.3).  
Table VI.3 –  Baseline animal parameters and perfusate composition  
 
Comparable animal weight and baseline hemodynamic parameters. No signs of systemic 
inflammation (normal WBC count, normal neutrophil count, normal temperature). Perfusate 
composition is similar between both gro ups for albumin, osmolality, glucose and electrolytes.  
Vt: Tidal Volume; HR: heart rate; MAP: mean arterial pressure; Peak AwP: peak airway 
pressure; PaO2/FiO2: partial oxygen pressure/fractional inspired oxygen concentration; WBC: 
white blood cell count;  Na: sodium; K: potassium; Cl: chloride; Ca: calcium  
Physiological assessment 
Physiological parameters PVR, Compl, and PaO2/FiO2 are depicted over time (hrs on EVLP) 
in panel A-C of Figure VI.9. All data points are depicted as median +/- IQR. 
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Physiologic parameters at the end of EVLP, are depicted in panel D-F. No statistical differences 
were detected in PVR (p=0.68), Compl (p=0.22) or PaO2/FiO2 (p=0.13) between the two 
groups.  
 
Figure VI.9 –  Monitoring of PVR (Panel A), Compl (Panel B) and PaO 2/FiO2  (Panel C) during 
6 hrs of EVLP. The final assessment at the end of EVLP did not show any statistical difference 
between both groups for PVR (Panel D), Compl (Panel E) or PaO 2 /FiO2 (Panel F).  
Lung edema estimation 
W/D of the tissue sample of the right lower lobe and CT density calculation of the left inflated 
frozen lung did not reveal a statistical difference between both groups (Figure VI.10). 
Administration of 150 million stem cells did not result in attenuation of lung edema formation 
in the warm-ischemic injured porcine lungs. 
 
Figure VI.10 –  Lung edema, estimated here with W/D and CT density, is not reduced in the MAPC  
cell group. Data are depicted as boxplot, and compared with a Mann -Whitney test.  
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Histology 
No significant differences were detected in the injury scores for both groups for the presence 
of congestion (p=0.92), necrotic cells (p=0.70) or influx of neutrophils (p=0.56) (Figure VI.11).  
 
Figure VI.11 –  No differences were seen in the injury score for congestion,  presence of necrosis 
and neutrophils.  
Inflammation bronchoalveolar lavage fluid 
Quantitative determination of IL-1β, IL-4, IL-8, IL-10, IFN-γ, IFN-α and TNF-α in BAL fluid 
showed a significant reduction of TNF-α, IL-1β and IFN-γ while IFN-α was similar in both 
groups (Figure VI.12). IL-4, IL-8 and IL-10 were below the detection limit.   
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Figure VI.12 – Significant reduction of inflammatory markers TNF-α, IL-1β and IFN-γ in BAL. 
Cell pellet analysis of the returned fractions of the BAL fluid showed a trend towards reduction 
in total cell count in the MAPC cell group (p=0.09). Also, differential cell count showed a 
significant reduction in neutrophils (p=0.02). Results are depicted as median (25% QI – 75% 
QI) in Table VI.4. 
Table VI.4 –  Total cell count (TCC) and differential cell count of BAL fluid cell pellet.  
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F)  DISCUSSION 
In this study, we report the immunoregulatory effects on pulmonary IRI, of MAPC cell 
administration in the airways. Distribution of 150 x 106 MAPC cells in the airways of warm-
ischemic porcine donor lungs resulted in a decreased concentration of TNF-α, IL-1β and IFN-
γ in the BAL supernatant. Also, a decreased percentage of neutrophils and a trend to a lower 
total cell count in the BAL cell pellet was observed. The attenuation of this inflammatory 
response to warm-ischemic injury, was not reflected by an improvement in physiologic 
parameters, histology or lung edema during EVLP assessment.  
Up to now, bone-marrow derived MSC are most frequently used for immunoregulation of the 
inflammatory response to pulmonary ischemia-reperfusion injury (29,30). MAPC cells are also 
bone-marrow derived mesenchymal cells and share many similarities with the MSC, however 
in different culture conditions they adapt different phenotypes (15). The interest in the use of 
cellular treatment for ischemia-reperfusion injury results from in vitro evidence of their 
immunoregulatory capacities published in the last decade (31). This immunoregulation is 
mainly described as the suppression of regulatory T-cells in vitro (16) while the interaction with 
neutrophils, the most important effector cell in IRI, is largely unexplored. MSC and MAPC 
share similar immunoregulatory capabilities, however MAPC cells are found to be the most 
potent (32). Furthermore, MAPC cell therapy is privileged over MSC for clinical translation 
since their low senescence and high population doubling allows for banking of large batches of 
cells from a single donor. A clinical grade product of MAPC, MultiStem, is produced by 
Athersys and is already being tested in Phase I and II clinical trials (Athersys, Cleveland, USA). 
Therefore, we chose this cell type as bone-marrow derived cellular treatment for attenuation of 
ischemia-reperfusion injury in lung transplantation. Also, xeno-transplantation and allo-
transplantation of these cells, is thought to be safe due to a low expression of MHC-I and lack 
of MHC-II expression (14,33). These immune-privileged properties avoid recognition by the 
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recipient’s immune system, and therefore, this immune mismatch is generally believed not to 
be an increased risk for patients.  
We used a validated injury model with exposure of the lung graft to 90 minutes of warm 
ischemia (22). This resulted in an accumulation of lung edema when perfused for 6 hours on 
EVLP, which is reflected by a high W/D (median 6.6 in CONTR) and high CT-density (median 
245 g/L in CONTR). An inflammatory cascade with infiltration of neutrophils was launched 
upon reperfusion of the donor lung on EVLP, even though we worked with an acellular 
perfusate. This is shown by an increased percentage of neutrophils in the BAL in the CONTR 
group (median 7.7% vs 1.7%). Most likely, these cells were trapped in the microvasculature of 
the lung despite adequate antegrade and retrograde flush of the lung upon procurement. Also, 
general inflammatory markers such as TNF-α, IFN-γ, IFN-α and IL-1β were increased in 
CONTR showing activation of the innate immune system with interaction of macrophages, 
lymphocytes, endothelial cells and epithelial cells.  
While Mordant et al could show an IL-8 reduction in the perfusate in their model of MSC 
therapy during EVLP (13), the detection limit of 0.56 pg/ml for IL-8 was not reached in our 
BAL sample. Therefore, we cannot speculate on the effect on IL-8 and its neutrophil chemotaxis 
effect. We did report a reduction in general inflammatory markers involved in the innate 
immune system, such as TNF-α, IL-1β, IFN-γ and saw a significant reduction in neutrophils in 
the BAL sample. While these immunoregulatory effects are highly significant, they were not 
reflected by an improved graft function on EVLP evaluation. The exact effect of this 
immunoregulatory effect, therefore, has to be further unraveled in a transplant experiment 
where the lung graft is reperfused with a pulsatile flow of whole blood and the full impact of 
IRI can be studied.  
Also, dose-response studies will have to be further conducted to determine the maximal effect. 
In this study, an intermediate dose of 3.75 million MAPC / kg body weight was administered. 
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In mice studies, 0.5 to 2 million cells are usually administered which corresponds to 100 to 200 
million cells/kg. These doses are probably irrelevant for clinical practice since we also have to 
watch out for entrapment of these large cells (15-19µm) in the microvasculature of the lung 
with micro-thrombi formation, increased PVR and hydrostatic pulmonary edema as potential 
dangerous consequence. A low dose of 0.24 million cells/kg has been shown not to be effective 
to tackle IRI as reported in the previous chapter. It might therefore be that one should be looking 
for an optimal dose instead of a linear dose-response effect. 
Finally, we acknowledge that biodistribution of our cells could not be shown. Entrapment and 
localization of the administered cells will have to be investigated to understand the underlying 
mechanisms of the immunoregulatory capacities of cellular therapy.  
In conclusion, we can state that, although no physiologic effect of immunoregulation was 
detected during EVLP, we did observe a reduction in pro-inflammatory cytokines and 
neutrophils in the BAL after MAPC cell distribution in the airways indicating a regulatory effect 
on the innate immune system. This effect might play an important role in critically modifying 
the process of PGD early after transplantation (34). The innate immune system is also involved 
in the etiology of bronchiolitis obliterans syndrome (BOS) (35), and therefore MAPC cell 
administration early in the process of lung transplantation might have an effect on the 
development of BOS, the main predictor of long-term outcome. Further experiments will have 
to elucidate the effect of MAPC cell administration on graft function after transplantation. 
  
201 
 
G)  REFERENCES 
1.  de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir 
Crit Care Med. 2003 Feb 15;167(4):490–511.  
2.  Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT working group on primary 
lung graft dysfunction part II: definition. A consensus statement of the International Society for Heart and 
Lung Transplantation. J Heart Lung Transplant. 2005 Oct;24(10):1454–9.  
3.  Rojas M, Cárdenes N, Kocyildirim E, Tedrow JR, Cáceres E, Deans R, et al. Human adult bone marrow-
derived stem cells decrease severity of lipopolysaccharide-induced acute respiratory distress syndrome in 
sheep. Stem Cell Res Ther. 2014;5(2):42.  
4.  Horie S, Laffey JG. Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress 
syndrome. F1000Research. 2016 Jun 28;5:1532.  
5.  Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for 
treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl 
Acad Sci U S A. 2009 Sep 22;106(38):16357–62.  
6.  Tian W, Liu Y, Zhang B, Dai X, Li G, Li X, et al. Infusion of mesenchymal stem cells protects lung 
transplants from cold ischemia-reperfusion injury in mice. Lung. 2015 Feb;193(1):85–95.  
7.  La Francesca S, Ting AE, Sakamoto J, Rhudy J, Bonenfant NR, Borg ZD, et al. Multipotent adult progenitor 
cells decrease cold ischemic injury in ex vivo perfused human lungs: an initial pilot and feasibility study. 
Transplant Res. 2014 Jan;3(1):19.  
8.  Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial 
protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem. 
2010 Aug 20;285(34):26211–22.  
9.  Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, Negishi K, et al. Bone marrow-derived 
mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. Gaetano C, editor. 
PLoS One. 2011 Apr 29;6(4):e19195.  
10.  Lange C, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, et al. Administered mesenchymal 
stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int. 
2005;68(4):1613–7.  
11.  Sinclair K, Yerkovich ST, Chambers DC. Mesenchymal stem cells and the lung. Respirology. 2013 
Apr;18(3):397–411.  
12.  Markel TA, Crafts TD, Jensen AR, Hunsberger EB, Yoder MC. Human mesenchymal stromal cells 
decrease mortality after intestinal ischemia and reperfusion injury. J Surg Res. 2015 Nov;199(1):56–66.  
13.  Mordant P, Nakajima D, Kalaf R, Iskender I, Maahs L, Behrens P, et al. Mesenchymal stem cell treatment 
is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor 
lungs after 18-hour preservation. J Heart Lung Transpl. 2016 Oct;35(10):1245–54.  
14.  Sohni A, Verfaillie CM. Multipotent adult progenitor cells. Best Pract Res Clin Haematol. 2011 
Mar;24(1):3–11.  
15.  Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, et al. Differentiation potential 
of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells 
reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells. 2011 
May;29(5):871–82.  
16.  Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, van’t Hof W, Deans R, et al. Human multipotent adult 
progenitor cells are nonimmunogenic and exert potent immunomodulatory effects on alloreactive T-cell 
responses. Cell Transplant. 2013 Jan;22(10):1915–28.  
17.  Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency 
of mesenchymal stem cells derived from adult marrow. Nature. 2002 Jul 4;418(6893):41–9.  
18.  Boozer S, Lehman N, Lakshmipathy U, Love B, Raber A, Maitra A, et al. Global characterization and 
genomic stability of human MultiStem, a multipotent adult progenitor cell. J Stem Cells. 2009 Jan;4(1):17–
28.  
202 
 
19.  Vaes B, Walbers S, Gijbels K, Craeye D, Deans R, Pinxteren J, et al. Culturing protocols for human 
multipotent adult stem cells. Methods Mol Biol. 2015;1235:49–58.  
20.  Cypel M, Keshavjee S. Extending the donor pool: rehabilitation of poor organs. Thorac Surg Clin. 2015 
Feb;25(1):27–33.  
21.  Van Raemdonck D, Neyrinck A, Cypel M, Keshavjee S. Ex-vivo lung perfusion. Transpl Int. 2015 
Jun;28(6):643–56.  
22.  Martens A, Boada M, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, et al. Steroids can reduce 
warm ischemic reperfusion injury in a porcine donation after circulatory death model with ex vivo lung 
perfusion evaluation. Transpl Int. 2016 Nov;29(11):1237–46.  
23.  Plessers J, Dekimpe E, Van Woensel M, Roobrouck VD, Bullens DM, Pinxteren J, et al. Clinical-Grade 
Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes. Stem Cells Transl Med. 
2016 Dec 1;5(12):1607–19.  
24.  Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human 
mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol. 2013 Jan;91(1):32–9.  
25.  Lehman N, Cutrone R, Raber A, Perry R, Van’t Hof W, Deans R, et al. Development of a surrogate 
angiogenic potency assay for clinical-grade stem cell production. Cytotherapy. 2012 Sep;14(8):994–1004.  
26.  Reading JL, Yang JHM, Sabbah S, Skowera A, Knight RR, Pinxteren J, et al. Clinical-grade multipotent 
adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and 
autoimmunity. J Immunol. 2013 May 1;190(9):4542–52.  
27.  Martens A, Montoli M, Faggi G, Katz I, Pype J, Vanaudenaerde BM, et al. Argon and xenon ventilation 
during prolonged ex vivo lung perfusion. J Surg Res. 2016 Mar;201(1):44–52.  
28.  Verleden SE, Vasilescu DM, Willems S, Ruttens D, Vos R, Vandermeulen E, et al. The site and nature of 
airway obstruction after lung transplantation. Am J Respir Crit Care Med. 2014 Feb;189(3):292–300.  
29.  Devaney J, Horie S, Masterson C, Elliman S, Barry F, O’Brien T, et al. Human mesenchymal stromal cells 
decrease the severity of acute lung injury induced by E. coli in the rat. Thorax. 2015 Jul;70(7):625–35.  
30.  Gotts JE, Matthay MA. Mesenchymal stem cells and acute lung injury. Crit Care Clin. 2011 Jul;27(3):719–
33.  
31.  Glenn JD, Whartenby KA. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and 
therapy. World J Stem Cells. 2014 Nov 26;6(5):526–39.  
32.  Sindberg GM, Lindborg BA, Wang Q, Clarkson C, Graham M, Donahue R, et al. Comparisons of 
phenotype and immunomodulatory capacity among rhesus bone-marrow-derived mesenchymal 
stem/stromal cells, multipotent adult progenitor cells, and dermal fibroblasts. J Med Primatol. 2014 
Aug;43(4):231–41.  
33.  Jacobs SA, Plessers J, Pinxteren J, Roobrouck VD, Verfaillie CM, Van Gool SW. Mutual interaction 
between human multipotent adult progenitor cells and NK cells. Cell Transplant. 2014 Sep 15;23(9):1099–
110.  
34.  Kreisel D, Goldstein DR. Innate immunity and organ transplantation: focus on lung transplantation. Transpl 
Int. 2013 Jan;26(1):2–10.  
35.  Gracon ASA, Wilkes DS. Lung transplantation: chronic allograft dysfunction and establishing immune 
tolerance. Hum Immunol. 2014 Aug;75(8):887–94.  
 
1.  de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir 
Crit Care Med. 2003 Feb 15;167(4):490–511.  
2.  Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT working group on primary 
lung graft dysfunction part II: definition. A consensus statement of the International Society for Heart and 
Lung Transplantation. J Heart Lung Transplant. 2005 Oct;24(10):1454–9.  
3.  Rojas M, Cárdenes N, Kocyildirim E, Tedrow JR, Cáceres E, Deans R, et al. Human adult bone marrow-
derived stem cells decrease severity of lipopolysaccharide-induced acute respiratory distress syndrome in 
sheep. Stem Cell Res Ther. 2014;5(2):42.  
203 
 
4.  Horie S, Laffey JG. Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress 
syndrome. F1000Research. 2016 Jun 28;5:1532.  
5.  Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for 
treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl 
Acad Sci U S A. 2009 Sep 22;106(38):16357–62.  
6.  Tian W, Liu Y, Zhang B, Dai X, Li G, Li X, et al. Infusion of mesenchymal stem cells protects lung 
transplants from cold ischemia-reperfusion injury in mice. Lung. 2015 Feb;193(1):85–95.  
7.  La Francesca S, Ting AE, Sakamoto J, Rhudy J, Bonenfant NR, Borg ZD, et al. Multipotent adult progenitor 
cells decrease cold ischemic injury in ex vivo perfused human lungs: an initial pilot and feasibility study. 
Transplant Res. 2014 Jan;3(1):19.  
8.  Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial 
protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem. 
2010 Aug 20;285(34):26211–22.  
9.  Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, Negishi K, et al. Bone marrow-derived 
mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. Gaetano C, editor. 
PLoS One. 2011 Apr 29;6(4):e19195.  
10.  Lange C, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, et al. Administered mesenchymal 
stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int. 
2005;68(4):1613–7.  
11.  Sinclair K, Yerkovich ST, Chambers DC. Mesenchymal stem cells and the lung. Respirology. 2013 
Apr;18(3):397–411.  
12.  Markel TA, Crafts TD, Jensen AR, Hunsberger EB, Yoder MC. Human mesenchymal stromal cells 
decrease mortality after intestinal ischemia and reperfusion injury. J Surg Res. 2015 Nov;199(1):56–66.  
13.  Mordant P, Nakajima D, Kalaf R, Iskender I, Maahs L, Behrens P, et al. Mesenchymal stem cell treatment 
is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor 
lungs after 18-hour preservation. J Heart Lung Transpl. 2016 Oct;35(10):1245–54.  
14.  Sohni A, Verfaillie CM. Multipotent adult progenitor cells. Best Pract Res Clin Haematol. 2011 
Mar;24(1):3–11.  
15.  Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, et al. Differentiation potential 
of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells 
reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells. 2011 
May;29(5):871–82.  
16.  Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, van’t Hof W, Deans R, et al. Human multipotent adult 
progenitor cells are nonimmunogenic and exert potent immunomodulatory effects on alloreactive T-cell 
responses. Cell Transplant. 2013 Jan;22(10):1915–28.  
17.  Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency 
of mesenchymal stem cells derived from adult marrow. Nature. 2002 Jul 4;418(6893):41–9.  
18.  Boozer S, Lehman N, Lakshmipathy U, Love B, Raber A, Maitra A, et al. Global characterization and 
genomic stability of human MultiStem, a multipotent adult progenitor cell. J Stem Cells. 2009 Jan;4(1):17–
28.  
19.  Vaes B, Walbers S, Gijbels K, Craeye D, Deans R, Pinxteren J, et al. Culturing protocols for human 
multipotent adult stem cells. Methods Mol Biol. 2015;1235:49–58.  
20.  Cypel M, Keshavjee S. Extending the donor pool: rehabilitation of poor organs. Thorac Surg Clin. 2015 
Feb;25(1):27–33.  
21.  Van Raemdonck D, Neyrinck A, Cypel M, Keshavjee S. Ex-vivo lung perfusion. Transpl Int. 2015 
Jun;28(6):643–56.  
22.  Martens A, Boada M, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, et al. Steroids can reduce 
warm ischemic reperfusion injury in a porcine donation after circulatory death model with ex vivo lung 
perfusion evaluation. Transpl Int. 2016 Nov;29(11):1237–46.  
204 
 
23.  Plessers J, Dekimpe E, Van Woensel M, Roobrouck VD, Bullens DM, Pinxteren J, et al. Clinical-Grade 
Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes. Stem Cells Transl Med. 
2016 Dec 1;5(12):1607–19.  
24.  Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human 
mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol. 2013 Jan;91(1):32–9.  
25.  Lehman N, Cutrone R, Raber A, Perry R, Van’t Hof W, Deans R, et al. Development of a surrogate 
angiogenic potency assay for clinical-grade stem cell production. Cytotherapy. 2012 Sep;14(8):994–1004.  
26.  Reading JL, Yang JHM, Sabbah S, Skowera A, Knight RR, Pinxteren J, et al. Clinical-grade multipotent 
adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and 
autoimmunity. J Immunol. 2013 May 1;190(9):4542–52.  
27.  Martens A, Montoli M, Faggi G, Katz I, Pype J, Vanaudenaerde BM, et al. Argon and xenon ventilation 
during prolonged ex vivo lung perfusion. J Surg Res. 2016 Mar;201(1):44–52.  
28.  Verleden SE, Vasilescu DM, Willems S, Ruttens D, Vos R, Vandermeulen E, et al. The site and nature of 
airway obstruction after lung transplantation. Am J Respir Crit Care Med. 2014 Feb;189(3):292–300.  
29.  Devaney J, Horie S, Masterson C, Elliman S, Barry F, O’Brien T, et al. Human mesenchymal stromal cells 
decrease the severity of acute lung injury induced by E. coli in the rat. Thorax. 2015 Jul;70(7):625–35.  
30.  Gotts JE, Matthay MA. Mesenchymal stem cells and acute lung injury. Crit Care Clin. 2011 Jul;27(3):719–
33.  
31.  Glenn JD, Whartenby KA. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and 
therapy. World J Stem Cells. 2014 Nov 26;6(5):526–39.  
32.  Sindberg GM, Lindborg BA, Wang Q, Clarkson C, Graham M, Donahue R, et al. Comparisons of 
phenotype and immunomodulatory capacity among rhesus bone-marrow-derived mesenchymal 
stem/stromal cells, multipotent adult progenitor cells, and dermal fibroblasts. J Med Primatol. 2014 
Aug;43(4):231–41.  
33.  Jacobs SA, Plessers J, Pinxteren J, Roobrouck VD, Verfaillie CM, Van Gool SW. Mutual interaction 
between human multipotent adult progenitor cells and NK cells. Cell Transplant. 2014 Sep 15;23(9):1099–
110.  
34.  Kreisel D, Goldstein DR. Innate immunity and organ transplantation: focus on lung transplantation. Transpl 
Int. 2013 Jan;26(1):2–10.  
35.  Gracon ASA, Wilkes DS. Lung transplantation: chronic allograft dysfunction and establishing immune 
tolerance. Hum Immunol. 2014 Aug;75(8):887–94.  
 
 
  
205 
 
CHAPTER VII 
GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
 
 
  
206 
 
  
207 
 
A)  GENERAL DISCUSSION 
Early outcome after lung transplantation is highly dependent on the availability and quality of 
donor organs. Currently, lung yield remains critically low and organ quality is often limited or 
unknown when assessed inside the donor chest. Consequently, there is a persistent mortality on 
the waiting list of 10% and, up to 30% of recipients develop severe primary graft dysfunction 
after lung transplantation. In order to improve early outcome after lung transplantation, this 
PhD project focused on novel strategies to increase both number and quality of available donor 
lungs.  
Aggressive donor assessment to increase the donor lung yield 
Donor selection nowadays is still based on donor age, chest X-ray, bronchoscopy, gas 
exchange, ABO compatibility, size matching, smoking history, medical donor history and 
physical examination of the pulmonary graft at the donor hospital during organ retrieval by an 
experienced transplant surgeon. With the latter being the most important step to assess for lung 
injury and transplant suitability (1). Costa et al also suggested to take selective pulmonary vein 
gases to provide corroborative objective support to the findings at bronchoscopy, palpation and 
visual assessment since central aortic gases did not always reflect true function of the lungs, 
having high false-positive rates towards the individual lower lobe gas exchange (2). Current 
selection criteria are however still largely subjective and have poor predictive power (3). In 
addition, the selection criteria of the “ideal lung donor” were based on expert opinion and are 
not based on large prospective, controlled trials. Therefore, all these criteria have to be critically 
evaluated separately for each donor. Safely liberalizing these strict criteria can only be done in 
view of the allocated recipient patient. That is, allocating an ECD lung to recipients with a high 
LAS score could lead to an impaired outcome both on the short- as the long term (4). Nowadays, 
60% of lungs transplanted in our transplant program are procured from ECD with excellent 
outcome. The practice of increasing the donor pool by recruiting also ECD donor lungs, has 
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been partly stimulated by the introduction of EVLP. EVLP was designed to properly evaluate 
a donor organ prior to transplantation and allows for transplantation of high-risk donor lungs. 
Keshavjee et al showed similar early outcome of high-risk donor lungs that were 
physiologically stable during 4 hours of ex vivo perfusion, compared to recipients transplanted 
with conventionally selected lungs (5). 
However nowadays, EVLP is not a prerequisite to transplant donor lungs from extended-criteria 
donors. More procurement teams are send out to donor hospitals to critically inspect and 
reassess the donor lungs inside the recipient chest. Often, these lungs are of excellent quality 
and don’t even need an additional evaluation on EVLP.  
The main reason why procurement teams are send out more often, is that traveling distances in 
Belgium are relatively short compared to other countries. Our transplant center, therefore, has 
a high organ yield of 38% compared to lower percentages of 10-25% in other transplant centers. 
In an editorial comment we addressed this issue of assessing more organs inside the donor chest 
to increase the number of available donor organs (6). Only in a minority of cases, EVLP is used 
for additional evaluation and preservation of these donor lungs. EVLP might still be able to 
further increase the donor pool, as several research groups report reconditioning on EVLP of 
donor lungs that were initially rejected for transplantation (7,8). However, there inclusion 
criteria for “rejected donor lung” is often based on low PaO2/FiO2 only and the potential of 
EVLP reconditioning might therefore be an overestimation of the true potential. Therefore, we 
investigated the potential role of EVLP evaluation, preservation and reconditioning and 
estimated that our current lung acceptance rate of 37.7% could be increased to 44.3% based on 
a retrospective data base analysis of registered donor data of unused donor lungs. 
Donor management to increase lung quality and organ yield 
Despite all efforts to increase the number of donor lungs, the difference between organ supply 
and organ demand is still existent. And with no foreseeable increase in the number of potential 
209 
 
donors, it is therefore of crucial importance that we maximize the organ yield of our current 
donor pool. Therefore, intensive care physicians are more involved to provide intensive care 
and organ support to the potential organ donor. Aggressive donor management protocols with 
pre-set goals have systematically improved organ yield in all solid organ transplant programs 
(9). Donor management of the DBD donor is based on endocrine support to counteract the 
collapse of the hypothalamic-pituitary axis, on hemodynamic support with short-acting agents 
to resuscitate the cardiovascular effects of the autonomic dysregulation following brain death, 
and on protective ventilatory support with frequent recruitment maneuvers of the lung (10). 
These strategies affect the pathophysiology of DBD, which is based on a systemic pro-
inflammatory response that ultimately can lead to organ dysfunction (11). Brain death leads to 
massive release of catecholamines and pro-inflammatory mediators in an attempt to overcome 
hypoperfusion of the brain. However, this response has a catastrophic systemic effect with 
failure of the microcirculation, leukocyte recruitment, release of ROS, etc (12). 
Donation after circulatory death (DCD) describes the retrieval of organs for the purposes of 
transplantation that follows death confirmed using circulatory criteria, rather than brain death 
criteria. Consequently, organ injury in donation after circulatory death is based on the warm-
ischemic time (WIT) rather than on the pathophysiological consequences of brain death. WIT 
is the time when there is insufficient circulation to the organs to deliver a minimum amount of 
oxygen and nutrients (13). The incidence of graft complications after transplantation is related 
to the length of this WIT and tolerance to WIT is organ-specific. Lungs could tolerate up to 60 
minutes of warm ischemia (14,15). Ischemia-reperfusion injury is inherent to the process of 
organ transplantation and also additional cold ischemia further contributes to the development 
of PGD in DCD. The pathophysiology of organ injury in DBD and DCD is therefore not 
completely similar (16). The question that follows is whether current organ support 
measurement in DBD donors also apply to organ support for DCD donors. Unfortunately, there 
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is a paucity of randomized clinical trials since organ donor management has not been a top 
priority in the ICU practice up to now (17), and evidence is mostly provided by observational 
studies only. Generally, it is agreed upon that aggressive donor DBD management protocols do 
make a difference in the number of organs transplanted. However, whether these findings will 
also apply on DCDs remains an open question due to the different pathophysiology of lung 
injury and the different ethical context. The dead donor rule (18) must be respected at all times, 
so no treatment can be administered with the aim on organ quality improvement as long as the 
donor does not meet valid criteria for death. It is only permissible after death declaration, either 
by the criteria of brain death or by permanent cessation of circulatory function. Criteria for 
determination of death should be followed meticulously for each individual donor, and no rules 
should be bend to increase the success rates of procuring good quality organs. Even though an 
altruistic viewpoint might seem tempting to defend the organ optimization in a DCD donor 
prior to death, since the consent for organ donation has been agreed upon, and the patient suffers 
from an end-stage pathology with natural death that will occur soon otherwise. The critical 
question should probably be to consider some treatments that do not hasten death, which is the 
reason why some countries already allow heparin administration. A retrospective study of the 
ISHLT DCD study group also revealed that 93% of centers do administer steroids before the 
withdrawal of life support therapies. This practice might be based on small observational studies 
in DBD donation that report improved donor hemodynamics, oxygenation, increased organ 
yield and even improved recipient and graft survival (19). Also, the steroids might have been 
administered for other reasons or might have been a part of general ICU practice (eg 
neuroprotection). However, data on the effect of steroids in DCD organ donation was lacking. 
With our porcine DCD model, we are the first to provide beneficial evidence to support the 
practice of steroid administration prior to withdrawal of life support therapies in donation after 
circulatory death. 
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Assessment and preservation on EVLP 
Worldwide, clinical experience with EVLP is growing since the beginning of the 21st century 
and different clinical protocols are validated. The largest clinical experience comes from the 
Toronto group, which has the largest clinical EVLP cohort of over 200 EVLP cases of both 
SCD and ECD (5,20). Also the LUND protocol is actively used. Henriksen et al recently 
published the Danish experience with improved PaO2/FiO2 after EVLP in 8 cases (21). The 
NOVEL trial (multi-center) in the United States (US) works with the XVIVO technology and 
is still recruiting unusable donor lungs for ex-vivo reconditioning to test clinical effectiveness 
and improved survival, to increase lung transplant activity in the US. Two large multicenter 
randomized controlled trials are being performed with the portable EVLP technology of the 
OCSTM Lung. The Inspire Trial, designed as a safety study, included SCD lungs and met all of 
its non-inferiority end-points including a significant reduction of PGD grade 3 (22,23). The 
Expand trial includes ECD lungs and is still ongoing. EVLP technology requires many 
resources, both technical and human. The expertise of a well-trained EVLP physician or 
perfusionist has to be available at all times for the procedure itself and to evaluate the graft 
quality on EVLP. It might therefore be advisable to combine these resources and expertise in 
EVLP centers. Currently, the Perfusix trial is assessing the efficiency of such an EVLP center 
in the US and Canada (24). Analysis of the recently completed and ongoing clinical EVLP trials 
with both SCD and ECD lungs will have to clarify which lungs and patients could benefit most 
of this EVLP technology so that resources can be applied in a cost- and clinical-effective 
manner. Also in unique, high-risk cases, EVLP can be applied to safely prolong the “out-of-
body time” of donor lungs as we have shown in our case report of a combined liver-lung 
transplantation with normothermic preservation of the lungs on EVLP. To implement EVLP in 
routine lung transplant preservation strategies, a risk score analysis could be performed 
incorporating the main risk factors for PGD development (25): 1) donor age, smoking 2) Single-
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lung transplant procedure, cardiopulmonary bypass expected during procedure 3) recipient 
diagnosed with pulmonary hypertension, sarcoidosis, obesity. These risk factors could all be 
individually weighed and combined to a risk score for PGD development. In this way, we can 
avoid to put all donor lungs on EVLP and apply EVLP only to those cases that could benefit 
most from it. In many centers, lung yield could already be increased by sending more retrieval 
teams to the donor hospital, even without EVLP. Dedicated retrieval teams and transportation 
costs should also be taken into account, but are still more profitable compared to EVLP 
technology. 
Three EVLP protocols are available (see Table I.4 Introduction, p.17) for clinical EVLP. These 
techniques differ in portability, pump type, ventilator settings, pump flow, perfusate 
composition and pressure control of the left atrium (open vs closed). Despite these differences, 
all are based on the principle of physiological evaluation, protective lung ventilation and high-
oncotic perfusate composition. No studies are available comparing these 3 techniques to one 
another. Data on individual aspects of these protocols are available but, they do not allow 
complete comparison. For example, Linacre et al report a superior graft function when there is 
a closed atrium with controlled left atrial pressure compared to open drainage of the left atrium 
(26). However, groups with elaborate experience with an open left atrium on EVLP, also report 
excellent results after lung transplantation (23). Since prolonged cold ischemia contributes to 
ischemia-reperfusion injury, it is found to be protective to avoid cold ischemia with a portable 
normothermic machine perfusion device such as the OCSTM Lung. However, other groups 
report better results if a short period of cold ischemia is introduced prior to normothermic 
evaluation (27). After a 3-year experience with both the Toronto, Lund and OCSTM protocol, it 
seems that the success of EVLP preservation and reconditioning is could be considered 
independent of the used technique or protocol, but related to the experience and trust build up 
on one technique. Research groups should therefore not only focus their resources in comparing 
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these protocols, but should extend their experience in trained organ perfusion teams and 
refinement of their own technique.  
Follow-up on the trend of physiological parameters is still the mainstay of evaluation during 
EVLP in all available protocols. More particular, we look at the pulmonary vascular resistance, 
oxygenation and dynamic lung compliance and want to see an improvement or steady state. 
However, which parameters are most predictive for organ function after transplantation, is still 
under debate. Some groups prefer to base their evaluation on oxygenation and lung compliance 
(28), other include pulmonary vascular resistance and oxygenation (22). In all protocols, lung 
compliance seems the first parameter to indicate lung injury, also in our experimental studies 
(29–31). It is known that in acellular perfusion protocols, oxygenation is not the most reliable 
parameter to evaluate lung injury in an ex-vivo setting (32). In an acellular perfusate, the shunt-
induced reduction in PO2 at the outflow due to lung edema is less pronounced since there is a 
linear relationship between oxygen content and PO2. Whereas in cellular, Hb-containing 
perfusate there is a sigmoidal relationship between oxygen content and PO2 and therefore shunt-
induced reduction in PO2 will be more pronounced and more easily detected (32). Which type 
of perfusate (cellular or acellular) we should use, is still a subject of debate. Only pre-clinical 
studies have been published so far comparing the use of an acellular or cellular perfusate. Two 
studies report similar physiological parameters (PVR, compliance, oxygenation) and amount of 
lung edema (W/D) after prolonged periods of lung preservation with either an acellular or a 
cellular perfusate (addition of packed RBCs). Data on whole-blood perfusion models have not 
been published yet but might be superior due to the beneficial effect of plasma on endothelial 
function as has been published in heart perfusion models (33). Despite the buffering and oxygen 
delivery advantages, the use of blood as part of the perfusate is more infrequent in reporting 
centers (34). Differences in shear stress and prolonged exposure time of the blood to the tubing 
and pump device can lead to hemolysis of the RBCs in the blood based perfusate. Therefore, 
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we work with an acellular perfusate for our prolonged preservation and reconditioning 
experiments. The perfusate used in our experiments, is a laboratory tested low-potassium, high-
oncotic albumin-containing acellular perfusate that is similar to Steen Solution (XVIVO).  
Also secretion of biochemical markers such as endogenous nitric oxide synthase levels (35), 
endotheline-1 (36), IL-1beta (37) and IL-8 (38) during EVLP may predict acceptable allograft 
function. That is, lungs perfused on ex-vivo lung perfusion have a specific cytokine expression 
profile that can be used in future analysis to predict outcome after lung transplantation (39). 
These parameters may become more important in the future to complement the physiologic 
evaluation EVLP.  
W/D measurements are still the golden standard for estimation of lung edema. In addition, we 
introduced CT-density measures that give an average density of the total lung instead of a W/D 
measurement of only a small piece of the lung (40). In all our experiments, this CT-density 
measurement correlated nicely with W/D. For these calculations, lungs were frozen solid and 
CT-scanned afterwards however, it is also feasible to scan the lung after the experiment to 
incorporate the density measurement as an additional parameter in your final evaluation of 
transplantability. We believe that performing high-tech imaging could improve the quality of 
our ex-vivo evaluation of donor lungs. But even more strongly, it might be easier to perform a 
CT-scan of the donor to assess donor lung transplantability prior to EVLP. This will avoid 
unnecessary transport costs of the retrieval team to retrieve eg emphysematous or severely 
infected donor lungs. On the other hand, there is of course the risk that we will reject donor 
lungs that we would have otherwise transplanted if there was no CT-scan available. CT-imaging 
will give us more information on the donor lung, however, for active donor reconditioning and 
evaluation of the treatment effect, we will still need EVLP in the near future. A pilot study was 
already conducted in our laboratory (Figure IV.4, chapter IV.A), where a CT-scan was 
conducted as an additional evaluation parameter prior and after EVLP to evaluate the possible 
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improvement in lung quality. Future research will elucidate the value of CT-imaging in 
assessing donor organ suitability with or without EVLP. 
Prolonged ex-vivo lung perfusion model with reproducible lung injury 
In order to evaluate the effect of a reconditioning therapy, we have to maximize the time period 
where the graft is exposed to this therapy and have to incorporate an observation period that is 
long enough to detect a difference in the development of sufficient ischemia-reperfusion injury 
resulting in primary graft dysfunction. In our laboratory, EVLP used to be employed for only a 
maximum of 2 hours to evaluate physiological parameters (16,41–43). However, a peak of 
inflammation is not reached up to 3 hours of perfusion which correlates with the absence of 
BAL neutrophilia in experimental perfusion protocols (44,45).  Therefore, for the first time in 
our laboratory setting, we prolonged the evaluation period on EVLP to six hours in our 
experimental set-up. Extending the ex-vivo lung perfusion time safely without inflicting injury 
to the donor lung requires correct pressure monitoring at the in- and outflow (left atrium) (26), 
protective lung ventilation, a high-oncotic perfusion solution and a gradual rewarming plus 
perfusion of the graft (46). Additionally, to study ischemia-reperfusion injury a reproducible 
injury model had to be validated. Lung injury in DCD organ donation is based on WIT and 
since our laboratory had most experience in this field, we continued with these warm ischemic 
injury models (42,47,48). An initial WIT of 120 minutes, seemed to be too severe for porcine 
donor lungs which was reflected by an excessive amount of lung edema and the presence of 
necrosis on pathology (Chapter V.A). Therefore, the following experimental study designs 
incorporated a WIT of 90 minutes (Chapter III, VI.A, VI.B) (37). In addition, we also validated 
a prolonged cold ischemic injury model in Chapter V.B that is also used by other research 
groups (49,50). The development of a stable and reproducible injury model is difficult to 
standardize in animal models. There is a lot of variation in time between reported studies and 
even between investigators. Although it might seem simple to perfuse and ventilate a donor 
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lung, detailed care has to be provided to the donor lung on EVLP. Meticulous pressure, volume, 
flow and temperature monitoring are pivotal in order to successfully preserve donor lungs on 
EVLP without inflicting injury that would result in edema formation.    
Organ reconditioning on EVLP 
Organ reconditioning, the improvement of organ quality, is the main topic in EVLP literature 
nowadays. Both simple (such as antibiotics, steroids) and more advanced (such as stem cells, 
viral vectors) treatment options have been proposed as ideal reconditioning strategies on EVLP. 
Within this PhD project, several strategies have been put forward to increase the number and 
quality of donor lungs. First of all, physical examination of the pulmonary graft at the donor 
hospital during organ retrieval by an experienced transplant surgeon allows for a more grounded 
decision to put lungs on EVLP. Additional evaluation could lead to acceptance of the 
pulmonary graft for transplantation. Secondly, also perfusion and ventilation itself on EVLP 
with reduction of neurogenic lung edema, reduction of the microbial load and recruitment of 
atelectatic areas could lead to acceptance of the pulmonary graft. Thirdly, we have investigated 
if active treatment with anti-apoptotic and anti-inflammatory agents on EVLP could lead to an 
improved quality of the donor lungs (= “reconditioning”). Noble gases Ar and Xe could be of 
particular interest for active organ reconditioning based on their organ protective effects seen 
in other research fields (51–53). However, further research in DBD transplant models has to be 
conducted to validate such an organoprotective effect in lung transplantation. Cellular treatment 
with MAPC in the airways of warm-ischemic porcine lungs was able to regulate the innate 
immune response however failed to induce an improved lung physiology. Further research will 
have to be performed to elucidate the full effect of this immunoregulatory effect after lung 
transplantation with an optimal dose of MAPC cells administered in the airways. 
Several experimental pre-clinical studies show beneficial effects of other individual treatment 
options, and even some clinical case reports have been published with improved organ quality 
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and good patient outcome. However, these strategies have not found their way into standard 
operating procedures for EVLP preservation and reconditioning prior to transplantation. In 
concordance with clinical pathology, different types of injury require different treatment 
options. Therefore, a decision tree that incorporates donor medical history, acquired lung injury, 
PGD risk of the recipient etc. could help to apply the correct treatment for its specific target. 
For example, lung emboli cannot be treated with antibiotic treatment or stem cells, but can be 
dissolved with a fibrinolytic agent such as urokinase (54). However, inflammation and infection 
following aspiration could be treated with surfactant (55) or stem cells (56) and ischemic injury 
with viral vector or gene therapy (57). One therapy that fits all is therefore not feasible, but it 
might be that there is one therapy for each injury type separately. Research groups worldwide 
should combine their experiences to design an organ-tailored treatment algorithm for ex-vivo 
organ reconditioning prior to transplantation.  
Is there need for further research with noble gases for organ protection? 
Several authors have already summarized the individual neuroprotective results for Ar (58). In 
a meta-analysis, De Deken et al showed that Xe had the most consistent effects, being 
neuroprotective in rodents, cardioprotective in rodents and pigs, and renoprotective in rodents 
(51).  
Often, an organ protective effect of noble gases is studied in combination with hypothermia. 
Broad et al showed neuroprotection by a combination of Ar and hypothermia, in a piglet model 
of neonatal asphyxia (59) whereas Zhao et al showed that Argon mediates neuroprotection in 
combination with hypothermia in a hypoxic-ischemic injury model in rats (60). Also for Xe, 
combinational therapy with hypothermia has been shown to be organoprotective in different 
injury models (61–64). It might therefore be that most beneficial organoprotective effects of 
noble gases can be achieved by an enhancement of the protective effect of hypothermia on 
hypoxic or ischemic tissue. Niemann et al showed that hypothermia of the organ donor alone, 
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also gives protection against ischemia-reperfusion injury and can increase the organ yield (65). 
Therefore, the combination of hypothermia and noble gases will have to be investigated further 
in solid organ transplantation. Introducing hypothermia plus noble gas ventilation is, however, 
cumbersome. And it might be more time- and cost-efficient to investigate simpler treatments 
for donor organ optimization.  
In contrast, also protective effects of noble gases have been shown in normothermic conditions 
already (66–69). Therefore, the organ protective effect of noble gases cannot be contributed to 
an enhancement of the protective effect of cooling alone. Unfortunately, most data come from 
in vitro and small-animal models and will have to be confirmed in larger animals such as pigs. 
Also, timing, dosing and duration of noble gas ventilation has to be further explored. 
In our results, the absence of a protective effect on pulmonary ischemia-reperfusion effect 
should be embedded in this broader discussion: whether the organoprotective effects of noble 
gases might be due to an enhancement of hypothermic protection or whether the chosen cold-
ischemic injury model was not appropriate to study organ protection by noble gases. That is, 
injurious processes involved in brain damage that could harm donor organs, such as apoptosis, 
excitotoxicity, brain-dead induced inflammation and hemodynamic instability might be 
subjectable for attenuation by noble gases by modulation of the MAPK-ERK1/2 pathways. 
Attenuation of IRI in a brain-dead model should therefore be investigated. In addition, to fully 
study the effect of our noble gas treatment on IRI we should transplant reconditioned lungs to 
have recruitment of neutrophils upon reperfusion in the recipient, the most important effector 
cell in the injurious process of IRI. Our reperfusion model with whole blood can only be seen 
as a surrogate for transplantation since we merely mimicked transplantation, and the full effect 
on primary graft dysfunction will have to be explored in an allotransplant model with 
recruitment of many more neutrophils upon reperfusion. 
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Immunoregulatory mechanisms of mesenchymal cell treatment on lung injury 
In the beginning of MAPC research, most studies referred to the differentiation of the MAPC 
into specific cell types for tissue repair. However, engraftment and differentiation of these cells 
is not found to be the major effector function of this cellular therapy since Gupta et al showed 
that after 48 hrs there was less than 5% engraftment of labeled MSCs in injured mice lungs 
(70). Much of the current interest in mesenchymal cell products comes from the ability to home 
to injured tissue and secrete paracrine factors such as growth factors, factors regulating 
epithelial and endothelial function, and anti-inflammatory cytokines. The administration of 
mesenchymal cells leads to a reduction of inflammatory cell recruitment (70,71). The 
pathophysiology of organ injury following ischemia-reperfusion injury is based on an 
inflammatory cascade with massive activation of macrophages, infiltration of neutrophils and 
nourishment of a pro-inflammatory cytokine profile. The therapeutic effect, of mesenchymal 
cells is most likely not primarily derived from a pure and selective anti-inflammatory effect but 
from a regulatory effect on the immune response following transplantation. Several candidate 
mediators have been identified so far, first: attenuated lung injury can be partially mediated by 
inhibition of TLR signaling, a key player in activation of the innate immune system (72). Also 
Wang et al recently showed that interaction of bone-marrow derived mesenchymal cells with 
TLR signaling is a key player in modulating acute lung injury (73). In this way, activation of 
macrophages in the early inflammatory IRI response, through MAPK and NF-kB signaling 
pathways, is inhibited and the devastating cascade of inflammatory lung injury is attenuated 
(74). This effect is most likely not cell-contact dependent, but depending on release of 
prostaglandins such as PGE2 that acts on macrophage-receptors (70,75). Second, mesenchymal 
stem cells are known to produce epithelial specific growth factors such as KGF. KGF can 
restore alveolar fluid clearance in rodent models through activation of the PI3K/AKT/mTOR 
signaling pathway (76). AKT phosphorylation can result in decreased apoptosis of monocytes 
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(77), which can lead to higher bacterial clearance and a therapeutic effect in case of infection 
(78). Third, clearance of developed lung edema can be inhibited by a high concentration of 
inflammatory cytokines that block fluid clearance in the lung (79). A reduction in several pro-
inflammatory cytokines such as TNF-α, IL-1β, IFN-γ as seen in our experiments could therefore 
lead to an improved alveolar fluid clearance. Although we did not investigate alveolar fluid 
clearance in our study, we did not detect a difference in its end-results: lung edema was not 
reduced in injured lungs treated with MAPC. And while Mordant et al indicate that reduction 
of circulating IL-8 levels is the main factor for reducing organ damage in an ex-vivo lung 
perfusion model (49), other groups, including our own, did not found this in their results (80). 
So although some involved pathways have been identified, there is paucity of pre-clinical 
models with convincing results and more research in this field will have to elucidate the true 
effect of mesenchymal cells on ischemia-reperfusion injury and the inflammatory environment 
of the donor lung.  
As mentioned, we also showed a reduction of cytokines in the bronchoalveolar lavage fluid in 
Chapter VI.B. Unfortunately, this was not reflected by an alteration in the composition of the 
cells present in the BAL fluid. Nevertheless, reduced levels of pro-inflammatory levels such as 
TNF-α and IFN-γ do support the inhibition of macrophage activation. However, the effects of 
decreased macrophage activation on ischemia-reperfusion injury could not be studied to its full 
extent since lungs were only perfused with an acellular perfusate in our ex-vivo perfusion 
model. Future studies should focus on the potential physiological effect of mesenchymal cell 
product treatment in pre-clinical transplant models.  
This thesis project was focused on the early inflammatory phase after reperfusion of the donor 
organ. Other clinical indications in solid organ transplantation could be the prevention of acute 
transplant rejection and improvement of long-term survival with a minimum of 
immunosuppression to decrease the incidence of chronic rejection. These effects are not based 
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on the innate immune effects described earlier, but on the adaptive immune system. Preliminary 
results of a MSC treatment for chronic lung allograft dysfunction study showed a doubling of 
T-regulatory cells and a significant increase in epidermal growth factor (EGF) in patients 
receiving low-dose MSC (81). Pro-inflammatory Th1-cytokines and chemokines were 
significantly decreased. Zhao et al also showed that mesenchymal stem cells could mitigate the 
development of chronic lung allograft dysfunction by preventing luminal obliteration after 
transplantation. This was obtained by protection against epithelial cell loss through promoting 
epithelial progenitor cells and modulation of the immune reaction by inducing regulatory T-
cells and suppression of cytotoxic effector T-cells (82). The effect of mesenchymal cells on 
effector and regulatory T-cells is also why these cells have gained interest to treat and prevent 
graft-versus-host-disease (83) and allograft rejection in solid organ transplantation (84). The 
implications of a reduction in inflammatory cytokines observed in our study (Chapter VI.B), 
could therefore also have implications on the long-term survival and prevention of chronic lung 
allograft dysfunction.  
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B)  CONCLUSION AND FUTURE PERSPECTIVES 
We have shown that an increased number and quality of donor lungs can be obtained by 
introducing simple measures to optimize the donor phase. By sending out more retrieval teams 
to the donor hospital, more organs will be evaluated inside the donor chest for their 
transplantability rather than evaluating their suitability on registered donor data only (Chapter 
IIIA). In this way, more donor organs will be procured even without additional evaluation on 
ex-vivo lung perfusion (EVLP). EVLP does come in handy when evaluating an interventional 
effect to improve organ quality. We have shown that pre-arrest corticosteroid administration to 
a DCD donor (donation after circulatory death) that is continued during EVLP, results in 
improved pulmonary graft function. We are the first group to report comparative experimental 
data to support the practice of pre-arrest steroid administration in DCD donation programs 
(Chapter IIIB).  
With a retrospective donor database analysis, we validated that ex-vivo lung perfusion (EVLP) 
indeed holds great potential to increase the number of transplantable donor lungs by including 
carefully evaluated and optimized extended-criteria donor lungs in the donor pool (Chapter 
IV.A). Our study resulted in improved donor data registration to further improve our results and 
will provide us with insights in the causes of donor lung decline in the future. Hereby, we want 
to stimulate our transplant physicians, transplant coordinators, transplant surgeons and 
anesthesiologists to invest in extended-criteria donor lungs by carefully evaluating and even 
selecting them as candidates for EVLP.  
We also showed that ex-vivo lung perfusion is widely applicable in for example combined solid 
organ transplantation or pediatric transplantation. We highlighted that anesthesiologists are 
often confronted with the remote impact of ischemia-reperfusion injury which results in organ 
failure. Their focus should therefore be extended from managing the peri-operative challenges 
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to an interest and investment in strategies to reduce ischemia-reperfusion injury by optimizing 
organ preservation (Chapter IV.B).  
Ex-vivo lung perfusion holds great potential to increase both number and quality of donor lungs 
and we demonstrated that this technology can be used as a platform for reconditioning. We 
investigated two innovative treatment strategies to attenuate the effects of ischemia-reperfusion 
injury on pulmonary graft function. Noble gases Ar and Xe, and bone-marrow derived 
multipotent adult progenitor cells (MAPC) were selected for their pro-survival and 
immunoregulatory properties.  
We showed that ex-vivo reconditioning with Ar and Xe post-injury (postconditioning) was not 
successful in a porcine model of warm-ischemic pulmonary injury (Chapter V.A). Also 
prolonged exposure to Ar prior, during and after cold ischemic injury could not alleviate 
ischemia-reperfusion injury (Chapter V.B). Organoprotective effects of noble gases in other 
injury models of brain and myocardial injury were mostly described in combination with 
hypothermia. Therefore, the amplifying effect of noble gases on the hypothermic protective 
effect against ischemia-reperfusion injury should be further investigated together with the 
pathophysiological working mechanisms.  
We identified that intratracheal administration of MAPC resulted in less edema formation in a 
porcine warm ischemic injury model. However, no significant improvement in lung physiology 
or inflammation could be detected (Chapter VI.A). In a second work package, higher dosing of 
MAPC in the airways resulted in a significant reduction of neutrophils and inflammatory 
cytokines in bronchoalveolar lavage fluid. This attenuation of the inflammatory cascade of 
ischemia-reperfusion injury, however, was not reflected in improved lung physiology (Chapter 
VI.B). The impact of the immunoregulatory effect of MAPC on the clinical entity of primary 
graft dysfunction early after lung transplantation should be further unraveled together with the 
pathophysiological working mechanisms and biodistribution of these cells.  
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In conclusion, we identified that EVLP is a valuable strategy to increase the number and quality 
of donor lungs for transplantation. Noble gases failed to improve lung graft function in 
normothermic conditions even after prolonged exposure. However, MAPC distributed in the 
airways in a high dose (3.75 million/kg) are able to alter the inflammatory environment of the 
lung. Even though they failed to induce an improved lung physiology, the impact and 
pathophysiology of this immunoregulatory effect should be unraveled to improve organ quality. 
We showed that pre-arrest donor management with corticosteroids resulted in improved graft 
function. Therefore, donor management strategies should be highlighted in transplant programs 
to improve outcome after lung transplantation. Also, transplant teams should be encouraged to 
invest in identifying, carefully evaluating and procuring as many qualified donor lungs as 
possible to increase the lung yield and our transplant activity.  
In this way, we can improve organ quality, further decrease the persisting organ shortage and 
ameliorate early outcome after lung transplantation. 
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Lung transplantation is a lifesaving treatment option in well-selected patients with end-stage 
lung disease. Due to the successes of lung transplantation, transplant programs are expanding 
rapidly worldwide. However, two major problems impede optimal outcome early after lung 
transplantation. First, 10 to 30% of all lung recipients develop primary graft dysfunction, which 
is the leading cause of early morbidity and mortality after lung transplantation. PGD is a form 
of organ failure, and is the end-result of an injurious process that already starts in the donor, 
continues during preservation of the donor organ and peaks upon reperfusion in the recipient. 
This results in accumulation of lung water and impaired oxygen transport. Secondly, many 
donors do not match the strict criteria of lung donation. Therefore, there are more patients listed 
for lung transplantation than there are donor lungs available, and consequently 12% of listed 
patients die while waiting in Europe. In addition, those lungs that are available are often of 
limited quality which again leads to a higher incidence of graft failure and limited early 
outcome.  
This PhD project focusses on two separate time intervals prior to the lung transplant procedure 
that influence the number and quality of donor lungs. During the donor phase, a suitable donor 
organ is selected after careful evaluation by the transplant team to obtain optimal organ quality. 
Secondly, preservation of the donor organ largely determines the organ quality. 
In this project, we commented that more donor organs can be made available for lung 
transplantation when more retrieval teams are send out to inspect the organ quality inside the 
donor rather than making a selection on medical donor information only. Also, we are the first 
to provide evidence to support the current clinical practice of administrating corticosteroids to 
donors who die of circulatory arrest, since this results in improved organ function after lung 
transplantation. 
To evaluate graft function prior to transplantation, ex-vivo lung perfusion (EVLP) was 
developed. With this technique, a preservation solution is pumped through the lung while it is 
234 
 
ventilated so we can evaluate the organ physiologically outside the body. It also offers the 
opportunity to treat the donor organ and evaluate the effect or the treatment prior to 
transplantation.  
By analyzing data of all donor organs that were not used for transplantation, we could show 
that there is a large potential for EVLP to make more donor lungs available for transplantation 
by carefully evaluating them and improve them prior to transplantation. We also described our 
experience in a pediatric combined liver-lung transplantation where the lungs were kept on 
EVLP before they were transplanted. We showed that EVLP is also possible in unique cases 
such as this one and stimulated anesthesiologists to be more involved in research of optimal 
preservation methods of donor organs to improve their quality. 
We investigated the effect of administrating noble gases and multipotent adult progenitor cells 
(MAPC, bone-marrow derived stem cells) on our EVLP device to improve lung quality. While 
we could not detect a beneficial effect of noble gases on the lung, we did show that the 
inflammatory process that follows lung injury was less pronounced when MAPC cells were 
administered in the airways of donor lungs. The impact of this effect will have to be clarified 
in future experiments.
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Longtransplantatie is de finale behandelingsoptie voor patiënten met ernstig longlijden. 
Omwille van het succes van longtransplantatie breiden longtransplantatie programma’s 
wereldwijd snel uit. Spijtig genoeg zijn er twee grote problemen die optimale resultaten vroeg 
na longtransplantatie belemmeren. Ten eerste ontwikkelen 10 tot 30 procent van alle 
longtransplantpatiënten primaire greffe dysfunctie (PGD), wat de voornaamste oorzaak van 
vroege morbiditeit en mortaliteit is na longtransplantatie. PGD is een vorm van orgaan falen, 
en is het eindresultaat van een schadeproces dat reeds start in de donor, verdergaat tijdens de 
bewaring van het donororgaan en zijn hoogtepunt bereikt tijdens de doorbloeding van het 
donororgaan in de ontvanger. Dit resulteert in de opstapeling van longwater en een belemmerd 
zuurstoftransport. Ten tweede voldoen vele orgaandonoren niet aan de strikte criteria van 
longdonatie. Hierdoor staan er meer patiënten op de wachtlijst dan dat er donorlongen 
beschikbaar zijn, en sterven er zelfs 12% van de patiënten op de wachtlijst in Europa. 
Daarenboven zijn de organen die wel beschikbaar zijn vaak van onvoldoende kwaliteit wat 
opnieuw leidt tot een hogere incidentie van orgaanfalen en verminderde outcome in de eerste 
dagen na longtransplantatie.  
Dit PhD project focust op twee tijdsintervallen vóór de longtransplantatie procedure die het 
aantal en de kwaliteit van de longen kan beïnvloeden. Tijdens de donorfase wordt een geschikt 
donororgaan geselecteerd na grondige evaluatie door het transplantteam om optimale kwaliteit 
te kunnen bekomen. Tijdens de bewaringsfase van het orgaan, bepalen de condities waarin de 
longen bewaard worden sterk de kwaliteit van het orgaan.  
In dit project werd er becommentarieerd dat er meer donororganen beschikbaar gesteld kunnen 
worden door meer teams uit te sturen om de longen te onderzoeken in de donor zelf in plaats 
van donororgaan selectie louter te laten afhangen van medische donorgegevens. Ook leverden 
we als eerste evidentie aan, om de huidige praktijk van corticosteroïden behandeling bij donoren 
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die sterven aan circulatie stilstand, te onderlijnen, gezien dit resulteert in een betere werking 
van de donor longen.  
Om de functie van het te transplanteren orgaan te evalueren vóór het getransplanteerd wordt, 
werd de techniek van ex-vivo longperfusie (EVLP) ontwikkeld. Bij deze techniek wordt er een 
preservatievloeistof door de donorlongen gepompt en worden ze geventileerd zodat ze 
fysiologisch geëvalueerd kunnen worden. Dit biedt ook de mogelijkheid om donororganen te 
behandelen buiten het lichaam en het effect van de behandeling te evalueren voor ze 
geïmplanteerd worden in de patiënt. 
Door een analyse te maken van alle donororganen die niet gebruikt werden voor 
longtransplantatie, zagen we dat er een groot potentieel is voor EVLP om meer longen 
beschikbaar te stellen voor transplantatie door ze aanvullend zorgvuldig te evalueren en te 
verbeteren voor transplantatie. We publiceerden ook onze ervaring met een pediatrische 
gecombineerde lever-longtransplantatie procedure waarbij de longen op EVLP bewaard werden 
voor ze getransplanteerd werden. We toonden hierbij aan dat EVLP ook mogelijk is voor 
uitdagende casussen zoals deze en stimuleerden anesthesiologen om meer betrokken te zijn in 
onderzoek naar de optimale bewaarmethodes van donororganen om te kwaliteit te verbeteren.  
We onderzochten het effect van toedienen van edelgassen en multipotent adult progenitor cells 
(MAPC, beenmerg stamcellen) op onze EVLP-machine om de kwaliteit van de donorlongen te 
verbeteren. We hebben geen gunstig effect van edelgassen kunnen aantonen, maar toonden wel 
aan dat de ontstekingsreactie die volgt op orgaanschade, minder uitgesproken was indien 
MAPC-cellen werden toegediend in de luchtwegen van donorlongen. De impact van dit effect 
zal verder uitgeklaard moeten worden in de toekomst.
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